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“One, two, three, biotechnology” 
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Abstract 
Recombinant protein production in Escherichia coli provides a cheap and efficient way of 
producing medically and industrially relevant proteins. Sequence features of individual genes 
and especially their 5’ terminal coding sequences act on the efficiency of gene expression by 
complex regulatory mechanisms which are still not fully understood. This study aimed to 
investigate the features of the 5’ coding region of recombinant mRNAs, and to optimize them 
for increased expression in E. coli.  
A previous study had found that a synonymous change of the bla reporter gene 2nd codon 
leads to an increased expression, and accordingly a synonymous library in the 5’ bla coding 
sequence was created by a directed evolution approach building on this feature. Variants 
conferring up to three-fold increases in active enzyme amounts were identified, and the 
increased expression was shown to stem from increased transcriptional efficiency. The effect 
of changing the 2nd codon synonymously was further investigated by synonymous 
substitutions of the 2nd codons of the bla and two other reporter genes, phoA and celB. These 
experiments showed that the effect of 2nd codon changes on the gene expression is determined 
by the sequence context, as changes in expression levels appeared to be gene specific. All the 
coding sequences of the study were also analysed in silico, and an application for calculating 
the tRNA adaptation index was programmed in Python and made freely available online. 
As the synonymous codon changes did not lead to a great improvement in protein amounts 
and any sequence features affecting the expression were hard to pinpoint, an alternative 
strategy involving 5’ terminal gene fusions was investigated. Combinatorial mutagenesis 
coupled to an effective screening technique was applied to further optimize a 5’ terminal 
fusion partner, previously shown to improve expression of several eukaryotic genes. The 
application of the best identified fusion partner candidate yielded a 3.8-fold improvement in 
IFN-α2b protein amounts over the original fusion, and showed twice as high protein amounts 
than a pelB-IFN-α2b fusion previously proven to give industrial expression amounts. The 
developed peptide fusion is thus an eligible candidate for further development for use in 
heterologous protein production. 
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Sammendrag 
Rekombinant proteinproduksjon i Escherichia coli er en billig og effektiv produksjonsmetode 
for medisinske- og industrielt relevante proteiner. Effektiviteten av genekspresjon styres av 
trekk i gensekvensene til de enkelte genene, og særlig deres 5’ terminale kodende sekvens av 
kompliserte regulatoriske mekanismer som enda ikke er fullt ut forstått. Målet med denne 
oppgaven var å undersøke trekk i den 5’ terminale kodende regionen av rekombinant mRNA, 
og å optimalisere regionen for økt genuttrykk i E. coli. 
En tidligere studie hadde vist at en  synonym endring av 2. kodon i bla reportergenet førte til 
økt genuttrykk, og et synonymt genbibliotek i den 5' terminale kodende sekvensen av bla ble 
følgelig konstruert ved en målrettet evolusjonstilnærming, der den positive endringen ble 
videreført. Varianter fra genbiblioteket ga opp til tre ganger økning i mengde aktivt enzym, og 
det økte genuttrykket ble vist til å stamme fra økt transkripsjonseffektivitet. Effekten av å 
endre 2. kodonet ble ytterligere undersøkt ved synonyme substitusjoner av 2. kodon i bla og 
to andre reportergen, phoA og celB. Disse eksperimentene viste at effekten av å endre 2. 
kodon synonymt avhenger av den omliggende gensekvensen, da endringene i genuttrykk var 
genspesifikke. Alle kodende sekvenser i denne oppgaven ble undersøkt in silico, og et script 
for å regne ut tRNA adapsjons indexen til en sekvens ble programmert i Python, og gjort fritt 
tilgjengelig på internett. 
Ettersom de synonyme endringene ikke førte til store forbedringer i mengden protein, og det 
ikke ble identifisert bestemte trekk i sekvensene som påvirket genuttrykket, ble en annen 
strategi fulgt der en 5’ terminal genfusjonpartner ble undersøkt. Kombinatorisk mutagenese 
sammen med en effektiv seleksjonsmetode ble brukt til å optimalisere en 5’ fusjonspartner 
som tidligere hadde vist seg effektiv til å forbedre genuttrykk av flere eukaryote gener. Fusjon 
av den beste optimaliserte fusjonspartneren til ifn-α2b genet ga 3,8 ganger høyere IFN-α2b 
proteinproduksjon enn vill-type fusjonen, og dobbelt så høy proteinproduksjon enn en pelB-
IFN-α2b fusjon som tidligere hadde vist industrielle produksjonsverdier. Dermed er den 
utviklede fusjonspartneren en godt kvalifisert kandidat for videre utvikling til bruk i heterolog 
protein produksjon. 
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Abbreviations 
A:  Adenine, nucleobase in RNA and DNA. Normally bonds with T or U 
bla: Gene encoding β-lactamase 
C:  Cytosine, nucleobase in RNA and DNA. Normally bonds with G 
celB:  Phosphoglucomutase 
celB23: Peptide fusion of the first 23 amino-acids of celB 
celB:  Gene encoding celB 
celB69:  Gene fusion of the 69 first nucleotides of celB 
DNA:  Deoxyribonucleic acid 
G:  Guanine, nucleobase in RNA and DNA. Normally bonds with C 
GM-CSF:  Granulocyte-macrophage colony-stimulating factor 
Gm-csf:  Gene encoding GM-CSF 
IB:  Inclusion body 
IFN-α2b:  Human interferon alpha 2b 
ifn-α2b:  Gene IFN-α2b 
mRNA:  Messenger RNA 
RBS:  Ribosome binding site 
RNA:  Ribonucleic acid 
S:  Svedberg sedimentation coefficient (Sharma et al., 2009).) 
scFv-phOx:  Single-chain antibody variable fragment 
SD:  Shine-Dalgarno site 
T:  Thymine, nucleobase in DNA. Normally bonds with A 
TIR:  Translation initiation region of mRNA 
T.I.R.:  Translation initiation rate 
U:  Uracil, nucleobase in RNA. Normally bonds with A 
UTR:  Un-translated region of mRNA 
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1 Introduction 
Heterologous protein production, where an organism is reprogrammed to produce a foreign 
protein of interest by genetic engineering, is of major importance in the production of 
therapeutics. Without for example the human insulin produced in Escherichia coli, diabetes 
may have still been treated using insulin extracted from animal pancreatic tissue (Junod, 
2007). Other examples of heterologously produced therapeutic proteins include Interferon 
α2b, used to treat viral infections and some forms of cancer (Srivastava et al., 2005), and 
human growth hormone used to treat growth failure (Sonoda and Sugimura, 2008). A variety 
of production hosts are used, such as yeasts, mammalian cells, plants, and even the mammary 
glands of goats, producing the proteins in their milk (Ferrer-Miralles et al., 2009). However, 
the gram-negative bacteria E. coli continues to remain the most popular choice, as it confers 
many advantages in the production process (Huang et al., 2012).  
It has been a favorite model organism of prokaryotic research since its discovery by Theodor 
Escherich (Escherich, 1885; Hacker and Blum-Oehler, 2007) and further characterization in 
1913 (Castellani and Chalmers, 1913), due to its high growth rate and ease of cultivation. 
Because of its qualities as a model organism, it was chosen for research on bacterial 
transformation (Lederberg and Tatum, 1946), leading to more research and increased 
knowledge of prokaryotic genetics. The successful recombination of genetic elements from 
different organisms, and their expression in E. coli (Cohen et al., 1973) spurred a 
biotechnological revolution in the 1970s and 1980s where therapeutic proteins and metabolic 
products could be produced cheaply and efficiently. The first recombinant therapeutic protein 
produced was somatostatin (Itakura et al., 1977), and in 1982 Humulin, human insulin 
produced in E. coli, became the first genetically engineered drug approved by the U.S Food 
and Drug Administration (FDA) (Junod, 2007).  
E. coli remains a valuable production host due to its ease of cultivation on cheap substrates, 
well studied genetics and proven versatility in terms of the variety of proteins it can produce 
at high quality (Huang et al., 2012). In 2009, 29.8 % of the 151 therapeutic proteins approved 
by the FDA and the European Medicines Agency was produced in E. coli (Ferrer-Miralles et 
al., 2009), demonstrating its dominance over other hosts in the industry. 
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However, in spite of its successes in production and the vast amount of research on the field, 
high-level protein production is not always a straight-forward matter in the bacterium (Jana 
and Deb, 2005). Due to the variety of intricate mechanisms that govern the regulation of its 
protein production and the different genetic features of individual heterologous genes, some 
proteins are produced in low amounts or none at all (Makrides, 1996). Thus more knowledge 
is needed on these regulatory mechanisms in order to increase, and efficiently control protein 
production. This holds for the field of protein production, but also very much so for metabolic 
engineering and the emerging field of synthetic biology, where genetic circuits and even 
entire genomes may be synthesized from scratch, and individual proteins must be expressed at 
fine-tuned levels (Lale et al., 2011).  
In the following chapters important aspects of protein expression in E. coli will be discussed. 
The regulation of gene expression will be discussed in chapter 1.1, followed by a description 
of various tools and strategies for improving heterologous protein production in chapter 1.2 
and 1.3. Chapter 1.4 will present the recombinant proteins used in this study, and the aim of 
the experimental study will be described in chapter 1.5 
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1.1 Control of Gene Expression in E. coli 
The central dogma of molecular biology states that genes are transcribed from DNA into a 
messenger RNA, which is further translated into proteins as shown in Figure 1-1 (Crick, 
1970). Thus the regulation of gene expression may be divided into transcriptional regulation 
and translational regulation, which both are regulated in various ways as indicated in the 
figure. The regulation of DNA transcription is described in chapter 1.1.1 and the regulation 
mechanisms of translation are described in chapter 1.1.2. 
 
 
Figure 1-1: Protein expression according to the central dogma of molecular biology, 
important steps in expression that are under heavy regulation are shown in italics. Points of 
regulation for the transcription and translation processes are described in 1.1.1 and 1.1.2, 
respectively. Adapted from (Crick, 1970; Browning and Busby, 2004).  
1.1.1 Regulation of DNA Transcription 
Transcription is the primary regulatory step of protein expression; if a gene is not transcribed 
from DNA into mRNA, the translational machinery has no blueprint of the gene and the 
protein is not expressed. Transcription of genes in all organisms is under the control of up-
stream DNA sequence elements called promoters that attract the transcriptional machinery 
with different affinities on account of sequence elements within them (Browning and Busby, 
2004). The process is usually divided in three parts; transcription initiation, elongation and 
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termination, as seen in Figure 1-1, the most important for regulation being the initiation step 
(Browning and Busby, 2004). 
Transcription initiation begins with the recognition of promoter elements by multi-domain 
proteins called σ-factors that attract the DNA dependent RNA-polymerase (RNAP). E. coli 
has seven σ-factors (Sharma and Chatterji, 2010), the most common one being σ70. Different 
σ-factors recognize different sets of promoters so that global transcription can be changed, for 
example from the house-keeping genes controlled by σ70, to heat-shock response genes under 
control of σ32 (Grossman et al., 1984).  
A schematic figure of promoter features discussed in this section is shown in Figure 1-2. The 
hexameric -10 and -35 elements (relative to the transcriptional start-site) are the most 
important parts of the promoter, and the spacing between them and their similarities to their 
consensus sequences are the main determinants of promoter strength (Fournier et al., 1999). 
The -10 element is called the Pribnow box and has the consensus sequence 5’-TATAAT-3’ 
(Pribnow, 1975; Lisser and Margalit, 1993). The -35 element has the consensus sequence 5’-
TTGACA-‘3. The -10 and -35 facilitate binding of domain 2 and 4, respectively, of the σ70-
subunit (Browning and Busby, 2004). The extended -10 element and the UP are additional 
important sequence elements of some promoters, which both act in the recruitment of σ-
factors and may enhance promoter activity 300-fold (Davis et al., 2011). The relative 
contribution of the four elements varies from promoter to promoter (Browning and Busby, 
2004). Promoter activity is also regulated by proteins known as transcription factors (TFs), 
which bind to regulatory regions called operators in the promoter. These may facilitate the 
binding of RNAP, or block its access to the promoter, acting as negative or positive regulators 
(Browning and Busby, 2004). TFs are produced naturally to respond to environmental 
changes, such as the presence of metabolites, allowing genes to be transcribed when needed.  
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Figure 1-2: Overview of promoter elements described in the text. The gray line depicts DNA, 
and the transcribed DNA lies 3’ of the transcriptional start site. Consensus sequences are 
shown for -35 and -10 elements. Adapted from (Browning and Busby, 2004).  
During transcription initiation, the RNAP core-enzyme binds to the σ-factor which is attracted 
to the sequence elements in the promoter. This allows the now called RNAP-holoenzyme to 
isomerize to an “open” complex, unwinding the DNA double helix around the transcriptional 
start-site (Davis et al., 2011). The RNAP may undergo a repetitive process called abortive 
transcription (Chan and Gross, 2001), where, short RNA transcripts are produced and released 
before the RNAP returns to the transcriptional start-site and starts over. The duration of the 
process is dependent on the +1 to +20 sequence relative to the transcriptional start site, and 
continues in a stochastic fashion until promoter escape where the RNAP clears the promoter 
(Hsu et al., 2006). Thus the DNA of the 5’ un-translated region of the mRNA has an affect on 
transcriptional efficiency (Berg et al., 2009; Berg et al., 2012), further discussed in 1.3.1. 
After promoter escape, the elongation complex is formed and nucleoside triphosphates 
complementary to the non-coding strand in the DNA template are bound in the complex’s 
active site and added chemically one by one to the 3’-OH group of the growing RNA chain, 
making a copy of the coding strand where (Roberts et al., 2008). Several mechanisms regulate 
the elongation. Local sequence features of the emerging RNA may cause transcriptional 
pausing, for example to synchronize translation with transcription in the tryptophan operon 
(Landick et al., 1985), and the NusA elongation factor helps prevent transcriptional 
termination during pauses (Roberts et al., 2008).  
Termination of transcription is achieved by two mechanisms. In intrinsic termination, local 
sequence features allow hairpins to form in the nascent RNA which destabilizes bindings in 
the elongation complex, facilitating termination (Nudler and Gottesman, 2002). Rho-
dependent termination depends on Rho protein monomers binding to specific sites in nascent 
RNA not protected by secondary structures or the translation complex and wrapping of the 
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RNA around the hexamer Rho complex, which may pull the RNA out of the active site of the 
elongation complex (Nudler and Gottesman, 2002).  
The regulation of transcription is manipulated to a great extent during heterologous protein 
expression, especially by use- and manipulation of promoters, which will be discussed in 
chapter 1.2.1. This manipulation usually leads to high amounts of mRNA transcript for 
expression of the protein of interest, but even though transcription is considered the primary 
regulatory step of expression, there is a substantial variance in translational efficiencies for 
various mRNAs (Makrides, 1996). A wide range of translational regulation mechanisms have 
been identified, and the most important for heterologous protein production are discussed in 
the following chapter. 
1.1.2 Translational Regulation 
The mRNA intermediate is translated into proteins by large macromolecules composed of 
ribosomal RNA and proteins, called ribosomes (Kaczanowska and Ryden-Aulin, 2007). Base 
triplets in the transcript code for amino acids which are brought to the translation complex by 
aminoacyl transfer RNAs (tRNAs) and linked together (Laursen et al., 2005). As the 
translation efficiency of heterologous transcripts vary widely (Park et al., 2007; Kudla et al., 
2009), an understanding of the regulatory mechanisms of translation is important for 
heterologous protein production and will be discussed below.  
The translation process is usually divided into three separate events; initiation where the 
ribosome binds to the transcript and commences translation, elongation where the ribosome 
traverses the transcript and synthesizes the peptide, and termination where the peptide is 
released from the ribosome (Kaczanowska and Ryden-Aulin, 2007). Initiation is rate limiting 
step of the process (Tuller et al., 2010), and it’s regulation depends heavily on the sequence 
and secondary structure of the translation initiation region of the transcript, as described in 
chapter 1.1.2.1. Elongation is also an important regulatory step that depends on the codon 
usage of the transcript, and is discussed in chapter 1.1.2.2. Termination is achieved when the 
ribosome reaches one of the three stop codons UAA, UAG, or UGA in the mRNA, 
recognized by Release Factors 1 or 2 which trigger hydrolysis and peptide release 
(Kaczanowska and Ryden-Aulin, 2007). An additional important regulatory mechanism of 
translation is the degradation kinetics of the mRNA, which is discussed in chapter 1.1.2.3 
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1.1.2.1 Translation Initiation Regulation 
The translational initiation region (TIR) denotes the region of the transcript that influences the 
translational initiation, and includes the transcript’s 5’ un-translated region (UTR), its 
ribosome binding site (RBS), the translational start-codon, and part of the 5’ coding sequence 
(Huang et al., 2012). Two main features of the TIR control the rate of initiation, namely the 
sequence of the Shine-Dalgarno (SD) site and the region’s secondary structure. 
In translation initiation the 70S ribosomal complex, which in E. coli is made up of two 
subunits, 50S and 30S (Julian et al., 2011), assembles on the RBS of the mRNA along with 
the initiating N-formylmethionine aminoacyl tRNA, which binds to the AUG start-codon. The 
RBS denotes the approximately 30 nucleotides of the transcript that is covered by the 
ribosome during binding (Laursen et al., 2005), and includes the SD sequence which attracts 
the ribosome by complementarity to a sequence in the 3’ end of the 16S ribosomal RNA 
subunit of 30S. The SD was discovered in bacteriophage mRNA (Shine and Dalgarno, 1974) 
and interaction between the site and the 16S RNA was later confirmed (Steitz and Jakes, 
1975). The SD’s stimulatory effect on translational initiation depends on its sequence, its 
length and the spacer region between the SD and the initiation codon (Ringquist et al., 1992), 
and variations of these has been shown to give a 3000-fold difference in translational yields 
(Barrick et al., 1994).  
The secondary structure of the TIR greatly affects translation initiation (deSmit and Vanduin, 
1990; Kudla et al., 2009; Goltermann et al., 2011). mRNA is single-stranded, and thus bases 
in the transcript may form internal base-pairs giving stem-loop structures. GC bindings, which 
have three Hydrogen-bonds, are stronger than AU bonds with only two, and structures and 
their stability may be predicted based on the sequence’s minimum folding energy (MFE) 
(Zuker and Stiegler, 1981). The stability of secondary structures forming in the UTR and 
around the ribosome binding site has a profound effect on translational efficiency by blocking 
the ribosome’s access to the SD (Park et al., 2007; Huang et al., 2012) and to the translational 
start-codon (Zhang et al., 2006). Both the 5’ UTR and the 5’ coding sequence nucleotides 
may contribute to the secondary structures (Kudla et al., 2009; Goltermann et al., 2011), and 
thus their nucleotide sequence greatly affects protein expression.  
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As the TIR has such a profound effect on the translation process, modifications of its features 
are frequently utilized in improving heterologous protein expression, and such methods will 
be described in chapter 1.3.1.  
1.1.2.2 Codon Usage Affects the Rate of Translational Elongation 
The genetic code is degenerate (Nirenberg et al., 1966), in that there are 61 codons coding for 
only 20 amino-acids in E. coli (Gustafsson et al., 2004). I.e. one amino-acid may be encoded 
by one to six different synonymous RNA codons. Although the choice of one synonymous 
codon over others has no effect on the peptide sequence, the use of codons in E. coli and other 
organisms is not at all random (Tuller et al., 2010). The speed of translational elongation is 
affected by the availability of the codon’s amino-acyl tRNA (Mitarai et al., 2008), and there is 
a clear codon bias where highly expressed native genes in E. coli are biased towards a 
different set of codons than other genes (Tuller et al., 2010).  
The use of synonymous codons was shown to be adapted towards the abundance of the 
codon’s respective major isoacceptor tRNAs in the organism, and the codon adaptation index 
(CAI) was developed to score genes on how well they are adapted to an organism (Sharp and 
Li, 1987). A reference set of highly expressed genes was used to score each codon against its 
synonymous ones by observing the frequency of which it occurs in the highly expressed 
genes, and a gene’s score is calculated as the geometric mean of all its codon scores. In 
prokaryotes, several ribosomes translate each mRNA simultaneously (Goodman and Rich, 
1963; Warner and Knopf, 2002), and it has been suggested that the high CAI of native highly 
expressed genes has evolved to increase the efficiency of the cell’s global translation. In that 
an increased elongation rate in highly expressed proteins leads to fewer ribosomes 
sequestered on the transcript, and thereby increases their availability for the translation of 
other proteins (Kudla et al., 2009). 
Another measure of the gene’s adaptation to the host’s tRNA pool is the tRNA Adaptation 
Index (tAI). It was developed on the same principle as the CAI, but is based on the tRNA 
genes’ copy-numbers and their availability for a given codon, along with weighted 
contributions for wobble-interactions where one tRNA may decode several codons (dos Reis 
et al., 2003). Thus a codon with a low tAI is translated at a slower rate than its synonymous 
mutants with higher tAI. Local tAI analysis of several genomes has identified an evolutionary 
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conserved occurrence of slowly translated codons in the start of genes (Tuller et al., 2010). 
They suggested that this “ramp” may have evolved to help distribute closely spaced 
ribosomes from genes with high translation initiation efficiency, thus reducing chances of 
ribosome collisions leading to abortive protein synthesis, which is a burden to the cell.  
Expressing heterologous proteins in E. coli often proves difficult as the source organism’s 
genes are adapted to a different tRNA pool (Gustafsson et al., 2004), and codons rare to the 
host may lead to growth arrest, premature translational termination and mistranslated proteins 
(Huang et al., 2012). Strategies for overcoming these problems include alteration of the host’s 
tRNA pool and codon optimization of the gene, which will be described in chapter 1.3.1.  
1.1.2.3 The Stability of the mRNA Molecule Affects Translational Efficiency 
The amount of time a transcript is available for translation has an effect on how much protein 
is produced (Belasco, 2010), and thus mRNA half-life can be used as a way to regulate gene 
expression. The rate of degradation of E. coli transcripts varies over a vast range, and half-
lives last from seconds, up to 20 minutes (Sorensen and Mortensen, 2005). mRNA is 
degraded via two pathways in E. coli, both of which are dependent on the low-specificity 
RNA degrading enzyme (a ribonuclease) RNaseE, along with 3’ exonucleases that degrade 
transcripts from the 3’ terminus  (Belasco, 2010).  
Intact transcripts are protected by a stem-loop structure forming in the 3’ UTR of the 
transcript, blocking the degradation from 3’ exonucleases (Belasco, 2010). In the 5’ 
independent pathway RNaseE repeatedly cuts the transcript in AU rich regions (McDowall et 
al., 1994) creating fragments with and without 3’ secondary structures, allowing 3’ 
degradation of the unprotected ones. Intermediates containing stem-loops are made accessible 
by 3’ polyadenylation (Xu and Cohen, 1995), allowing the exonucleases to degrade them.  
In addition to the stabilizing 3’ structures, 5’ tri-phosphate caps and 5’ stem-loops also 
increase the stability of E. coli transcripts (Emory et al., 1992; Mackie, 1998). In the 5’ 
dependent pathway, the RNA pyrophosphohydrolase H (RppH) removes a pyrophosphate 
from the transcript, leaving a mono-phosphorylated transcript (Celesnik et al., 2007; Deana et 
al., 2008). This allows its binding to a discrete pocket in RNaseE (Callaghan et al., 2005), 
enhancing the efficiency of RNaseE cleavage and increasing the rate of degradation by over 
an order of magnitude compared to tri-phosphorylated transcripts (Mackie, 1998; Belasco, 
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2010). Stem-loop structures in the 5’ terminus of transcripts sterically block RppH, and thus 
lead to stabilization of the transcript (Deana et al., 2008) 
Another factor influencing the degradation of mRNA is its association with ribosomes, which 
blocks RNaseE’s access to the transcript (Deana and Belasco, 2005). A poor SD sequence 
lowers the rate of ribosomal binding to the transcript and thus lowers the translation initiation, 
and it has been shown to destabilize the mRNA (Wagner et al., 1994). An efficient translation 
initiation could allow closer spacing of ribosomes on the transcript thus protecting it. 
However a study showed that ribosome binding to the RBS of transcripts without translation 
also protected the mRNA, suggesting that RBS occupancy by a ribosome may work as a 
barrier against the 5’ bound RNaseE (Deana and Belasco, 2005).  
A ribosomal spacing model showed that the spacing of ribosomes does affect the transcript’s 
stability (Pedersen et al., 2011). It predicted that inserting slowly translated codons before 
codon 20 of the lacZ transcript would slow the translating ribosomes, creating a gap in front 
of them as the previous ribosome would have reached the faster translated codons, speeding 
away from it. The gap would allow RNaseE access to the transcript, thus lowering its 
stability. Experiments supported the prediction, and also the stability increase predicted by 
inserting slowly translated codons after codon 45 to increase ribosome density in the 20-45 
region, was confirmed.  
The use of mRNA stabilization as a technique for increasing heterologous protein expression 
in E. coli has not been utilized as extensively as increasing transcription or the translational 
efficiency. However the UTR of the unusually stable ompA mRNA, which contains two stable 
hairpins in the extreme 5’ terminus, has been successfully used to increase the stability of β-
lactamase (Belasco et al., 1986) and β-galactosidase transcripts (Hansen et al., 1994) through 
UTR-gene fusions. Another study created a synthetic UTR library with stem-loop structures 
in the 5’ terminus of the UTR, which varied lacZ transcript over an order of magnitude 
(Carrier and Keasling, 1999). 
The manipulation of the translational regulation that has been described in this chapter is used 
extensively for optimizing heterologous protein expression, as will be discussed in chapter 
1.3. However, the heterologous gene needs to be established in the host and transcribed for 
efficient protein production, which will be discussed in the following chapter. 
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1.2  Heterologous Protein Expression in E. coli 
Heterologous protein production requires the introduction and expression of heterologous 
genes in the host organism and is usually performed using specially designed expression 
vectors developed from natural plasmids (Ferrer-Miralles et al., 2009). In this chapter the 
features of expression vectors will be discussed, followed by a description of the vector used 
in this study in chapter 1.2.4. 
1.2.1 General Features of Expression Vectors 
Natural plasmids are circular DNA entities capable of replicating independently from the 
host’s chromosome that usually confer an advantage to the host, like antibiotic resistance or 
additional metabolic pathways (Frost et al., 2005). A variety of plasmids with different origins 
have been developed for heterologous protein production, and vectors suited for various types 
of protein expression are available commercially (Promega, Invitrogen, Stratagene, Novagen). 
Most expression vectors have a general set of common features needed for their function 
(Jana and Deb, 2005), and a schematic view of these is given in Figure 1-3 
 
 
Figure 1-3: General features of protein expression vectors, not drawn to scale. TF: gene 
coding for transcription factor; SD: Shine-Dalgarno site. Details on features are given in the 
text. Adapted from (Jana and Deb, 2005). 
The origin of replication (ori) is necessary for the plasmid to take advantage of the host cell’s 
DNA replication machinery and proliferate along with the cell (Baker and Wickner, 1992). 
Their role and mechanism in expression are discussed in chapter 1.2.3. Expression cassettes 
containing promoters, regulatory proteins and multiple cloning sites (MCS) are used for 
expression of the protein, and are discussed in further detail in chapter 1.2.2. Transcriptional 
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terminator sequences are often positioned behind the MCS so that they hinder transcriptional 
read-through of the gene of interest, which may cause promoter occlusion (Makrides, 1996) 
and plasmid instability by transcription of the ori (Sorensen and Mortensen, 2005).   
To keep a selective pressure for cells harboring the expression plasmid, an antibiotic 
resistance selection marker is normally used (Sorensen and Mortensen, 2005). The hok/sok 
system is often used in addition to increase plasmid stability, and consists of a locus 
specifying two RNAs (Franch et al., 1997). The hok mRNA encodes two reading frames, mok 
and hok (modulation of killing, and host killing) which are tightly coupled translationally. The 
sok RNA binds to the TIR of mok, thus inhibiting translation of hok, keeping the cell alive. 
The sok RNA degrades faster than hok/mok mRNA which will linger in the cytoplasm after 
cell division and will be translated if the cell does not contain a plasmid, killing the cell 
(Franch et al., 1997). 
1.2.2 Expression Cassettes 
To regulate and promote high expression of the protein of choice, a tightly controlled and 
efficient promoter system, along with its regulatory gene(s) are needed (Huang et al., 2012). 
Transcription factor (TF) regulated promoters are widely used in recombinant protein 
production, as they allow controlled induced expression of the gene of interest by adding the 
chemical that naturally acts on the TF to start expression. A low basal expression is desirable, 
meaning there should be little expression of the gene of interest before induction (Sorensen 
and Mortensen, 2005). This is especially important if the protein produced is host-toxic, 
allowing high cell density to be reached before induction, which gives a higher yield of the 
product (Jana and Deb, 2005). However, for industrial scale production of proteins inducer 
cost and its toxicity to the host may be limiting factors (Jana and Deb, 2005). Alternative 
induction methods have been developed, such as thermal induction (Hasan and Szybalski, 
1995) or pH-dependent induction (Chou et al., 1995). 
Several promoter systems have been constructed for high-level protein production (Terpe, 
2006). One early example is the tacI promoter (de Boer et al., 1983) which was constructed 
from the -35 region of the trp promoter and the -10 region of the lac promoter. This synthetic 
promoter gave 11 and 3 times more efficient transcription than the lac and trp promoters, 
respectively, while maintaining the ability to be induced by the lactose analog Isopropyl β-D-
1-thiogalactopyranoside (IPTG). Perhaps the most widely used expression systems today are 
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based on the T7 RNA polymerase (Terpe, 2006). This system utilizes the RNA polymerase 
from the phage T7, which only transcribes genes from T7 promoters (Studier and Moffatt, 
1986). Use of the system requires a special production strain for its function where the 
polymerase has been cloned into the chromosome of E. coli strain BL21 under control of a lac 
derived promoter, allowing its strong induction from IPTG (Terpe, 2006). A third example is 
the pBAD/AraC promoter system, derived from the arabinose operon (Guzman et al., 1995). 
The AraC repressor/activator controls the pBAD promoter which is induced using L-
arabinose, a relatively inexpensive inducer. Ara negative E. coli strains are maximally 
induced at 0.001 % L-arabinose, making the process even cheaper (Terpe, 2006). 
Improving the strength and efficiency of promoter systems has received much attention in 
studies trying to optimize protein expression. Studies where the promoter sequence has been 
partially or fully randomized have proven successful in creating a wide range of promoter 
strengths and induction ratios (Miksch et al., 2005; Bakke et al., 2009). The TFs of promoter 
systems has also been targeted for improving the expression system. A randomized library 
followed by directed evolution of the XylS regulatory protein of the Pm promoter improved 
expression nine-fold while maintaining low basal expression (Vee Aune et al., 2010). 
In addition to the promoter system, the 5’ UTR of the transcript is important in protein 
translation as discussed in chapter 1.1.2, and downstream of the promoter there is usually a 
high efficiency UTR with a consensus SD sequence allowing high translational efficiency 
(Jana and Deb, 2005). For eased cloning of the gene of interest, a MCS with a range of 
restriction sites, or restriction sites that allow in-frame cloning with the start-codon is placed 
after the UTR. Another consideration for the vector’s gene expression is the gene dosage, 
which is discussed below. 
1.2.3 Gene Dosage 
The ori and its regulatory system keep the plasmid replicating, but also determine how many 
copies of the plasmid are present in the cell (Wild and Szybalski, 2004). This is an important 
factor for the number of genes of interest available for transcription, the gene dosage. 
Expression vectors use different replicons and mechanisms for maintaining their copy number 
in the cells, and a high copy number generally leads to high expression of the gene of interest 
(Huang et al., 2012). However, the maintenance demand of keeping high numbers of plasmids 
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imposes a heavy metabolic burden on the cell, and may lead to low growth rates and low 
expression (Jana and Deb, 2005). 
The detrimental effect of high copy number plasmids may be avoided by use of copy-control 
plasmids, where the copy number may be increased by induction (Jana and Deb, 2005). RK2-
based plasmids replicate from a region called the origin of vegetative growth (oriV) in a 
manner controlled by two gene products from the trfA gene, and trfA up-mutants have been 
identified (Durland et al., 1990). In the pBAD/oriV expression vectors, the trfA up-mutant 
gene along with the gene of interest, are under control of the arabinose inducible promoter 
Para (Wild and Szybalski, 2004). The increase in copy number, along with induction of the 
gene’s promoter leads to a 50 000-fold increase in expression of the gene upon induction. In 
addition to lowering the maintenance burden, this gives the system a very low background 
expression making it useful for the production toxic proteins. 
1.2.4 RK2 based Pm/XylS Expression Vector 
The plasmids used in this study are based on the pJBn vectors constructed by Blatny et. al. to 
be tightly controlled broad host-range expression vectors that were easily regulated in terms 
of their induction (Blatny et al., 1997). The RK2 based plasmids contain the oriV and TrfA 
gene, which are known to be functional in many gram-negative, and some gram-positive 
bacteria. The XylS/Pm promoter system of the plasmid stems from the TOL plasmid of 
Pseudomonas putida (Ramos et al., 1997), and is a strong and active promoter in many hosts 
(Sletta et al., 2004), transcribed from σ32 and σ38 in E. coli (Marques et al., 1999). The 
promoter has been subjected to random mutagenesis in the vector, which strongly increased 
expression of three reporter genes and doubled HCDC production of GM-CSF under industry-
simulated conditions (Bakke et al., 2009). The XylS protein is constitutively produced from 
its native promoter in low numbers, and is induced to become a transcriptional activator for 
the Pm promoter by several cheap and harmless benzoate derivatives, such as m-Toluic acid 
(Ramos et al., 1997; Sletta et al., 2004).  
The expression vector system also includes the hok/sok system, transcriptional terminators in 
front of the promoter (rrnBT1T2) and after the MCS (tLPP) and TrfA (t), an antibiotic 
resistance marker, origin of transfer for conjugative replication (oriT), and an M13 origin of 
replication (M13 ori) which can yield high levels of single stranded DNA upon infection with 
the M13 phage (Zagursky and Berman, 1984). The system is highly versatile, and has been 
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used successfully in industrial scale protein production in E. coli (Sletta et al., 2004; Bakke et 
al., 2009). For research on the regulatory mechanisms governing its expression, several 
designs are available where features such as the promoter or UTR may be exchanged by DNA 
cassette exchange. 
Expression vectors are excellent tools for expressing genes in E. coli. However, even with the 
optimized features of expression vectors, protein expression often encounters problems that 
require further strategies to be solved. The problems include features of the gene sequences 
and the UTR, or drawbacks E. coli itself as a production host, and will be discussed in the 
following chapter. 
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1.3 Strategies for Effective Heterologous Expression 
Due to the intricate mechanisms regulating gene expression discussed in 1.1, many genes may 
require optimization before they can be efficiently produced in E. coli. Problems also arise 
when expressing eukaryotic proteins, as they often require post-translational modifications 
such as disulfide bridges or proteolytic cleavage, and they are often produced in insoluble 
inclusion bodies (Jana and Deb, 2005; Kamionka, 2011). Strategies for optimizing expression 
and overcoming these problems will be covered in the following chapters. 
1.3.1 Modification of the TIR 
The rate limiting step in translation is translation initiation, as discussed in chapter 1.1.2.1. Its 
efficiency is mostly determined by the secondary structure and sequence features of the TIR, 
which starts in the 5’ UTR and extends into the 5’ coding region. The sequence of the UTR 
may be changed for fine-tuning of translational efficiency by decreasing the stability of 
secondary structures and varying the sequence of the SD (Park et al., 2007). By varying the 
stability of a hairpin structure in the RBS, de Smit et. al could vary the relative expression of 
a target protein from <0.003 % at higher stability, to 100 % at lower stability (deSmit and 
Vanduin, 1990).  
The 5’ coding region also contributes to secondary structure formation and should be taken 
into consideration along with the UTR. As GC bonds are stronger than AT bonds (Zuker and 
Stiegler, 1981), increasing the AT content of the TIR may lower the stability of secondary 
structures forming and increase translational efficiency (Nishikubo et al., 2005; Krishna Rao 
et al., 2008). Given the degeneracy of the genetic code (Nirenberg et al., 1966), i.e. one 
amino-acid may be coded for by one- up to six different synonymous RNA codons 
(Gustafsson et al., 2004), it is possible to change the 5’ coding region to alter the transcript’s 
propensity for forming stable secondary structures in the TIR without changing the amino 
acid sequence of the translated protein.  
A synthetic library was constructed in a study by Kudla et. al. with 154 synonymous variants 
of green fluorescent protein (GFP) that gave 250-fold variations in GFP levels (Kudla et al., 
2009). Local and global RNA structures of the genes were predicted and compared to the 
fluorescence levels, and stable local structures forming in the -4 to +37 nucleotide window 
explained more than half of the variation in the dataset. In a different experiment, a 
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randomized synonymous mutation library was created in an artificial 10 amino acid linker in 
front of GFP, giving ~300-fold increase in fluorescence compared to the wild-type linker-GFP 
construct (Goltermann et al., 2011).  
Optimization of the codon following the translational start site (+2 codon) has also been 
suggested as a technique for improving protein expression (Stenstrom et al., 2001; Tang et al., 
2011). By exchanging the codon following the initiation codon AUG (the +2 codon), a 20 
fold effect on gene expression could be obtained (Stenstrom et al., 2001), and a correlation 
between high adenine content of the +2 codon with high expression was observed. The effects 
seen were not correlated to change in secondary structures forming around the RBS, mRNA 
stability, or tRNA abundance. Most synonymous codons decoded by the same tRNA showed 
similar effects, indicating tRNA involvement in the effect on gene expression. Stenstrøm et. 
al. also found that the codons they identified as giving high expression were over-represented 
as +2 codons in natural genes with high expression, and vice versa.  
Placing NGG (N is not G) as the +2 codon in transcripts has been shown to drastically reduce 
expression (Gonzalez de Valdivia and Isaksson, 2004), also in a manner not apparently 
affected by mRNA secondary structure, but instead a specific NGG codon effect. Replacing 
GUG with less G-containing +2 codons also increased expression (Tang et al., 2011). 
However, here it was correlated to a reduction in secondary structure stability.   
Clearly modification of the UTR and the 5’ coding region of transcripts may be used to 
enhance translational efficiency, both by altering the SD and the stability of the secondary 
structures. However, random mutagenesis of the UTR of the XylS/Pm system interestingly 
produced UTRs giving up to 20-fold increases in both transcript and protein levels without 
affecting mRNA stability (Berg et al., 2009), indicating that the DNA corresponding to the 
UTR also has a role in transcription as well as translation. This may be explained by changes 
in promoter escape efficiency by changes in the initially transcribed region (Hsu et al., 2006). 
The effect of the UTRs were shown to be gene specific as transcription of two other genes 
using the UTR were not as highly up-regulated, suggesting a dependency of the UTR 
sequence together with the 5’ coding sequence (Berg et al., 2012). 
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1.3.1 Codon Optimization and tRNA Pool 
Expressing mammalian proteins in E. coli often proves difficult, even with high amounts of 
transcript and an effective TIR, as the source organism’s genes are adapted to a different 
tRNA pool (Gustafsson et al., 2004), and codons rare to the host may lead to growth arrest, 
premature translational termination and mistranslated proteins (Huang et al., 2012). One 
strategy for overcoming this problem is to modify the host’s tRNA pools by overexpressing 
genes coding for the rare tRNAs, especially tRNA4Arg reading AGG and AGA, tRNA2Ile  
reading CUA and CUG, and tRNA2Pro reading CCC and CCU as these are codons that reduce 
efficiency (Kane, 1995). However, this may overload the tRNA amino-acylation machinery 
(Wahab et al., 1993) along with other problems that lead to low expression (Gustafsson et al., 
2004).  
A simple, more common solution now that the cost of DNA synthesis is low, is to synthesize 
a codon optimized gene of interest where codons rare to the expression host are exchanged for 
more common ones following the CAI (Angov, 2011). This has been successful in many 
cases, especially with human proteins produced in E. coli (Gustafsson et al., 2004; Sletta et 
al., 2007). One study reported an increase in human phosphatidylcholine transfer protein from 
trace levels, using the native cDNA of the gene, to over 10 % of cytosolic protein, using an 
optimized version of the gene synthesized using a recursive PCR strategy (Feng et al., 2000). 
Despite several successful stories involving CAI optimization of genes for production in E. 
coli, a high CAI of the gene does not universally correlate with high expression (Kudla et al., 
2009; Welch et al., 2009). As in (Kudla et al., 2009), the study by Welch et. al. found no 
correlation to CAI when two genes were randomized so that common codons would appear 
more often in their synonymous codons, and features of the coding sequence were analyzed 
with respect to expression levels. The 40-fold difference in expression was instead explained 
by the synonymous codon choice of a subset of highly represented amino acids in the 
proteins, and it was suggested that the sensitivity of the respective tRNAs to amino-acid 
starvation influences the expression, as amino-acylation of tRNAs may become the limiting 
factor during protein overexpression (Welch et al., 2009). 
Tuller et. al. describe a “ramp” of slowly translated codons with low tAI in the early coding 
region of genes as described in 1.1.2.2, and suggest this feature may be used in the design of 
genes for heterologous expression. This might reduce the burden imposed on cells by 
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heterologous protein production and increase the fitness of the cell, as it could increase the 
rate of successful translations by evenly spreading the ribosomes on the transcript (Tuller et 
al., 2010).  
1.3.2 E. coli as a Production Host 
Achieving high expression efficiency of a protein of interest in E. coli doesn’t necessarily 
mean it is produced in high quality. Some major obstacles when expressing mammalian 
proteins in E. coli are its lack of post-translational modification systems and its inability to 
form disulfide bonds (Jana and Deb, 2005). Mammalian proteins may fold incorrectly, form 
inclusion bodies (IBs), or have lowered or no activity without modifications such as 
glycosylation, proteolytic maturation, or the formation of disulfide bridges in the peptide 
(Huang et al., 2012). The cytoplasm is a too reductive environment for the formation of 
disulfide bridges (Mergulhão et al., 2005), and enzymes for glycosylation and correct 
proteolysis aren’t native to E. Coli (Kamionka, 2011). Many therapeutic proteins are therefore 
produced in mammalian cells, losing the ease-, and low cost of cultivation that comes with 
using E. coli..  
One strategy to overcome the reducing environment of the cytoplasm involves translocation 
of the peptide to the periplasmic space (Mergulhão et al., 2005). By fusing a translocation 
signal peptide, such as those from PelB (Hauser and Ryan, 2007), OmpA (Pines and Inouye, 
1999), or the Consensus Signal Peptide (CSP), designed based on sequence alignments of 
several signal peptides (Sletta et al., 2004), to the 5’ end of the protein, it is targeted to the 
periplasmic space between E. coli’s two membranes. Here the environment is less reducing 
and contains enzymes that help form disulfide bonds (Mergulhão et al., 2005). The signal 
peptide is cleaved off following translocation, which also removes the problem of the 
sometimes present initiation amino acid methionine (Mergulhão et al., 2005). In addition to 
the folding-wise more favorable environment, periplasmic expression allows for easier 
purification of the protein as the variety and amount of proteins in the periplasm is 
considerably lower than the bacterial cytoplasm (Sandkvist and Bagdasarian, 1996). 
Strategies for the improvement of cytoplasmic expression have also been developed, for 
example for natively glycosylated proteins which may form aggregates leading to lowered 
activity and need for higher dosages (Kamionka, 2011).. The neutral asparagine N-
glycosylation target residues in human erythropoietin were changed to lysine residues, 
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reducing its rate of aggregation without affecting its activity (Narhi et al., 2001). To aid in the 
correct folding of proteins native E. coli chaperone proteins may be overexpressed along with 
the protein of interest, a technique which has yielded higher solubility and increased 
production of heterologous proteins (Kolaj et al., 2009).  
Human insulin is an example of a mammalian protein that needs proteolytic cleavage for 
activation (Son et al., 2008). It is produced natively as preproinsulin, with a signal peptide 
that is cleaved off, followed by proteolytic cleavage into two chains which are bonded 
together by two disulfide bonds (Kamionka, 2011). E. coli is unable to perform the proteolytic 
cleavage, and disulfide bonds cannot form in the reducing environment of its cytoplasm. It is 
produced as inclusion bodies which are resolubilized, denatured and reduced before in vitro 
enzymatic treatment for cleavage of the peptide, renaturation and disulfide bond formation 
(Son et al., 2008). Like insulin, the production of many commercial proteins utilizes inclusion 
bodies as an advantage, as it offers high yields and protection against proteases (Kamionka, 
2011; Huang et al., 2012).  
1.3.3 Fusion Peptides 
In addition to the beneficial effects discussed above, translocation of heterologous proteins in 
E. coli may serve to increase translational efficiency (Sletta et al., 2007). The three medically 
important proteins granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon 
alpha 2b (IFN-α2b), and single-chain antibody variable fragment (scFv-phOx) were expressed 
in the cytoplasm of E. coli, as they don’t contain disulfide bridges, using the XylS/Pm vector 
system described above. The genes were initially poorly expressed, but when various 
translocation signal peptides were fused N-terminal to the GM-CSF and scFv-phOx proteins, 
industrial expression levels were achieved. The improvement could also be shown for a codon 
optimized ifn-α2b.  
Quantitative real-time PCR analysis of the GM-CSF constructs showed only a ~three-fold 
increase in transcript levels for pelB and CSP constructs, suggesting that the increase in 
translational efficiency exceeds that of the increase in transcription (Sletta et al., 2007). A 
decrease in folding energy was observed for all genes when fused to signal peptides, which 
might explain the increased translation. However, the codon optimized IFN-α2b already had 
low secondary structure stability before fusion. It was also noted that the +2 codon was 
changed to AAA for all signal peptides, which could influence the expression as previously 
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discussed, but this has been shown to not be universally beneficial (Sletta et al., 2007). The 
authors hypothesize that it is the translocation process itself that affects the translation, as the 
two mechanisms are closely coupled.  
However, recent studies by the Microbiology and Molecular Genetics (MOLGEN) research 
group at NTNU have shown similar increases in both gm-csf and the codon optimized ifnα2b 
gene expression when using a 5’ terminal fusion of a short celB gene fragment (Kucharova, 
unpublished). As the celB gene is coding for cytoplasmic phosphoglucomutase enzyme, it 
indicates that translocation is not necessary for the increased expression effect from protein 
fusions. Given the high expression efficiency of celB, it may hold a 5’ coding sequence which 
forms a particularly good TIR together with the Pm and UTR of the pJBn vectors. Another 
study showed that fusing the first 21 nucleotides of the infB gene encoding translation 
initiation factor II 5’ to GFP increased its expression five-fold (Hansted et al., 2011). The 
small ubiquitin-related modifier (SUMO) tag is a popular expression enhancer for poorly 
expressed proteins that serves togreatly enhance expression, while also increasing the 
solubility of the produced protein (Satakarni and Curtis, 2011). The SUMO fusion may 
effectively be cleaved off by SUMO specific proteases post-production.  
Another use for protein fusions are as affinity tags which may be utilized in the purification of 
proteins (Terpe, 2003). By fusing such a tag to the protein of interest, it may be adsorbed to 
columns with affinity for the tag. The tags are commonly small, so as not to interfere with the 
protein’s tertiary structure, and some are removable by enzymatic treatment (Terpe, 2003). 
Tags also allow simple visualization on Western blots as described in chapter 2.2. If an 
antibody is not available for the protein of interest, an antibody against the affinity tag may be 
used.  
A common affinity tag is the poly-histidine tag (his-tag) (Hochuli et al., 1987), which is a tag 
of normally six histidine residues that may be fused to the C- or N-terminal of the protein of 
interest (Terpe, 2003). The histidine residues bind to transition metal ions that are 
immobilized on a matrix, for example Ni2+, and may be eluted by imidazole. The his-tag is 
believed to minimally affect proteins due to its small size but it has been shown to reinstate 
the dimerization of a monomeric π protein(Wu and Filutowicz, 1999), proving that 
structure/function may be affected. 
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1.3.4 Combinatorial Mutagenesis 
As is evident from the subjects discussed so far, many different factors in the DNA and the 
transcript affect protein expression to different extents, and it is hard to predict the outcome of 
certain designs on a given protein in a given expression vector. Rationally incorporating all 
the different factors to optimize the design of transcripts would be difficult, and the testing of 
such designed constructs would be time-consuming (Kim et al., 2008). By utilizing 
randomized libraries and good screening techniques, large amounts of different sequence 
variants can be tested, and up-mutants that may be compromises of all the factors affecting 
gene expression may be successfully selected (Kim et al., 2008; Bakke et al., 2009; 
Goltermann et al., 2011). A directed evolution approach where positive features identified in 
one round are kept in a new mutagenesis could lead to even better results (Vee Aune et al., 
2010). A good screening technique and quantitative measurement of mutational effects are 
greatly aided by the use of reporter genes, which are described in the following chapter. 
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1.4 Recombinant Proteins Used in the Expression Studies 
Reporter genes are valuable tools when studying the molecular events associated with 
changes in gene expression. These are genes that, when introduced in a biological system, 
produce  measurable phenotypes (Wood, 1995), which may illustrate the effect of the changes 
made to the system when compared to the wild-type. A well known example is the lacZ gene 
encoding β-galactosidase, which hydrolyzes ortho-Nitrophenyl-β-galactoside (ONPG) to a 
yellow product, allowing colorimetric measurement of enzyme amount and activity (James et 
al., 1996). Another widely popular reporter gene is gfp, encoding Green Fluorescent Protein, 
which can be measured fluorometrically without the need to lyse cells or provide additional 
substrates (Ghim et al., 2010). The reporter genes may be expressed in their native form, for 
example to measure promoter strength (Bakke et al., 2009), or mutated to study effects of for 
example synonymous mutations (Kudla et al., 2009).  
In this chapter the reporter genes utilized in this study will be presented along with the 
medically important human protein IFN-α2b, which was used for demonstration of successful 
heterologous protein expression. 
1.4.1 β-lactamase 
β-lactamase encoded by the bla gene breaks down the β-lactam ring, and thus confers 
resistance to β-lactam containing antibiotics, among others ampicillin (Bakke et al., 2009). 
The ability to grow on increasing concentrations of ampicillin has been shown to correlate 
well to the amount of β-lactamase produced by E. coli (Winther-Larsen et al., 2000; Bakke et 
al., 2009; Berg et al., 2012). It is therefore a well suited reporter protein in screening for 
increased expression in vivo, as high growing mutants are likely to produce high amounts of 
protein (Bakke et al., 2009; Berg et al., 2009). As the β-lactam ring of penicillin G absorbs 
light at 240nm, the relative amounts of β-lactamase in cell extract may be measured by 
observing the degradation of penicillin as the decrease in absorbance at 240nm (Fukagawa et 
al., 1980). The bla gene was used in this study to investigate changes in the synonymous 
codons of its 5’ coding region, by screening for up-mutants on increasing ampicillin 
concentrations. The gene was also used in this study to investigate the effects of 2nd codon 
synonymous mutations on gene expression. 
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1.4.2 Phosphoglucomutase 
The phosphoglucomutase protein, encoded by celB, originates from Acetobacter xylinum 
(Brautaset et al., 1994) and was previously produced successfully at high levels using the 
XylS/Pm expression vector (Blatny et al., 1997). The intracellular protein converts glucose-1-
phosphate to glucose-6-phosphate (Najjar, 1948), and has been proven useful as a reporter 
protein as a simple enzyme assay has been developed to measure its activity (Valla et al., 
1989). The use of short 5’ terminal celB fragments as gene fusions has been shown to 
dramatically increase expression of poorly expressed genes, as discussed previously 
(Kucharova, unpublished). The 5’ celB gene fragment of 69 nucleotides (corresponding to 23 
amino acids) was chosen to be used as a basis for constructing a genetic library of optimized 
5’ terminal fusion partners. The celB gene was also used in this study to investigate the effects 
of 2nd codon synonymous mutations on gene expression. 
1.4.3 Alkaline Phosphatase 
Alkaline phosphatase, encoded by the phoA gene, is expressed in a wide range of organisms 
and has the ability to dephosphorylate a broad range of substrates (Jiang et al., 2008), among 
others p-nitrophenyl phosphate (p-NPP). p-NPP is degraded to the colored product p-
nitrophenol which can be colorimetrically measured at 405 nm (Akcakaya et al., 2007). The 
phoA gene was used in this study to investigate the effects of 2nd codon synonymous 
mutations on gene expression. 
1.4.4 Aminoglycoside-(3)-acetyltransferase IV 
The aac(3)-IV gene encodes an aminoglycoside acetyltransferase that acetylates the 
aminoglycoside antibiotic apramycin, thus hindering its ability to block translational 
elongation (Han et al., 2005). In this study it was used as a reporter gene for screening of a 
combinatorial genetic library of the celB69 based 5’ terminal fusion partners. The mutant 
library was cloned in frame with the 5’ end of the aac(3)-IV gene, allowing screening of the 
library with respect to increased host apramycin tolerance. 
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1.4.5 Interferon α-2b 
IFN-α2b is a human cytokine used for the treatment of viruses and certain cancers (Srivastava 
et al., 2005), and it is encoded by the ifn-α2b gene. The protein has proven difficult to express 
in E. coli, nevertheless high level production was achieved by codon optimization and N-
terminal translocation peptide fusion (Sletta et al., 2007). 
1.5 Aims of this Study 
Recombinant protein expression in E. coli is of high-value, as important therapeutic proteins 
may be produced at low cost and high quality. However, as explained in the previous 
chapters, production is not always straight-forward as the expression efficiency varies from 
protein to protein due to intrinsic factors of its gene sequence, and thus more research is 
needed to be able to optimize any given gene. As the main effectors on protein expression lies 
in the translation initiation region, the 5’ coding sequence of the transcript is an interesting 
target for optimization. It is part of the TIR and may affect secondary structures forming 
around the RBS and the translational start-site. It may also provide slowly- or rapidly 
translated codons, affecting translational elongation and ribosome density on the transcript. 
Recent findings also suggest that the UTR and the 5’ coding region together play a role in 
transcriptional regulation. 
The main focus of this study has been to investigate and optimize the 5’ coding region of 
transcripts in an effort to obtain knowledge for enhanced heterologous protein expression, 
which was addressed by three different strategies. A directed evolution approach was applied 
to results obtained from a previous synonymous mutation library, where a 2nd codon change 
in the bla translocation signal sequence led to increased β-lactamase expression. To further 
investigate the cause of this effect and to achieve higher expression, a new library was created 
containing the identified 2nd codon mutant. Another part of the project was to further 
investigate the specific effect achieved by changing only the 2nd codon, and the differential 
expression due to 2nd codon synonymous change from the reporter genes bla, phoA and celB 
were examined. 
Both the aforementioned strategies involved synonymous mutations of the 5’ coding region, 
which is preferable in optimization as it does not lead to changes in the amino-acid sequence 
of the protein. However, some difficult-to-express proteins such as interferon α-2b may 
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require protein fusions to be expressed (Sletta et al., 2007), and recent research has shown that 
IFN-α2b may be expressed by fusion of the first 69 nucleotides of the celB gene 5’ to ifn-α2b. 
In an effort to explain the reasons for this and to further enhance the positive features of the 
fusion, a randomized celB69 gene fusion library was created and screened for increased 
expression by use of the apramycin resistance reporter gene aac(3)-IV.   
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2 Materials and Methods 
This chapter first gives an overview of the various media and buffers used in this study in 
chapter 2.1, followed by protocols for the experimental techniques in 2.2. Chapter 2.3 
contains information on the various plasmids and oligonucleotides used, and chapter 2.4 gives 
a short description of various bioinformatics tools that were used to analyze the results 
obtained. 
2.1 Growth Media and Buffers 
Lysogeny Broth (LB medium) 
BactoTMTryptone (Becton, Dickinson& Co.,Sparks, USA) 10 g/L 
Yeast Extract (Oxoid, Basingstoke, Hampshire, England) 5 g/L 
NaCl  5 g/L 
Components were dissolved in MQ-water. pH was adjusted to 7.4 using NaOH, before 
autoclaving 20 minutes at 121 °C. 
LB Agar (LA) 
LB medium 
DifcoTM Agar Noble (Becton, Dickinson and Company, Sparks, USA) 15 g/L 
LB components were dissolved in MQ-water before adding agar. pH was adjusted to 7.4 
using NaOH before autoclaving 20 minutes at 121 °C. The agar was cooled to approximately 
50 °C before addition of appropriate selective antibiotic and casting of plates 
Psi medium 
BactoTMTryptone (Becton, Dickinson& Co.,Sparks, USA) 20 g/L 
Yeast Extract (Oxoid, Basingstoke, Hampshire, England) 5 g/L 
MgSO4 5 g/L 
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Components were dissolved in MQ-water. pH was adjusted to 7.6 using KOH, before 
autoclaving 20 minutes at 121 °C. 
Hi + YE reduced broth 
Hi+YE broth is a rich media used for increased growth and expression, and has many 
nutritional additives for this purpose. It considers different nutritional needs before and after 
induction, and has a basic broth and an induction broth.  
The basic broth is made by mixing three different solutions, A, B and C.  
Solution A, concentrations denote final concentration of induced medium: 
Na2HPO4*2H2O 8.60 g/L 
KH2PO4 3.00 g/L 
NH4Cl 0.30 g/L 
NaCl 0.50 g/ L 
Fe(III) citrate hydrate (3.30 mL from 6 g/L stock solution) 19.8 mg/mL 
H3BO3  (0.03 mL from 30 g/L stock solution)  0.9 mg/mL 
MnCl2*2 H2O (0.50 mL from 10 g/L stock solution) 5.00 mg/mL 
EDTA*2H2O (0.03 mL from 84 g/L stock solution) 2.52 mg/mL 
CuCl2*2H2O (0.03 mL from 15 g/L stock solution) 0.45 mg/mL 
Na2Mo4O4*2H2O (0.03 mL from 25 g/L stock solution) 0.75 mg/mL 
CoCl2*6H2O (0.03 mL from 25 g/L stock solution) 0.75 mg/mL 
Zn(CH3COO)2*2H20 (0.67 mL from 4 g/L stock solution) 2.68 mg/mL 
Yeast extract (Oxoid, Basingstoke, Hampshire, England) 2.68 g/mL 
Glucose*H2O 2.00 g/L 
MQ-water 650 g 
 
Solution B, concentrations denote final concentration of induced medium: 
Citric acid 1 g/L 
The pH was adjusted to approximately 7 with NaOH. 
 
Solution C: 
MgSO4*7H2O 24.6 g 
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MQ-water 100 g 
The solution was autoclaved at 120 °C for 20 minutes. 
 
Solutions A and B were mixed, and 0.9 mL solution C was added before sterile filtration. 
Appropriate antibiotics were added before use. 
Hi+YE Induction solution 
Glycerol (100 %) 12.75 g 
Yeast extract (Oxoid, Basingstoke, Hampshire, England) 12 g 
Tap water  to 500 mL 
The solution was sterile filtered, and appropriate antibiotics were added before use. 
Kanamycin stock 
Kanamycin sulphate 50 mg/mL 
The antibiotic salt was dissolved in MQ water, sterile filtered, aliquoted and stored in -20 °C. 
Ampicillin stock solution 
Ampicillin sodium salt 100 mg/mL 
The antibiotic salt was dissolved in MQ water and sterile filtered before use. 
Transformation buffer I (TFB I) 
Potassium acetate (CH3CO2K) 0.03 M 
RbCl 0.1 M 
CaCl2  0.0133 M 
MnCl2  0.08 M 
Glycerol 15 % (v/v) 
Components were dissolved in MQ-water. pH was adjusted to 5.8 using acetic acid, before 
sterile filtration. 
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Transformation buffer II (TFB II) 
MOPS  10 mM 
CaCl2 0.1 M 
RbCl 10 mM 
Glycerol 15 % (v/v) 
Components were dissolved in MQ-water. pH was adjusted to 6.5 using NaOH, before sterile 
filtration. 
β-lactamase assay buffer 
KH2PO4 80 mM 
NaH2PO4 20 mM 
Components were dissolved in MQ-water. pH was adjusted to 6.5 using NaOH, before sterile 
filtration. 
Alkaline phosphatase assay buffer 
Tris-HCl 100 mM 
CaCl2  5 mM 
Tween 20 0.1 % (v/v) 
Components were dissolved in MQ-water. pH was adjusted to 9.5 using NaOH 
Phosphoglucomutase assay buffer 
Immidazole 0.1 M 
Components were dissolved in MQ-water. pH was adjusted to 7.4 using HCl. 
SDS-PAGE 10x running buffer 
Tris-HCl 250 mM 
Glycine 2 M 
Sodium dodecyl sulphate (SDS) 1 % (w/v) 
Components were dissolved in MQ-water. pH was adjusted to 8.3 using concentrated HCl. 
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3x sample buffer 
Tris, pH 6.8 150 mM 
Glycerol 30 % (v/v) 
SDS 6% (w/v) 
Bromophenolblue 0.3 % (w/v) 
Dithiothreitol (DTT) 300 mM 
Components were dissolved in MQ-water. 
Blotting buffer 
Tris 25 mM 
Glycine 192 mM 
Methanol 20 % (v/v) 
SDS 0.05 % (w/v) 
Components were dissolved in MQ-water, and the buffer was stored in 4 °C. 
Tris-buffered saline (TBS) 
Tris-HCl, pH 7.5 20 mM 
NaCl 150 mM 
Components were dissolved in MQ-water. 
TBST 
Tween 20 0.05 % (v/v) 
Tween 20 was added to TBS. 
Blotto buffer 
Bovine serum albumin (BSA) 3 % (w/v) 
BSA was dissolved in TBS and kept at 4 °C. 
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2.2 Protocols 
Rubidium chloride competent cells 
Treatment of bacterial cells with divalent cations such as Ca2+ and Mn2+ in addition to other 
cations such as Rb+ weakens the cell membrane and induces binding of exogenous DNA to 
the membrane. (Weston et al., 1981; Aune and Aachmann, 2010). A subsequent heat-shock 
followed by cold incubation allows the DNA to permeate into the cell.  
E. coli DH5α cells were inoculated ON in 10mL Psi-broth at 37 °C, 225 rpm. 1% of the ON 
culture was inoculated in pre-warmed Psi-broth and grown to OD600=0.4 (measured with 
Lambda 35 UV/VIS Spectrometer) at 37 °C, 225 rpm, followed by incubation on ice for 15 
minutes. The cell culture was centrifuged (4500 rpm, 5 minutes) (Sorvall RC5C) and the 
pellet was resuspended in 40 mL cold TFB I before incubation on ice for 15 minutes followed 
by centrifugation (4500 rpm, 5 minutes). The pellet was resuspended in 3 mL TFB II and the 
cell solution aliquoted (100µL), snap-frozen using dry-ice chilled ethanol and stored in -80 
°C. 
Transformation 
Competent cells were thawed on ice, added to ligation mix / plasmid DNA, briefly vortexed 
and incubated on ice for 30 minutes. The cells were heat-shocked in a water-bath holding 42 
°C for 37 seconds before addition of 1 mL LB and incubation on ice for 2 minutes. Cells were 
centrifuged (5000 rpm, 2 minutes) and the pellet resuspended in approximately 100µL of the 
supernatant before plating on L-agar plates with selective antibiotic followed by incubation at 
37 °C.  
Isolation of plasmid DNA 
Plasmid DNA was isolated using the Wizard® Plus SV Miniprep DNA Purification System 
(Promega). Single colonies were picked from freshly streaked plates and incubated ON for 
16-18 hours at 30 °C, 225 rpm in 15 mL LB with selective antibiotic in 125 mL Erlenmeyer 
flasks for high plasmid yield, or 6 mL LB with selective antibiotic in 13 mL tubes. Cells were 
centrifuged (10 000 g, 10 min), and the pellet was resuspended in 300 µL Resuspension 
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Solution and transferred to an Eppendorf tube. 400 µL Cell Lysis solution was added, along 
with 10 µL Alkaline Protease solution and tubes were inverted 4 times before incubation at 
room temperature for five minutes. 400µL Neutralization Solution was added, tubes inverted 
four times before centrifugation at 13 000 rpm for 10 minutes. Supernatant was decanted into 
spin columns, inserted into collection tubes and centrifuged at 13 000 rpm for 90 seconds. 
Columns were washed twice with 750 µL and 250 µL wash solution, at 13 000 rpm for 90 
seconds. Plasmid DNA was eluted into Eppendorf tubes using 100 µL MQ-water, the 
concentration was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific), 
and samples were stored in -20 °C.  
Restriction digests 
Restriction endonucleases are part of archaeal and bacterial defense against viral DNA, and 
cleave DNA in specific recognition sequences. Restriction enzymes used in cloning usually 
recognize palindromic DNA, and cut it leaving “sticky end” overhangs of bases so that DNA 
digested with the same enzyme have matching ends and may be ligated together (Roberts, 
2005). 
All restriction digests were performed using restriction endonucleases purchased from New 
England Biolabs, using the recommended conditions and buffers obtained with the Double 
Digest Finder Tool for enzymes A and B, and the following reaction mixture. 
Plasmid DNA (approximately 1500ng) 20-30 µL  
NEB buffer specified by Double Digest Finder 10 µL 
Restriction endonuclease A 2.5 µL 
Restriction endonuclease B 2.5 µL 
BSA (if recommended by Double Digest Finder) 1 µL 
MQ-water to final volume 100µL  
The reaction mixtures were incubated at 37 °C over night before adding 1 µL of each enzyme 
in the morning followed by 1 hour incubation at 37 °C. 3 µL calf intestinal phosphatise (CIP) 
was added to remove 5’ phosphates from the backbone to reduce religation (Wu et al., 2008), 
and the mixture was incubated for another 1,5 hrs. The cut DNA backbone was purified using 
the QIA quick PCR Purification Kit (Qiagen) and eluted with 100 µL MQ-water.  
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Ligation reactions 
The “sticky” overhangs of DNA cut with the same restriction enzymes are attracted to each 
other, and may be joined together by ligases. DNA ligases catalyze the phosphodiester bond 
formation between the 5’-phosphoryl and 3’-hydroxyl termini of DNA, thus ligating the two 
ends together (Brown and Ray, 1992). The T4 DNA ligase is commercially available and 
often used in genetic recombination in vitro for cloning purposes. 
All ligation reactions were performed using T4 DNA Ligase from New England Biolabs, 
along with its buffer, and in the following reaction mixture.  
Purified cut plasmid backbone DNA 16 µL 
T4 DNA ligase buffer 2 µL 
T4 DNA ligase (10x diluted in Diluent A (NEB)) 1 µL 
DNA insert (diluted annealed oligos) 1 µL 
Ligation efficiency and religation were evaluated by including negative ligation mixes 
without DNA inserts. Ligation reaction mixtures were incubated over night at 4 °C before 
transformation into E. coli competent cells.  
Glycerol stocks 
10 mL LB containing appropriate antibiotic was inoculated with a single colony from freshly 
transformed sequence confirmed plasmids, and incubated at 37 °°C, 225 rpm for 20 hours. 
400 µL 60 % glycerol and 800 µL cell culture were mixed in an Eppendorf tube, and 
immediately frozen at -80 °C. 
Annealing of synthetic oligonucleotides 
Synthetic DNA oligonucleotides as described in Table 2-2 were ordered from Sigma-
Aldrich®, resuspended to 100 µM. The oligonucleotides were treated with T4 polynucleotide 
kinase (PNK) to add 5’ phosphate of the oligonucleotides, to increase ligation efficiency 
(Rittie and Perbal, 2008). The following reaction mixture was incubated in 37 °C for 30 
minutes. 
Forward oligo  7µL 
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Reverse oligo 7 µL 
T4 DNA ligase buffer 1.5 µL 
T4 Polynucleotide Kinase 0.85 µL 
T4 PNK was inactivated by incubation at 65 °C for 30 minutes, before the oligo mixes were 
annealed using an Eppendorf Mastercycler® with the “ANNEAL” program, showed in 
appendix Appendix A. 
Construction of bla 5’ coding sequence synonymous library, SII 
A new wild-type for the library containing the TCT 2nd codon, pBS2P1, was constructed by 
ligation of the annealed product of Bla.TCT.fwd and Bla.TCT.rev, shown in Table 2-2, into 
NdeI, NcoI digested pBSP1 backbone. The randomized oligonucleotide Bla-TC-5’spiked.fwd 
was annealed to its wild-type oligonucleotide Bla.TCT.rev, ligated into NdeI, NcoI digested 
pBS2P1and used to transform competent cells as described above. Transformants were plated 
on 15 cm L-agar plates, and in dilution series to count the number of clones. The library was 
harvested by adding 1 mL LB to the centre of the plates before homogenizing the colonies in 
the LB using a sterile rod. The cell medium was extracted from the plates with a pipette, and 
half the volume collected of 60 % glycerol was added before mixing. Five 1 mL samples were 
distributed in Cryo tubes for long time storage, and the remaining library was aliquoted in 
Eppendorf tubes, 500 µL each before freezing samples at -80 °C. All work was performed in 
a sterile fume hood, and samples were kept on ice at all times.  
Construction of a randomized library of 5’ celB69 based fusion partners 
A randomized library was designed in the celB69 sequence fused to the apramycin resistance 
reporter gene aac(3)-IV, encoding aminoglycoside-(3)-acetyltransferase IV resitance, to 
screen for mutants with higher tolerance of the antibiotic. The fp69-aac(3)-IV library was 
created by ligation into NdeI, NcoI digested pAR69 (Table 2-1) of the annealed insert of the 
oligos celB69-mut.Fwd and celB69-wt.Rev shown in Table 2-2. The annealed library was 
then used to transform competent cells as described above, and plated and harvested as 
described for the bla 5’ coding sequence synonymous library. 
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Screening libraries for increased antibiotic tolerance 
To search for mutants with increased antibiotic resistance created in the libraries, the libraries 
were screened in the following way. L-Agar plates (15 cm) were prepared with increasing 
concentration of the antibiotic in question, and the appropriate amount of inducer. Control 
plates were prepared without inducer for the bla library, and with only the resistance marker 
antibiotic for both. 500 µL library from -80 °C stock was inoculated in 500 mL LB with 
kanamycin, and incubated for 2 hours at 30 °C, 225 rpm. OD600 was measured to be between 
0.7 and 1.5, before 300 µL 1:1000 diluted culture was applied and distributed on the plates 
and incubated at 30 °C for 2 days. High growing colonies were picked and their plasmids 
were isolated, as described above, for further analysis. 
Replica plating to determine antibiotic concentration tolerance 
To determine tolerance levels of the antibiotic concentration from the screening candidates, 
plasmids isolated from the library screening were retransformed as described, and single 
colonies were inoculated in 100 µL LB with appropriate selection antibiotic in 96-well plates 
(Nunc) and incubated at 30 °C overnight. The cultures were diluted to approximately 1:10 
000 by twice transferring culture with a 96-pin replicator to 100 µL fresh LB with selection 
antibiotic in 96 well plates, before using the 96-pin replicator to apply the cells to agar plates 
with increasing concentrations of the screening antibiotic, with and without inducer. Plates 
were incubated at 30 °C for two days, the highest growths of the candidates were recorded 
and their gene variants were sequenced. 
Gene sequencing 
All gene sequencing was performed by Eurofins MWG Operon, using the PmUTR.fwd 
sequencing primer shown in Table 2-4. The primer targets the Pm promoter in all used 
plasmids, starting 97 base-pairs upstream of the translational start-site of the genes of interest.  
Cell culturing for enzyme assays and accumulated transcript evaluation 
Cells harboring plasmids containing the enzyme to be studied were inoculated in 10 mL LB + 
appropriate antibiotic in 125 mL Erlenmeyer flasks from fresh overnight streaks from glycerol 
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stock and grown overnight at 30 °C and 225 rpm. Cultures were inoculated from the overnight 
culture to a final OD of 0.05 in 20 mL LB + appropriate antibiotic, and incubated in a water 
bath at 30 °C, 225 rpm. Cultures were induced to the appropriate final concentration (0.05 
mM or 0.1 mM) with 200 mM m-Toluate at OD 0.1, and grown for 5 hours. 
Samples for enzyme assays were prepared harvesting 5 mL culture which was centrifuged at 
6 000 rpm for 10 minutes. The pellet was resuspended in assay buffer followed by another 
centrifugation before storing the pellet at -80 °C. Samples for mRNA studies were prepared 
by mixing 0.5 mL culture with 1.0 mL RNAprotect Cell Reagent from QUIAGEN followed 
by thorough vortexing and incubation for five minutes in room temperature. The samples 
were pelleted by centrifugation at 5000 rpm for 10 minutes at 4 °C, the supernatant was 
discarded and the pellets were frozen at -80 °C. 
Expression of recombinant proteins in low-scale 
Single colonies from overnight streaks from glycerol stocks were inoculated in 14 mL Hi+YE 
basic broth containing appropriate antibiotic in 250 mL baffled Erlenmeyer flasks and grown 
overnight at 30 °C, 225 rpm. OD600 was measured to inspect growth before adding 6mL 
Hi+YE broth containing appropriate antibiotics and m-Toluate to a final concentration of 0.5 
mM. Cultures were incubated at 30 °°C, 225 rpm for 3 hours before harvest as described 
below for SDS-PAGE and Western Blot. Transcript samples were also taken from the cultures 
using RNAprotect as described above. 
Preparation of cell extract by sonication  
Sonication lysis of cells utilizes the cavitations created by localized areas of high- and low 
pressure created by ultrasonic waves (Brown and Audet, 2008).  
Sonication of samples for enzyme assays was performed with the samples kept on ice, using 
the tapered microtip of a Branson Sonifier 250 for 3 minutes at 30 % duty control and output 
control 3 for 3 minutes. Samples for Western blots were sonicated 90 seconds at 90 second 
intervals five times.  
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β-lactamase assay 
Cell pellets were resuspended in 5 mL β-lactamase assay buffer, sonicated as described, and 
centrifuged for 20 minutes at 8 000 rpm and 4 °C. Samples were kept on ice and total protein 
concentration of the supernatant was determined using the Bradford method. Reaction 
kinetics of the supernatant was measured in 5 duplicates for each sample in a 96-well UV 
Transparent Nunc plate with the following reaction mixture: 
Sample supernatant 20 µL 
Bla assay buffer 170 µL 
Penicillin G stock solution (10 mg / mL assay buffer) 10 µL 
The penicillin was added before 30 seconds shaking at 200 rpm and immediately reading 
absorbance at 240 nm every 30 seconds for 15 minutes at room temperature. Expression 
values were calculated as the average of the duplicates’ slopes in the linear range of the 
penicillin degradation, divided by total protein concentration of the sample. 
Phosphoglucomutase assay 
Phosphoglucomutase (celB) activity was measured as the increase in NADPH concentration 
due to the increased availability of glucose-6-phosphate (G6P) substrate from glucose-1-
phosphate and glucose-1,6-bisphosphate (G1,6BP) conversion by phosphoglucomutase, 
following reactions (1) and (2) (Worthington, 2011). Reaction (2) is catalyzed by G6P 
dehydrogenase. 
G1P + celB-P  G1,6BP + celB  G6P + celBP (1) 
G6P + NADP+  6-Phosphoglucono-δ-lactone + NADPH + H+ (2) 
Master mix was made with the following recipe, volume denotes amount per well of reaction: 
Imidazole-HCl (0.1M, pH 7.4)  80 µL 
MgCl2 (0.1M) 10 µL 
NADP+ (6.2 mM; Sigma N0505) 16.1 µL 
G6P dehydrogenase (100 U/mL; Sigma G4134) 2µL 
Glucose-1,6-bisphosphate (1.0 mM; Sigma G7137) 1.6 µL 
Glucose-1-Phosphate (0.1 M; Sigma G7000) 4 µL 
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MQ-water 86.3 µL 
 
Cell pellets were resuspended in 5 mL phosphoglucomutase assay buffer, sonicated as 
described, and centrifuged for 60 minutes at 8 000 rpm and 4 °C. The supernatant was 
transferred to new tubes, kept on ice, and total protein concentration of the supernatant was 
determined using the Bradford method. Reaction kinetics of the supernatant was measured in 
5 duplicates for each sample in a 96-well Nunc plate, by adding 5 µL sample to 200 µL 
master mix, 30 seconds shaking at 900 rpm, and measuring absorbance at 340 nm every 30 
seconds in a [NEW SPECTROMACHINE]. Expression values were calculated as the average 
of the duplicates’ slopes in the linear range of the increase in, divided by total protein 
concentration of the sample. 
Alkaline phosphatase assay 
Cell pellets were resuspended in 5 mL alkaline phosphatase assay buffer, sonicated as 
described, and centrifuged for 60 minutes at 8 000 rpm and 4 °C. The supernatant was 
transferred to new tubes, kept on ice, and total protein concentration of the supernatant was 
determined using the Bradford method.  
Reaction kinetics of the supernatant was measured in 5 duplicates for each sample in a 96-
well Nunc plate. Stock substrate solution of 5 mg/mL p-Nitrophenyl phosphate was prepared 
and kept on ice covered by aluminium foil. 128 µL sample was added to each well and 
incubated for 10 minutes at 37 °C, before addition of 32 µL substrate stock solution to each 
well, mixing at 900 rpm for 30 seconds. Absorbance was measured at 405 nm every 12 
seconds for 20 minutes. Expression values were calculated as the average of the duplicates’ 
slopes in the linear range of the absorbance increase, divided by total protein concentration of 
the sample. 
Bio-Rad Bradford assay 
Coomassie Brilliant Blue G250 exists in a red- and a blue color conformation. When it binds 
to protein, the red form is converted to the blue form, with an absorption maximum at 595 nm 
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(Bradford, 1976). The increase in absorbance is linear between 0.05 mg/mL and 0.5 mg/mL 
protein when using the Bio Rad Protein Assay reagent (Laboratories). 
The Bio Rad Protein Assay reagent was diluted 1:5 in MQ-water, and a standard curve of 0.1, 
0.2, 0.3, 0.4 and 0.5 mg/mL BSA was prepared for each Bio Rad dilution made.  
Samples were diluted until absorbance at 595 after reaction was within the linear range of the 
standard curve (usually 0.6 - 1.1), and measured in five duplicates by adding 10 µL diluted 
sample to each well of a 96-well Nunc plate before addition of 200 µL Bio Rad Protein Assay 
reagent. The plated were incubated for five minutes in room temperature before shaking at 
900 rpm for 30 seconds, and the absorbance was measured at 595 nm. 
RNA isolation and cDNA preparation 
RNAprotect treated cell pellets were resuspended in 100 µL TE buffer with lysozyme and 
RNA was extracted using the RNAqueous® Kit from Ambion according to its manual, with 
the exceptions of using 600 µL wash solution 1, and eluting in 2 x 50 µL elution buffer. 
RNA concentration was measured using a NanoDrop 1000 (Thermo Scientific), and DNA 
contamination was removed using the TURBO DNA-free™ Kit, according to its manual. 
cDNA was prepared from the samples using the First-Strand cDNA Synthesis Kit with the 
following reaction mixtures: 
Bulk first-strand cDNA reaction mix 2.5 µL 
DTT solution 0.5 µL 
Pd(N)6 0.5 µL 
RNA sample 4 µL 
Samples were incubated at 37 °C for 60 minutes, and kept at -20 °C. 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
SYBR® Green is a fluorescent dye that emits substantially more fluorescence when bound to 
double stranded DNA (Wong and Medrano, 2005). Thus, the more dsDNA in the solution, the 
more fluorescence. DNA is duplicated in an exponential manner in the exponential phase of 
PCR (Mullis et al., 1986), and SYBR® Green is used to quantify the starting amount of a 
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specific DNA molecule during qRT-PCR (Mullis et al., 1986; Wong and Medrano, 2005). 
The PCR cycle, or point in time, at which the fluorescence from the sample is higher than the 
background fluorescence is called the cycle threshold value (CT), and is used in calculations. 
In relative quantitation of mRNA transcript cDNA, primers specific for the gene in question 
are used, and the sample gene expression is measured compared to an internal reference here 
16S RNA. The relative expression is calculated in this study using the comparative CT method 
(2-∆∆Ct) (Livak and Schmittgen, 2001).  
Primers for the different genes of interest are shown in table 2.1, and were diluted to 2 
mg/mL before the reaction. cDNA samples for endogenous control (16S) were diluted 1:400 
and target cDNA was diluted 1:100. qRT-PCR strips were used, and the reaction mixture for 
each well was as follows: 
Power SYBR® Green master mix 12.5 µL 
Forward primer 2.5 µL 
Reverse primer 2.5 µL 
MQ-water 2.5 µL 
cDNA sample 5 µL 
Each sample was made in triplicates and a non-template control was included to exclude 
contamination. The strips were capped and spun down shortly before qRT-PCR was 
performed in an Applied Biosystems 7500 Real Time PCR sytem with the standard settings. 
CT values were recorded and relative gene expression was calculated using the comparative 
CT method. 
SDS-PAGE and Western Blot 
Proteins in solution may be separated based on their molecular weight using sodium-dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), where proteins are denatured with 
DTT and treated with SDS to get a negative uniform charge to mass ratio (Weber and Osborn, 
1969). Smaller weight proteins wander farther due to lower resistance from the gel matrix, 
and the proteins in the gel may be electrophoretically transferred to a nitrocellulose membrane 
for further analysis after separation (Towbin et al., 1979). This blotting is referred to as a 
Western blot. (Burnette, 1981), and allows the detection and quantification of specific 
proteins using antibodies against the protein itself, or against a protein fusion tag. For such 
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immunoblots, the nitrocellulose membrane is blocked by incubation in protein rich solutions 
to avoid unspecific binding of the antibody (Towbin et al., 1979), before incubation with the 
antibody against the protein- or tag of interest.  
In direct detection systems, such as the HisProbe-HRP (Thermo Fisher Scientific #15165) 
where a his-tag antibody is fused to horseraddish peroxidase (HRP), the probe binds to the 
protein of interest and may be directly detected. In indirect systems the primary antibody is 
bound to the protein of interest on the membrane, followed by a detection by a secondary 
antibody, with affinity for the primary and is fused to for example HRP. The Pierce ECL 
Western Blotting Substrate (Thermo Fisher Scientific #32209) allows chemiluminescent 
detection of HRP from the luminescence emitted at 425nm by cleavage of luminol in the 
substrate (Bhandari et al., 2010). 
Procedure: 
E. coli containing plasmids with β-lactamase were cultured as described for enzyme assays, 
and cells containing IFN-α2b constructs were cultured following the described Protein 
Expression in low-scale cultivation. The cultures were pelleted at 6000 rpm for five minutes 
at 4 °C (Eppendorf 5810R centrifuge) and the pellets were thoroughly resuspended in 1 mL 
0.9 % NaCl per 100 mg pellet. 1 mL cell suspension was transferred to Eppendorf tubes 
before centrifugation at 13 000 rpm for three minutes and removal of supernatant. The pellets 
were kept at -80 °C overnight. 
Pellets were resuspended in 500 µL 1x SDS running buffer, and sonicated as described above 
and total protein concentration of the cell lysate was determined by Bio-Rad Bradford protein 
assay. 50 µL cell lysate was combined with 25 µL 3x sample buffer in Eppendorf tubes, and 
boiled at 95 °C for five minutes before being stored in -20 °C. SDS-PAGE was performed 
using precast ClearPAGE™ SDS-gels (C.B.S. Scientific), 12 % for  β-lactamase and 16 % for 
IFN-α2b and the Dual Cool Electrophoresis System (DCX-700, C.B.S. Scientific). Precision 
Plus Protein Dual Color (Bio-Rad) was used as a standard, and the gels were run with 150V 
for at least 90 minutes, or overnight at 35V until proper separation had been achieved. 
The plastic casing around the gel was removed and gels were rinsed with MQ-water. The 
sponge, filter paper and gel were incubated in blotting buffer for approximately 30 minutes. 
Immobilon™ PVDF Transfer Membrane (Millipore) was incubated in methanol for 15 
seconds, MQ-water for two minutes, and blotting buffer for 10 minutes, before assembly of 
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the Western cassette as described in the Dual Cool Electrophoresis System manual. The 
blotting was run at 100V for 1.5 - 3 hours before incubation in TBS for 5 minutes with gentle 
agitation. Blocking was performed by incubation in blotto buffer for 60 minutes with gentle 
agitation before washing 3 times with TBST incubation for 10 minutes, and once with TBS 
for 2 minutes with gentle agitation.  
For β-lactamase, the membrane was incubated overnight at 4 °C with Anti-Beta Lactamase 
antibody (Abcam, ab12251) diluted 1:5000 in blotto buffer with gentle agitation before 
washing 3 times with TBST incubation for 10 minutes, and once with TBS for 2 minutes with 
gentle agitation. The membrane was then incubated with Polyclonal Rabbit Anti-Mouse 
Ig/HRP (Dako, P 0260) in blotto buffer for 1 hour, before repeating the washing steps. For 
IFN-α2b, the membrane was incubated in HISprobe-HRP (1:12500 in blotto), for 60 minutes 
with gentle agitation before repeating the washing steps.  
Chemiluminescent detection was performed by incubating the membrane in a mix of 5 mL 
solution A, and 5 mL solution B of the Pierce ECL Western Blotting Substrate for 1 minute, 
before reading chemiluminescence with a Chemi Doc™ XR+ Imager (Bio-Rad) every 30 
seconds for 15 minutes. 
Study of mRNA decay by inducer wash-out method 
m-Toluate, a commonly used inducer for the XylS/Pm system, is a small organic compound 
that has been shown to freely and rapidly diffuse in over the cell membrane of E. coli 
(Kucharova, unpublished). High-performance liquid chromatography showed no m-toluate 
present in cell extracts following filtration from induced culture and resuspension in fresh 
medium (Kucharova, unpublished), thus ending the inducer signal. By sampling RNA as 
described earlier from the resuspended cell culture at time intervals, the decay of transcript 
could be followed by plotting the relative amounts obtained by the comparative CT method. 
Analysis of transcript from the KmR gene of the plasmid vector used showed that only mRNA 
transcribed from the Pm promoter was affected by the inducer wash-out (Kucharova, 
unpublished). 
To analyse the decay of transcript, freshly streaked cells inoculated in 20 mL LB containing 
appropriate antibiotic were grown over-night in 125 mL Erlenmeyer flasks at 30 °C, 225 rpm. 
Cultures were inoculated to OD 0.05 in 20 mL LB containing appropriate antibiotic in 250 
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mL baffled Erlenmeyer flasks and incubated in a water bath at 30 °C, 225 rpm, before 
induction to 0.5 mM m-Toluate at OD 0.5. Cells were grown for 90 minutes to reach steady-
state levels of transcript (Berg et al., 2009), before harvesting 5 mL culture by vacuum 
filtration with  0.2 µm pore size filters, washing of the filter with 10 mL PBS, and 
resuspension of the filter in 10 mL prewarmed LB without inducer in a 250 mL baffled 
Erlenmeyer flask. The cultures were kept at 30 °C, 225 rpm in a water bath and culture 
samples for RNA isolation were taken as described, at 0, 2, 4, 6, 8 and 10 minutes after 
resuspension of the cells. Transcript amounts were measured by qRT-PCR and calculated 
relative to the 0 minute sample following the comparative CT method (Livak and Schmittgen, 
2001). 
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2.3 Bacterial Strains, Plasmids and Oligonucleotides  
2.3.1 Bacterial Strains and Plasmids 
The E. coli strain and plasmid constructs used in this study are described in Table 2-1, 
selected plasmid maps are shown in chapter 2.3.3.  
Table 2-1: Bacterial strains and plasmids 
Strain or plasmid Description 
Source or 
reference 
Strain   
Escherichia coli 
DH5α 
General cloning strain, genotype: F-., end, hsdR17, (rk-, mk+), supE44, thi-
1, λ-, recA1, gyrA96, relA1, ϕ80dlacZ∆M15. 
(Bethesda, 
1986) 
Plasmids   
Bla plasmids   
pBSP1 RK2-based expression vector containing bla, with its wild type signal 
sequence (AGT 2nd codon), as reporter gene under control of XylS/Pm 
system; rrnBT1T2; tlPP; hok/sok; M13 ori; t; Pneo; trfA; oriV; oriT;  
Kmr; 9.5kb. 
(Kucharova, 
unpublished) 
pBSP1-X pBSP1 derivatives; X denotes bla 2nd codon synonymous mutations 
(TCT, AGC, TCC, TCA, TCG), or bla signal sequence synonymous 
mutations (C19, C20) inserted using inserts from annealed 
oligonucleotides shown in Table 2-2; Kmr, 9.5kb. 
This study 
pMS2 pBSP1 derivative containing the following synonymous codon mutations 
in bla signal sequence; 2nd: AGTTCT, 7th: CGTCGC; Kmr, 9.5kb 
(Kucharova, 
unpublished) 
pMS3 pBSP1 derivative containing the following synonymous codon mutations 
in bla signal sequence; 2nd: AGTTCT, 9th: GCCGCT; Kmr, 9.5kb 
(Kucharova, 
unpublished) 
pMS4 pBSP1 derivative containing the following synonymous codon mutations 
in bla signal sequence; 2nd: AGTTCT, 9th: GCCGCT, 18th: 
TGCTGT; Kmr, 9.5kb 
(Kucharova, 
unpublished) 
pCSP1 pBSP1 derivative with CSP signal peptide (Sletta et al., 2004) substituted 
for bla’s signal peptide; Kmr, 9.5kb 
(Kucharova, 
unpublished) 
pTMB17 pBSP1 derivative with deletion of bla’s signal peptide; Kmr, 9.5kb (Kucharova, 
unpublished) 
celB plasmids   
pLB11 RK2-based expression vector containing celB as reporter gene under 
control of XylS/Pm system; rrnBT1T2; tlPP; hok/sok; t; Pneo; trfA; oriV; 
oriT;  Kmr; 9.0kb. 
(Lale et al., 
2011) 
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Strain or plasmid Description 
Source or 
reference 
pLB11-X pLB11 derivatives; X denotes celB 2nd codon mutations (CCT, CCA, 
CCG) from inserting annealed synthetic oligonucleotides listed in Table 
2-2; Kmr; 9.0kb 
This study 
phoA plasmids   
pASP1 RK2-based expression vector containing phoA as reporter gene under 
control of XylS/Pm system; rrnBT1T2; tlPP; hok/sok; M13 ori; t; Pneo; 
trfA; oriV; oriT;  Kmr; 10.0kb. 
(Kucharova, 
unpublished) 
pASP1-AAG pASP1 derivative; phoA second codon mutated to its synonymous mutant 
AAG by inserting annealed synthetic oligonucleotide listed in Table 2-2; 
Kmr; 10.0kb. 
This study 
pCSP1phoA pCSP1 derivative where the NcoI - BstAPI fragment encoding the bla 
reporter gene was replaced by a PCR-fragment encoding the mature 
phoA gene. KmR; 10.0kb. 
(Kucharova, 
unpublished) 
aprR plasmids   
pAR69 RK2-based expression vector containing aac(3)-IV with the 69 first 
nucleotides of celB as a 5’ fusion partner as the reporter gene under 
control of XylS/Pm system; rrnBT1T2; tlPP; hok/sok; Pneo; trfA; t; oriV; 
oriT;  Kmr; 8.2kb. 
(Kucharova, 
unpublished) 
pAR69-D11 pAR69 derivative with celB69 sequence exchanged by mutated celB69-
D11 annealed synthetic oligonucleotides listed in Table 2-2; Kmr, 8.2kb. 
This study 
IFN-α2b plasmids   
pAT63 RK2-based expression vector containing the codon optimized  version of 
ifn-α2b under control of XylS/Pm system, with a c-myc-his6 affinity tag; 
rrnBT1T2; tlPP; hok/sok; M13 ori; t; Pneo; trfAcop271C; oriV; oriT;  
Ampr; 8.8kb. (Published as pIFN30S) 
(Sletta et al., 
2007) 
pAT64 pAT63 derivative with a 5’ pelB signal peptide fusion to ifn-α2b; Ampr; 
his6; 8.9kb. (Published as pIFN30SpelB) 
(Sletta et al., 
2007) 
pIN69 pAT64 derivative with pelB exchanged by the first 69 nucleotides of celB 
as a 5’ fusion partner to ifn-α2b; ; Ampr; his6; 8.9kb. 
(Kucharova, 
unpublished) 
pIN69-D11 pIN69 derivative with celB69 sequence exchanged by mutated celB69-
D11 annealed synthetic oligonucleotides listed in Table 2-2; Ampr; his6; 
8.9kb. 
This study 
 
2.3.2 Synthetic Oligonucleotides, qRT-PCR- and Sequencing Primers  
The synthetic DNA insert oligonucleotides shown in Table 2-2 were used for cassette 
exchange cloning to create variants of the bla, phoA, and celB genes. Oligonucleotides were 
Table 2-1: Continued 
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designed using Clone Manager Suite (Sci-Ed Software), and the corresponding forward and 
reverse primers were annealed as described above before ligation. The randomized oligos 
were designed by Veronika Kucharova, and Their doping percentages are shown in Table 
2-3. Primers used for sequencing or qRT-PCR are listed in Table 2-4. 
Table 2-2: Oligonucleotides used to construct synthetic DNA inserts. Numbers in sequences 
correspond to base doping percentages shown in Table 2-3. 
Name  Sequence (5’ to 3’ direction) 
Length 
(bp) Tm (°C) 
Restriction 
enzymes 
Manu-
facturer 
Bla oligos      
Bla-TC-
5’spiked 
TATGTC1AT2CA3CA4TT5CG1GT6GC6C
T1AT2CC6TT4TT4GC7GC8TT4TG5CT1
CC1GT1TT5GC 
69 - NdeI, NcoI Eurogentec 
Bla.wt.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAA
TGTTGAATACTCA 
71 82 NdeI, NcoI Sigma-
Aldrich 
Bla.TCT.fwd TATGTCTATTCAACATTTCCGTGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 90.7 NdeI, NcoI Sigma-
Aldrich 
Bla.TCT.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAA
TGTTGAATAGACA 
71 92.7 NdeI, NcoI Sigma-
Aldrich 
Bla.AGC.fwd TATGAGCATTCAACATTTCCGTGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 91.3 NdeI, NcoI Sigma-
Aldrich 
Bla.AGC.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAA
TGTTGAATGCTCA 
71 93.2 NdeI, NcoI Sigma-
Aldrich 
Bla.TCC.fwd TATGTCCATTCAACATTTCCGTGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 91.3 NdeI, NcoI Sigma-
Aldrich 
Bla.TCC.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAA
TGTTGAATGGACA 
71 93.2 NdeI, NcoI Sigma-
Aldrich 
Bla.TCA.fwd TATGTCAATTCAACATTTCCGTGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 90.7 NdeI, NcoI Sigma-
Aldrich 
Bla.TCA.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAA
TGTTGAAT TGACA 
71 92.7 NdeI, NcoI Sigma-
Aldrich 
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Name  Sequence (5’ to 3’ direction) 
Length 
(bp) Tm (°C) 
Restriction 
enzymes 
Manu-
facturer 
Bla.TCG.fwd TATGTCGATTCAACATTTCCGTGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 91.3 NdeI, NcoI Sigma-
Aldrich 
Bla.TCG.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAA
TGTTGAATCGACA 
71 93.2 NdeI, NcoI Sigma-
Aldrich 
Bla.C19.fwd TATGTCTATTCAACATTTCCGTGTTGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 90.4 NdeI, NcoI Sigma-
Aldrich 
Bla.C19.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCAACACGGAAA
TGTTGAATAGACA 
71 92.3 NdeI, NcoI Sigma-
Aldrich 
Bla.C20.fwd TATGTCAATTCAACATTTCCGAGTCGCCC
TTATTCCCTTTTTTGCGGCATTTTGCCTT
CCTGTTTTCGC 
69 90.4 NdeI, NcoI Sigma-
Aldrich 
Bla.C20.rev CATGGCGAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACTCGGAAA
TGTTGAATTGACA 
71 92.3 NdeI, NcoI Sigma-
Aldrich 
PhoA oligos      
phoA-
AAG.fwd 
TATGAAGCAAAGCACTATTGCACTGGCAC
TCTTACCGTTACTGTTTACCCCTGTGACA
AAAGC 
63 85.9 NdeI, NcoI Sigma-
Aldrich 
phoA-
AAG.rev 
CATGGCTTTTGTCACAGGGGTAAACAGTA
ACGGTAAGAGTGCCAGTGCAATAGTGCTT
TGCTTCA 
65 88.3 NdeI, NcoI Sigma-
Aldrich 
CelB oligos      
celB-
CCT.fwd 
TATGCCTAGCATAAGCCCATTTGCCGGCA
AGCCGGTCGATCCG 
44 91.8 NdeI, RsrII Sigma-
Aldrich 
celB-CCT.rev GTCCGGATCGACCGGCTTGCCGGCAAATG
GGCTTATGCTAGGCA 
43 89.6 NdeI, RsrII Sigma-
Aldrich 
celB-
CCA.fwd 
TATGCCAAGCATAAGCCCATTTGCCGGCA
AGCCGGTCGATCCG 
44 93.2 NdeI, RsrII Sigma-
Aldrich 
celB-CCA.rev GTCCGGATCGACCGGCTTGCCGGCAAATG
GGCTTATGCTTGGCA 
43 91.1 NdeI, RsrII Sigma-
Aldrich 
celB-
CCG.fwd 
TATGCCGAGCATAAGCCCATTTGCCGGCA
AGCCGGTCGATCCG 
44 94.1 NdeI, RsrII Sigma-
Aldrich 
celB-CCG.rev GTCCGGATCGACCGGCTTGCCGGCAAATG
GGCTTATGCTCGGCA 
43 92.0 NdeI, RsrII Sigma-
Aldrich 
Table 2-2: Continued 
50 
Name  Sequence (5’ to 3’ direction) 
Length 
(bp) Tm (°C) 
Restriction 
enzymes 
Manu-
facturer 
celB69-
mut.Fwd 
TATG6668768188766681117667768
87667716781667786671611716881
8167867666177CG 
73 - NdeI, NcoI Eurogentech 
celB69-
wt.Rev 
CATGGCCAGGGCGTCGATATTGACAAGAC
GGTCCGGATCGACCGGCTTGCCGGCAAAT
GGGCTTATGCTGGGCA 
74 X NdeI, NcoI Sigma-
Aldrich 
celB69-
D11.fwd 
TATGTCTAGCATAAACCCATTTACCGGCA
AGCCGGTCGTTCCGGACTGTCTTTTCAAT
ACCGACGCCCTGGC 
73 X NdeI, NcoI Sigma-
Aldrich 
celB69-
D11.rev 
CATGGCCAGGGCGTCGGTATTGAAAAGAC
AGTCCGGAACGACCGGCTTGCCGGTAAAT
GGGTTTATGCTAGACA 
74 X NdeI, NcoI Sigma-
Aldrich 
 
Table 2-3: Base composition in synthetic oligo mixtures from Sigma-Aldrich. Percent 
denotes probability of the given base being incorporated at a given position. 
Mix no: Base composition 
1 79% T, 7% A, 7% G, and 7% C  
2 80% T, 10% A and 10% C 
3  80% A and 20% G 
4 80% T and 20% C  
5 80% C and 20% T 
6 79 % C, 7 % A, 7 % T, and 7 % G 
7 79 % G, 7 % A, 7 % T, and 7 % C 
8 79 % A, 7 % T, 7 % G, and 7 % C 
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Table 2-4: Primers used for and sequencing and qRT-PCR. qRT-PCR primers were designed 
using the Primer Express software (Applied Biosystems), and the sequencing primer were 
designed using Clone Manager Suite (Sci-Ed Software) 
Name DNA Sequence (5’ to 3’) Target gene 
Sequencing primer   
PmUTR.fwd AAGAAGCGGATACAGGAGTG Pm promoter, 97 bp 
upstream of ATG 
qRT-PCR primers   
bla.fwd ACGTTTTCCAATGATGAGCACTT β-lactamase 
bla.rev TGCCCGGCGTCAACAC β-lactamase 
RT-celB.Fwd ACCAGCTTCAATGAAAACCACA celB 
RT-celB.Rev CGCCCTTGCGGTAATCG celB 
phoA-73F GCACCAGAAATGCCTGTTCTG phoA 
phoA-134R CCGCCGGGTGCAGTAA phoA 
APR69-11F CAGCGGTGGAGTGCAATG aac(3)-IV 
APR69-79R GGTTGAGAAGCTGACCGATGA aac(3)-IV 
ifna2b324.fwd CGAGACCCCGCTGATGAA Ifn-α2b,celB69-ifn-
α2b 
ifna2b396.rev CAGATACAGGGTGATACGCTGAAA Ifn-α2b,celB69-ifn-
α2b 
 
2.3.3 Plasmid Maps 
Plasmids described in Table 2-1 are shown below. Plasmid maps were created using Clone 
Manager Suite (Sci-Ed Software), and edited using Inkscape (www.inkscape.org). 
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Figure 2-1: Map of pBSP1-X plasmids; X ss denotes the inserted signal sequence variant: 
wild-type, synonymous second codon mutations, or candidates identified from screening of 
randomized library; bla: β-lactamase. Oligos used for ligation of inserts are shown in Table 
2-2. Elements of the plasmids are described in section 1.2.4.  
 
Figure 2-2: Map of pLB11-X plasmids; X denotes the 2nd codon of the inserted 5’ coding 
sequence between NdeI and RsrII; celB: gene encoding phosphoglucomutase. Elements of the 
plasmids are described in section 1.2.4. 
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Figure 2-3: Map of pVK8 plasmid; phoA: gene encoding alkaline phosphatase (AP). The AP 
signal sequence (AP ss) was exchanged with annealed oligos described in Table 2-2 to give 
the pVK8-AAG construct containing the 2nd codon synonymous mutation AAAAAG. 
Elements of the plasmid are described in section 1.2.4. 
 
Figure 2-4: Map of pAR69 plasmid; aprr: aac(3)-IV gene encoding 3-N-Acetyltransferase, 
giving apramycin resistance; celB69; gene fusion of first 69 nucleotides of celB DNA. The 
randomized celb69-aac(3)-IV library was created by exchanging the celB69 gene fusion with 
celB69-mut.Fwd annealed to celB69.Rev, described in Table 2-2. 
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2.4 Bioinformatics Tools 
Clone Manager Suite 
Clone Manager Suite (Sci-Ed Software) allows the management and of DNA and amino acid 
sequences in silico. In this study it was used for planning of cloning, sequence analysis, 
sequence alignment and the generation of plasmid maps. 
EMBOSS CAI web application 
The open source software package ”European Molecular Biology Open Software Suite” 
(EMBOSS) consists of over 100 molecular biology and bioinformatics applications (Rice et 
al., 2000). Its codon adaptation index tool gives the option of reference codon tables from a 
variety of organisms, and is freely available as a web application at http://services.cbib.u-
bordeaux2.fr/pise/cai.html. The application was used to analyze the CAI of the 5’ end of 
various transcripts in this study.  
Python tAI Calculator 
As no program for calculating the tRNA adaptation index of a sequence was freely available 
in a programming language known to the author, a script for calculating the tAI was written in 
Python 2.7 (Van Rossum, 2012). The script may be run in the Python distribution’s shell, 
IDLE, and allows the pasting of DNA sequences in caps (A, T, G, C) containing whitespace, 
that are dividable by 3. The tAI data is retrieved from a comma-separated file, tAI.csv, with E. 
coli tAI values for the individual codons obtained from (Tuller et al., 2010). The geometric 
mean is taken from the input sequence’s scores, and displayed. A comma-separated output 
file, output.csv, is created/overwritten for each run with the individual tAI values for all 
codons analyzed. The code of the tAI.py script and the tAI.csv contents is showed in appendix 
Appendix D. The script and the E. coli tAI table are included in the attached .zip-file, and are 
also freely available at http://folk.ntnu.no/adrianer/tAIcalculator/.  
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RBS calculator 
The RBS calculator combines thermodynamic data from the major molecular interactions of 
translation initiation with an optimization algorithm to be to predict an RBS with a target 
translation initiation rate for a given gene (Salis et al., 2009). The model analyzes the UTR 
and the 5’ sequence of the gene by calculating the attractive forces to the 16S rRNA, and its 
repulsion by mRNA secondary structures. The program also features a reverse engineering 
mode, where potential start-codons in an mRNA transcript may be analyzed for their 
translation initiation rate based on their putative RBS. This feature has been shown to give 
rates proportional to protein expression, and was used in this study to analyse various 
transcripts for their translation initiation efficiencies. The tool is freely available online at 
https://salis.psu.edu/software/forward.  
Quikfold  
The Quikfold server is part of the Mfold web server, which provides a range of DNA and 
RNA sequence structure prediction tools of varying complexity, all based on the minimum 
free energy for the folding of the input sequence (Zuker, 2003). Quikfold has a simple user 
interface and allows the prediction of several structures at once. It allows DNA or RNA 
folding and allows variation of, for example the maximum distance between paired bases. It 
returns a table of the smallest minimal free energies for given sequences, and provides models 
of the structures in pdf format. In this study, the RNA 3.0 folding energies and a maximum 
distance of 30 bases were used to analyze local secondary structures forming in the nascent 
transcript before the ribosome is able to bind. The tool is freely available online at 
http://mfold.rna.albany.edu/?q=DINAMelt/Quickfold.  
Minitab® 
Minitab® is a statistical analysis software distribution, used in this study under NTNU’s license to 
calculate Pearson’s correlations between gene expression and variations in features that might affect 
expression. The Pearson correlation reflects the degree to which two variables are related, ranging from 
+1 to -1, indicating a perfect positive or negative linear relationship, respectively (Rodgers and 
Nicewander, 1988). A correlation close to 0 means no correlation. Minitab also gives a P-value 
for the correlation, which denotes the probability of finding the given result if the correlation was 
0, and a value of P<0.05 was chosen as the cut-off for statistical significance in this study.  
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3 Results 
This study aimed to examine the effect of changes to the 5’ coding sequence of recombinant 
mRNAs for efficient protein expression from pJBn derived expression vectors. The 
development of a tAI calculation tool used in the study is briefly described in chapter 3.1, 
followed by a description of the generation and characterization of a synonymous library in 
the 5’ bla coding sequence in chapter 3.2. A finding that a different synonymous 2nd codon of 
bla had a profound influence on its expression is further explored by analysis of alternative 
2nd codons of bla and two additional reporter genes in chapter 3.3. Lastly, the generation of a 
completely randomized library of a 5’-terminal celB gene fragment fused to the aac(3)-IV 
gene encoding apramycin resistance, and its screening for increased expression is described in 
chapter 3.4, along with the investigation of an identified celB-based fusion partner candidate’s 
effect on the expression of a poorly expressed human protein.  
3.1 Development of a tAI Calculation Tool 
In the process of analyzing the sequences in this study in silico, a program for the calculation 
of the tRNA adaptation index (tAI) of a DNA sequence was developed in Python, as no tool 
to calculate the tAI of genes were available in a language known to the author. The script 
implements the tAI algorithm (Tuller et al., 2010) and obtains tAI data from a separate file, 
allowing the calculation of tAIs of other organisms by exchanging the data file. The program 
is relatively user-friendly, as it allows pasting of DNA sequences for analysis in a text based 
user-interface, and returns the given sequence’s tAI. The tool is described in chapter 2.4, and 
its code is presented in Appendix D. 
3.2 Selection for Optimized 5’ Coding Sequences of the bla Gene 
by Directed Evolution 
In previous work the effect of synonymous mutations of the 5’ coding region of bla mRNA 
on its protein expression was investigated by the creation of a combinatorial mutagenesis 
synonymous codon library in the 69 nucleotide bla signal sequence (Kucharova, 
unpublished). As previously described, alterations in expression of the bla gene may be 
identified by screening the ampicillin tolerance of the host-cells, and mutants growing at 
increased ampicillin concentrations have higher expression. Several up-mutants were 
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identified from screening the library, and most of the highest growing ones (up to eight-fold 
higher than wild-type at 0.05 mM inducer) contained the 2nd codon mutation AGTTCT on 
the DNA level, which in itself conferred an increase in resistance from 0.2 g/L to 1.0 g/L 
ampicillin. 
3.2.1 Directed Evolution of the bla 5’ Coding Sequence by Synonymous Mutations 
To further increase the expression of the protein by synonymous mutations of the bla signal 
sequence, a directed evolution approach was applied in the design of a second library where 
the stimulating 2nd codon change was kept. A new wild-type expression vector for the library 
containing the TCT 2nd codon in the bla coding sequence, pBS2P1, was constructed by 
annealing and ligation of synthetic oligonucleotides, and the library was created in the vector 
as described in chapter 2.2 . By transformation of E. coli DH5α, approximately 140 000 
clones were obtained as the SII library.  
The SII library was screened on a gradient of ampicillin concentrations from 0 to 6 g/L 
ampicillin supplemented with 0.5 mM inducer, as described in 2.2. The previously made SI 
library was also screened for comparison, and the survival rates of the E. coli DH5α host cells 
were determined. The SII library gave colonies growing up to 5.5 g/L ampicillin, while SI 
colonies were found to grow up to 2 g/L.  The maximum growth of cells containing pBSP1 
was 0.26 g/L. Survival frequencies from SI, SII, and pBSP1 wild-type are shown in Figure 
3-1. 
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Figure 3-1: The SI and SII libraries were plated on solid LA with increasing ampicillin 
concentration at 0.05 mM m-Toluate induction, and the E. coli host cell’s survival frequencies 
were determined as % survival at given concentrations compared to the growth on solid media 
containing only kanamycin. pBSP1 wild type’s survival frequency had been previously 
determined (Kucharova, unpublished). Survival frequency is given as log10 of the % survival 
at the given ampicillin concentration. Data is shown in Appendix D. 
Given the semi conservative mechanism of DNA-replication in E. coli (Meselson and Stahl, 
1958), approximately 50 % of all the clones in the SII library should harbor the wild-type 
signal sequence, as the non-coding strands of the ligated inserts were designed to be 
complementary to the pBS2P1bla signal sequence. To initially characterize the library, 12 
individual colonies from the kanamycin plate from the SII library screening were randomly 
picked for sequencing. These showed that 9 out of 12 contained the wild type TCT signal 
sequence (alignment shown in Table C-1). Surprisingly, two of the three remaining mutants 
contained in-frame stop-codons as well as amino acid substitutions, and the third contained 
one amino-acid mutation. 
Further characterization of the library was continued by plasmid isolation from 72 selected 
single colony E. coli host candidates, inoculated from different ampicillin concentrations 
between 1.2-5.5 g/L. The isolated plasmids were used to transform new E. coli DH5α cells for 
replica plating, described in chapter 2.2. This was done to confirm that the increased 
resistances did indeed arise from the synonymous mutations in the signal sequence, and not 
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from mutations in the chromosome of the host cells. Thirty-six of the retransformed 
candidates were found to grow on higher ampicillin concentration than cells harboring 
pBS2P1, and subsequently their signal sequences were sequenced as described in chapter 2.2. 
Three of these candidates, termed C19, C20 and C22, were shown to only have synonymous 
mutations in the bla signal sequence, and C22 was found to be identical to MS3, a mutant 
identified in the SI library (Table 3-1). Three candidates harbored the wild-type pBS2P1 bla 
signal sequence, and 30 had deletions or non-synonymous mutations in the signal sequence. 
The C19 and C20 bla signal sequence variants were commercially synthesized and cloned 
into pBS2P1 to exclude plasmid mutations. The new constructs were confirmed by sequencing 
and used for further characterization by sequence analysis and expression experiments, as 
described below. 
3.2.2 Sequence and Expression Analysis of Optimized 5’ bla Synonymous Variants 
The C19, C20 and C22 bla sequence variants, along with the best performing TCT second 
codon mutants from the SI library, MS2 and MS4, were initially characterized by replica 
plating and sequence analysis. The DNA sequence of their signal peptides is shown in Table 
3-1, along with analysis data. All the mutations shown in the table are synonymous, and no 
other mutations were detected upstream or downstream of the displayed sequence. As there 
were no mutations downstream of codon 18 in any of the candidates, the sequence from the 
start codon up to codon 18 was used for calculation of tAI, CAI and translation initiation rate 
(T.I.R.) prediction, using the tools described in chapter 2.4. The T.I.R. was predicted 
including the UTR of the Pm promoter (appendix Appendix B) (Berg et al., 2009). The 
ampicillin tolerance values of the E. coli host cells were determined by replica plating in two 
biological occurrences at 0.05 mM inducer. 
All analyzed bla signal sequence variants conferred higher ampicillin resistance than pBS2P1, 
however none of the SII candidates were found to give resistance values exceeding those of 
the candidates already obtained in the SI library. The average number of point mutations in 
the shown SII library candidates was 1.33, compared to 3.33 for the analyzed SI library 
candidates. One of the variants obtained from the SII library had TCA as the second codon, 
and showed only a 0.05 g/L improvement in ampicillin tolerance over pBS2P1. A trend was 
observed in the variants with mutations additional to the TCT 2nd codon in candidates from 
both libraries, where codons with low tAI had been inserted in the signal sequence, lowering 
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the total tAI of the analyzed sequence. The codon adaptation index (CAI) showed no 
correlation to increased ampicillin tolerance, and neither did the predicted translation 
initiation rate or the AT content of the bla signal sequences (not shown).  
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Table 3-1: bla signal sequence from selected SI and SII library candidates, along with ampicillin tolerance of the E. coli DH5α host cells and 
sequence analysis data. Candidates above the line were isolated in the SII library, MS2 and MS4 were only isolated in the SI library. 
 DNA Sequence of the first 18 codons of the bla signal sequence 
Ampicillin tolerance 
(g/L) 1 
Induced 
Un-
induced 
 
CAI2 tAI2 
Codon change on DNA 
level (tAI) T.I.R.3 
pBSP1 ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTCGCC 0.20 0.020 0.600 0.165 - 2207 
pBS2P1 ...TC................................................................ 1.00 0.020 0.625 0.171 
(AGTTCT) 
(0.0548750.10975) 2207 
C19 ...TC..................T............................................. 1.65 0.020 0.646 0.164 GTCGTT (0.250.10975) 2207 
C20  ...TCA..............A................................................ 1.05 0.010 0.542 0.103 
TCTTCA 
(0.109750.125) 
CGTCGA  
(0.50.00005) 
4962 
C22 
(MS3) ...TC.....................T.......................................... 1.70 0.020 0.620 0.164 
GCCGTT 
(0.200.10975) 2207 
MS2 ...TC...............C................................................ 1.95 0.020 0.615 0.168 CGTCGC (0.50.36) 2207 
MS4 ...TC.....................T..........................T............... 2.40 0.020 0.609 0.156 
GCCGTT 
(0.250.10975) 
TGCTGT 
(0.1250.054875) 
2207 
1) Induced determined to +/- 0.05 g/L, uninduced determined to +/- 0.001 
2) Calculated as described in 2.4 from the first 18 codons. 
3) Predicted as described in 2.4 from Pm UTR+coding sequence 
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The relative expression of bla from the candidates was further quantified by qRT-PCR to 
determine the accumulated transcript amounts, and by β-lactamase assays to determine the 
protein expression levels (Figure 3-2), as described in chapter 2.2. Expression vector pCSP1 
containing the CSP signal sequence instead of the native bla signal sequence and a slightly 
different UTR (see appendix Appendix B), and pTMB17 without a signal sequence for bla 
were included as positive and negative controls, respectively.  
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Figure 3-2: Relative expression and accumulated transcript-levels of the bla gene signal 
sequence variants at 0.1 mM m-Tol induction. pBSP1: native bla signal sequence (ss); 
pBS2P1: bla ss with TCT second codon; C19, C20, C22 (MS3): pBS2P1 vector containing bla 
ss variants identified in the SII library; MS2, MS4: pBS2P1 vector containing bla ss variants 
identified in the SI library; CSP1: CSP instead of bla ss; pTMB17: deleted bla ss. β-lactamase 
protein expression was characterized by its cenzyme assay, performed in two biological 
replicas except for pTMB14; error bars indicate standard deviations between them. 
Accumulated transcript levels were determined by qRT-PCR, performed in two or three 
biological replicas; error bars indicate the accumulated incorporated standard deviation. 
Values are relative to pBSP1 which was arbitrarily set to 1. Data is shown in appendices E, F 
and I. 
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The relative protein expression values between the candidates followed the relative ampicillin 
tolerance values reasonably well, except MS4 which did not show a correspondingly higher 
amount than the others (Figure 3-2, Table 3-2). The fold differences between candidates 
were lower for the determined active enzyme amounts than the ampicillin tolerance fold 
differences. In accordance with the ampicillin tolerance levels, the SII library candidates did 
not show improvement over the SI library candidates. The accumulated transcript values were 
also increased relative to pBSP1, corresponding to the increase in protein expression. pCSP1 
showed a lower relative accumulated transcript than protein expression. pTMB17 protein 
expression was 7 % that of the wild-type pBSP1, and its transcript levels 27 %.  
Western blot analysis of total protein from the candidates was performed, which confirmed 
the increases in β-lactamase protein production relative to the wild type pBSP1 (Figure 3-3). 
The protein amounts for the synonymous signal sequence candidates corresponded to the 
relative enzyme amounts from the assay. No protein was detected from the pTMB17 
expression vector. 
 
Figure 3-3: Western blot analysis of bla signal sequence synonymous signal sequence 
candidates from SI and SII libraries at 0.1 mM inducer. pBSP1 1and pBS2P1 were prepared in 
a separate cultivation from pBSP1 2 and the other variants. 21.7 µg total protein was loaded in 
each well, and the experiment was performed as described in chapter 2.2.  
To identify possible secondary structures in the transcripts that might affect the transcript 
stability or the translational initiation efficiency leading to the observed changes in 
expression, their RNA sequences were analyzed using Quikfold (Markham and Zuker, 2005). 
The structures were predicted from the constructs’ UTRs to +69, including all of the bla 
signal sequence. However, for most constructs the sequence downstream of codon 18 did not 
affect the predicted structure or its stability, and structures excluding the last five codons are 
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shown (Figure 3-4). For C19 and CSP, the predicted conformation and stability were affected 
by including the last five codons, and the structure of C19 is displayed including its full bla 
signal sequence. The CSP construct is displayed including its UTR and codons up to +69.  
 
 
Figure 3-4: The most stable secondary structures of the different 5’ synonymous bla 
transcripts predicted by Quikfold, as described in 2.4. See text for details on included 
sequence.  pBSP1: native bla signal sequence (ss); pBS2P1: bla ss with TCT second codon; 
C19, C20, C22: pBS2P1 vector containing bla ss variants identified in the SII library; MS2, 
MS4: pBS2P1 vector containing bla ss variants identified in the SI library; CSP: CSP instead 
of bla ss; SD sites are marked green, translational start sites are marked yellow. Red bonds 
indicate GC pairs. The analyzed sequences have U bases instead of T, as they were analyzed 
on the RNA level. 
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Most of the synonymous mutants were predicted to fold in similar conformations with a stem-
loop forming around the TIR and one forming in the middle of the bla signal sequence. The 
predicted stabilities varied from -11.0 to -7.0 kcal/mol. The C19 bla synonymous ss variant 
was predicted to fold in a different manner, where two stem-loops formed in the TIR, and a 
smaller one in the middle of the ss. The predicted CSP structure had a stem-loop forming in 
the 5’ terminal end and two towards the 3’ terminal end of the analyzed sequence.  
3.2.3 Investigation of mRNA Stability of Selected bla 5’ Synonymous Variants 
The C19 candidate was chosen, as the best performing bla signal sequence candidate from 
only the SII library, for further characterization by mRNA turnover analysis to investigate if 
increased mRNA half-lives could be the cause of the improved transcript accumulation 
values. Its mRNA degradation profile, along with that of pBSP1, was examined following the 
inducer wash-out protocol described in 2.2. The C19 synonymous bla signal sequence did not 
appear to confer increased stability on the bla transcript (Figure 3-5). 
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Figure 3-5: bla mRNA decay data for pBSP1 and signal sequence synonymous mutant 
variants C19 determined by the inducer wash-out method and qRT-PCR as described in 
chapter 2.2. Experiments were performed in three biological replicas; error bars indicate the 
standard deviation between them. C19 t=0 values were arbitrarily set to one to compare rate 
of decay; original values compared to pBSP1 t=0 are shown in the upper right corner. Data is 
shown in Appendix I. 
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3.3 2nd codon Synonymous Mutation Effects on Protein 
Expression 
As the second codon was determined to be a major contributor to stimulation of the bla gene 
expression, this study was continued with investigation of all possible synonymous bla 
codons. To examine if a second codon synonymous change plays an important role in 
determining the expression level of other genes, two additional reporter genes, phoA and celB, 
were also examined with respect to the effect of synonymous 2nd codon usage. 
3.3.1 β-lactamase 
The second amino acid of β-lactamase is serine, and is encoded by six synonymous codons. 
The four remaining second codon variants of the bla signal sequence were constructed using 
the Bla.(AGC, TCC, TCA).fwd and .rev oligonucleotides (Table 2-2) as described in chapter 
2.2, and confirmed by sequencing. Their host cells’ ampicillin tolerances were determined by 
replica plating (2.2) at 0.05 mM induction in two biological replicas. The CAI and tAI of their 
18 first codons were examined, as synonymous changes in this region was shown to affect 
expression for the SI and SII mutants (Table 3-3). The T.I.R. was found to be 2207 for all 2nd 
codon variants. The various 2nd codons conferred different ampicillin tolerance values to the 
host cells, and TCC was found to give the highest. AGT and AGC gave similar tolerance 
values. There was no correlation between CAI or tAI and tolerance values, and the AT 
content of the bla signal sequences did not correlate to the tolerance values either (not 
shown). 
Table 3-3: Ampicillin tolerance of the E. coli DH5α host cells and sequence analysis data 
from the various 2nd codon synonymous bla signal sequence constructs. 
2nd codon of bla 
signal sequence 
in pBSP1 
Ampicillin tolerance 
(g/L) 1 
Induced  Uninduced 
 
CAI2 tAI2 
Codon change on DNA 
level (tAI)3 
AGT 0.20 0.02 0.600 0.165  
TCT 1.00 0.02 0.625 0.171 AGTTCT  (0.054875  0.10975) 
AGC 0.175 0.02 0.635 0.173 
AGTAGC  
(0.0548750.125) 
TCC 1.20 0.02 0.624 0.179 
AGTTCC  
(0.0548750.25) 
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2nd codon of bla 
signal sequence 
in pBSP1 
Ampicillin tolerance 
(g/L) 1 
Induced  Uninduced 
 
CAI2 tAI2 
Codon change on DNA 
level (tAI)3 
TCA 
0.80 0.01 0.596 0.173 
AGTTCA  
(0.0548750.125) 
 
TCG 0.50 0.01 
0.609 0.175 AGTTCG  (0.0548750.165) 
1) Induced determined to +/- 0.025 g/L, uninduced determined to +/- 0.01 
2) Calculated as described in 2.4 from the first 18 codons. 
3) Predicted as described in 2.4 from Pm UTR+coding sequence 
To further characterize the bla synonymous 2nd codon variants, their relative expression of the 
bla gene was investigated by β-lactamase assays, and qRT-PCR analysis of the bla transcripts 
(Figure 3-6). The expression values followed the pattern of the ampicillin tolerance levels, 
except that TCC showed lower enzyme amounts than pBS2P1. Transcript levels were also 
affected to a similar extent as the enzyme amounts. 
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Figure 3-6: Relative β-lactamase expression and accumulated transcript-levels from the bla 
synonymous 2nd codon variants at 0.1 mM m-Tol induction. pBSP1: native bla signal 
sequence (ss), ATG as 2nd codon; pBS2P1: bla ss with TCT second codon; AGC, TCC, TCA, 
TCG: pBS2P1 vector with indicated 2nd codon; pCSP1: CSP instead of bla ss; β-lactamase 
protein expression was characterized by its enzyme assay, performed in at least two biological 
replicas; error bars indicate standard deviations between them. Accumulated transcript levels 
were determined by qRT-PCR in four technical replicas; error bars indicate their accumulated 
Table 3-3: Continued 
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incorporated standard deviations. Values are relative to pBSP1 which was arbitrarily set to 1. 
Data is shown in appendices E, F and I. 
The β-lactamase protein expression was also examined by Western blot detection to confirm 
the relative protein expression values observed in the enzyme assay (Figure 3-7). Intensities 
of the protein bands appeared to correspond to the determined relative enzyme amounts, 
except for the higher amounts from the TCA and TCC constructs 
 
Figure 3-7: Western blot analysis of bla synonymous 2nd codon variants at 0.1 mM inducer. 
pBSP1: native bla signal sequence (ss), ATG as 2nd codon; pBS2P1: bla ss with TCT second 
codon; AGC, TCC, TCA, TCG: pBS2P1 vector with indicated 2nd codon; 21.7 µg total protein 
was loaded in each well, and the experiment was performed as described in chapter 2.2.  
The secondary structure of the 2nd codon variants were predicted as described in chapter 2.2, 
to investigate if varying structures or stabilities could explain the variations in expression. 
Prediction of the UTR and the 69 nucleotides of the bla signal sequence revealed two stem-
loops forming where the second one was identical to the second hairpin of pBSP1 (Figure 
3-4). The second hairpin and the nucleotides downstream of it were not affected by the 2nd 
codon changes (data not shown), and thus the sequence downstream of the 6th codon was 
excluded to study only the structure and free energy of the varying hairpin. The most stable 
predicted secondary structures of the mRNA transcripts from transcriptional start site to the 
6th codon are shown in Figure 3-8.  
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Figure 3-8: The most stable secondary structures of the synonymous 2nd codon bla transcripts 
predicted by Quikfold, as described in 2.4. See text for details on included sequence.  AGU, 
UCU, AGC, UCC, UCA, UCG: pBSP1 variants containing indicated 2nd codon. SD sites are 
marked green, translational start sites are marked yellow. Red bonds indicate GC pairs. The 
analyzed sequences have U bases instead of T, as they were analyzed on the RNA level. 
3.3.2 Alkaline Phosphatase 
To investigate the effect of 2nd codon mutations on the expression level of the phoA reporter 
gene encoding alkaline phosphatase, its 2nd codon AAG’s synonymous mutant, AAG, was 
created in the pASP1 plasmid using the phoAAAG-fwd and phoAAAG-rev oligonucleotides 
(Table 2-2), and the correct insertion was confirmed by sequencing. The expression levels of 
the two phoA 2nd codon variants were analyzed by alkaline phosphatase enzyme assays and 
qRT-PCR. The pCSP1phoA construct containing the CSP instead of phoA’s native 
translocation signal sequence was included as a control. The results showed insignificant 
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differences in protein expression and accumulated transcript levels between the two phoA 
synonymous 2nd codon mutants and the pCSP1-phoA (Figure 3-9).  
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Figure 3-9: Relative alkaline phosphatase expression and accumulated transcript-levels from 
the synonymous 2nd codon phoA variants at 0.1mM m-Tol induction. AAA, AAG: pASP1 
vector with indicated 2nd codon; CSP: pCSP1-phoA, CSP-phoA fusion. Alkaline phosphatase 
expression was characterized by its enzyme assay in two biologicalreplicas; error bars 
indicate standard deviations between them. Accumulated transcript values were determined 
by qRT-PCR, performed in three technical replicas; error bars indicate their incorporated 
standard deviations. Values are relative to AAA, which was arbitrarily set to 1. Data is shown 
in appendices E, G and I. 
CAI, tAI and Quikfold analysis of the transcripts was performed as described for the bla 
second codon variants. Lower CAI, tAI and T.I.R. and secondary structure stability was 
observed for the AAG 2nd codon variant (Table 3-4, Figure 3-10).  
Table 3-4: Sequence analysis data of the synonymous 2nd codon phoA variants. 
Construct CAI1 tAI1 
Codon change on 
DNA level (tAI) 
Translation 
initiation rate2 
PASP1 0.552 0.222  2526 
pASP1-
AAG 
0.518 0.208 AAAAAG 
(0.750.24) 
2207 
1) Calculated as described in 2.4 from the first 18 codons. 
2) Predicted as described in 2.4 from Pm UTR+ coding sequence 
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Figure 3-10: The most stable secondary structures of the synonymous 2nd codon phoA 
transcripts predicted by Quikfold, as described in 2.4. AAA, AAG: pASP1 variants containing 
indicated 2nd codon. SD sites are marked green, translational start sites are marked yellow. 
Red bonds indicate GC pairs. The analyzed sequences have U bases instead of T, as they were 
analyzed on the RNA level. 
3.3.3 Phosphoglucomutase 
The 2nd codon’s effect on gene expression was also investigated for phosphoglucomutase 
(celB). Its 2nd codon synonymous mutants (CCA, CCG, CCT) were created in the pLB11 
plasmid using the celB.X.fwd and celB.X.rev oligonucleotides (Table 2-2), and the correct 
substitutions were confirmed by sequencing. The expression levels from the constructs were 
analyzed by phosphoglucomutase enzyme assays and qRT-PCR analysis. The results showed 
that CCA and CCT gave slightly higher expression than CCC, while CCG gave lower 
expression (Figure 3-11). Relative enzyme amounts and accumulated transcript values varied 
accordingly. 
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Figure 3-11: Relative phosphoglucomutase expression and accumulated transcript-levels 
from the synonymous 2nd codon celB variants at 0.1 mM m-Tol induction. CCC, CCA, CCG, 
CCT: pLB11 vector with indicated 2nd codon. Phosphoglucomutase expression was 
characterized by its enzyme assay in two biological replicas; error bars indicate standard 
deviations between them. Accumulated transcript values were determined by qRT-PCR, 
performed in two biological replicas; error bars indicate the standard deviation between them. 
Values are relative to CCC, which was arbitrarily set to 1. Data is shown in appendices E, H 
and I. 
CAI, tAI and Quikfold analysis of the transcripts were performed on the transcript sequences 
as described for the bla second codon variants. Predicted secondary structures are shown in 
Figure 3-12, and transcript data are shown in Table 3-5. The CAI and tAI did not correlate 
with expression levels, but there was an indication of positive correlation between T.I.R. and 
relative phosphoglucomutase amounts (Pearson: 0.913, P=0.087). The AT content did not 
correlate to the changes in expression (not shown), and no change in predicted secondary 
structures or their stabilities were observed by the changed 2nd codons.  
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Table 3-5: Sequence analysis data of the synonymous 2nd codon celB variants. 
Construct CAI1 tAI1 
Codon change on 
DNA level (tAI) 
Translation 
initiation rate2 
pLB11 (CCC) 0.530 0.204  3461 
pLB11-CCA 0.557 0.204 CCCCCA 
(0.1250.125) 
3461 
pLB11-CCG 0.597 0.207 CCCCCG 
(0.1250.165) 
2764 
pLB11-CCT 0.546 0.195 CCCCCT 
(0.1250.054875) 
3461 
1) Calculated as described in 2.4 from the first 18 codons. 
2) Predicted as described in 2.4 from Pm UTR+ coding sequence 
 
 
Figure 3-12: The most stable secondary structures of the synonymous 2nd codon celB 
transcripts predicted by Quikfold, as described in 2.4. CCC, CCA, CCG, CCT: pLB11 
variants containing indicated 2nd codon. SD sites are marked green, translational start sites are 
marked yellow. Red bonds indicate GC pairs. The analyzed sequence has U instead of T as it 
was analyzed on the RNA level. 
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3.4 Randomization of a 5’ Fusion Partner Sequence and its 
Application for Effective ifn-α2b Expression 
As the SII bla 5’ coding region synonymous library did not give great increases in expression, 
a different approach to optimizing 5’ coding sequences of heterologous genes was taken. It 
was recently observed that fusions of short 5’ terminal fragments of the highly expressed celB 
gene to the 5’ coding region of the difficult-to-express ifn-α2b gene allowed high-level 
expression of the protein (Kucharova, unpublished). In order to increase the fusion partner’s 
positive effect on expression, optimization of its coding sequence was performed by a 
randomized library of the celB69 sequence fused to the reporter gene aac(3)-IV, encoding 
Aminoglycoside-(3)-acetyltransferase IV. As the gene confers apramycin resistance to the 
host-cells, the approach allowed screening for high expression mutants of the fusion partner 
by plating on solid media containing increasing concentrations of the antibiotic. 
3.4.1 Combinatorial Mutagenesis of a Short 5’ Terminal celB Fusion Partner for 
Increased Recombinant Gene Expression 
A wild-type celB69-aac(3)-IV fusion was established in the pAR69 plasmid, and shown to 
confer a resistance of 0.100 g/L apramycin (Kucharova, unpublished). The   library was 
constructed and used to transform E. coli DH5α cells as described in chapter 2.2, and 
approximately 141 000 clones were obtained and pooled. To initially characterize the library, 
12 individual colonies from a control kanamycin plate were randomly picked for sequencing, 
which showed that five contained the wild type celB69 gene fragment fusion and 7 contained 
amino acid substitutions (Table C-2).  
To isolate fusion partners giving increased expression, the library was screened on a gradient 
of apramycin concentrations as described in chapter 2.2 and few fp69-aac(3)-IV host-cells 
grew at high concentrations (Figure 3-13). Twenty-four individual colonies growing at 0.12 
to 0.70 g/L apramycin, termed D1-D24, were picked for sequencing. Fourteen unique celB69 
based fusion partners were identified (Table 3-6), D9 and D18 were identical in their fusion 
partner sequence, as were D20 and D22. The variants’ AT contents were calculated and the 
nucleotide point mutation average for the displayed variants was 5.5, the average amino acid 
change was 4.23. The apramycin tolerance levels of the E. coli host cells were determined by 
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replica plating at 0.05 mM inducer levels after transformation by the constructs harboring the 
unique fusion partners. The concentrations used in the replica plating ranged from 0.1 to 0.85 
g/L apramycin, as no constructs had been isolated from higher than 0.70 g/L. However, six 
constructs were found to confer strong growth at 0.85 g/L in the replica plating, and thus their 
upper tolerance levels were not determined. The tolerance levels of all variants were higher 
than what they had been isolated from, and a clear trend was seen where most of the fusion 
partners had an amino-acid change in the second codon from proline to serine. A correlation 
was also found between rising AT content of the fusion partner and ampicillin tolerance 
(Pearson 0.648, P=0.009), indicating a higher AT content positively affecting expression. 
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Figure 3-13: The fp69-aac(3)-IV library was plated on solid LA with increasing apramycin 
concentration at 0.05 mM m-Toluate induction, and the E. coli host cell’s survival frequencies 
were determined as % survival at given concentrations compared to the growth on solid media 
containing only kanamycin. Survival frequency is given as log10 of the % survival at the given 
ampicillin concentration. Data is shown in Appendix D. 
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Table 3-6: DNA and amino acid sequence of celB69 based fusion partners of the up-mutants identified from screening of the fp69-aac(3)-IV 
library.  
 DNA Sequence 
Translated amino acid 
sequence 
Apramycin 
tolerance 
(g/L) % AT
2
 
celB69 ATGCCCAGCATAAGCCCATTTGCCGGCAAGCCGGTCGATCCGGACCGTCTTGTCAATATCGACGCCCTGGC MPSISPFAGKPVDPDRLVNIDAL 0.100 39.4 
D2 ...T.T.CT..T........................................................... .ST.................... >0.8501 43.7 
D3 ...T.......T.T.A.....T................................................. .S..IT.S............... >0.8501 45.1 
D4 .....A.......T.......A....T..........T.......G.....C................... ....I..T....V..G.L..... >0.8501 45.1 
D5 ...T....................C...........T....C..G.......................... .S......R...Y.E........ 0.675 42.3 
D7 ...T...CT.A.........C.......G...............T...T..T................... .STK.....R......FF..... >0.8501 43.7 
D9/D18 ...T...TA....T......................................................... .SI.I.................. >0.8501 45.1 
D10 ...A.A.......A...T.A.T................................................. .T..N.YS............... 0.725 45.1 
D11 ...T.T.......A.......A...............T.......T.....T......C............ .S..N..T....V..C.F.T... >0.8501 47.9 
D13 ...A.A....A.....A.A..A........................A...A.....A.............. .T.K.QIT.......H..K.... 0.700 46.5 
D15 ...T.........T......................C.................................. .S..I.......H.......... 0.725 42.3 
D17 ...T..........TG...G........................A.......................... .S...AC.......E........ 0.550 42.3 
D19 ...T............A...........T.......C...AC..A....C..................... .S...Q...M..HHE.P...... 0.850 43.7 
D20/D22 ...T................................................................... .S..................... 0.750 40.8 
D21 ...T.........A..T...................................................... .S..NL................. 0.8501 43.7 
1) Strong growth at 0.850 g/L apramycin 
2) AT content of the celB69 based fusion partner   
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The celB69 gene fusion adds 23 amino acids (celB23), to the AAC(3)-IV protein and it is 
possible that the various amino acid composition of the screened N-terminal tags could have 
altered the conformation of the proteins,  which could affect their enzymatic activity. Thus the 
increased apramycin resistance observed for some of the celB69 based fusion partners could be 
due to a more effective enzyme instead of the desired increase in expression. In order to 
identify fusion partners that increase the expression levels, the 14 unique mutants were 
evaluated by relative quantitation of their aac(3)-IV  transcript amounts. The qRT-PCR results 
showed one variant, D11, giving approximately 4.5-fold increase in the amount of transcript 
compared to the wild-type celB69 sequence (Figure 3-14). Three variants showed reduced 
accumulated transcript values, while nine showed moderate increases. There was no 
significant correlation between the accumulated transcript amounts and the AT content. 
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Figure 3-14: Accumulated aac(3)-IV transcript amount relative to celB69-aac of the mutants 
identified by screening the fp69-aac(3)-IV library, determined by qRT-PCR. All experiments 
were performed in three technical replicas except D11, which was analyzed in two biological 
replicas to verify the increase in accumulated transcript. D11’s error bars indicate standard 
deviation between the two biological replicas, other variants’ error bars indicate the 
incorporated standard deviations from their technical replicas. Data is shown in Appendix I. 
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3.4.2 Increased Expression of Human Interferon α2b by Application of an Optimized 
celB23 based N-terminal Fusion Partner 
Given the positive effect on aac(3)-IV transcript levels observed from the D11 celB69 based 
fusion partner, the 5’ terminal celB69 fusion to ifn-α2b in the pIN69 expression vector was 
replaced by the synthetic insert of celB69-D11.fwd and celB69-D11.rev, as described in 
chapter 2.2, to create pIN69-D11. IFN-α2b protein expression levels from the two vectors, in 
addition to expression levels from pAT64, containing the pelB translocation peptide fusion, 
and pAT63, without a peptide fusion, were compared by Western blot analysis, showing a 
clear increase in intensity for the D11 fusion partner compared to the wild type celB69 (Figure 
3-15). D11-IFN-α2b also showed stronger intensities than the high-level expression proven 
pelB-IFN-α2b fusion (Sletta et al., 2007).  
 
Figure 3-15: Chemiluminescent Western blot detection of IFN-α2b with the N-terminal pelB, 
D11 and celB23 fusion peptides, and IFN-α2b without an N-terminal fusion. The pelB fusion 
and IFN-α2b without a fusion peptide were included as controls. Total protein from cell 
extracts was loaded in dilution series, in amounts shown in the figure for all fusion-IFN-α2b 
samples. 50 µg total protein from sample IFN-α2b without fusion partner was loaded.  
Relative quantification of expressed IFN-α2b was determined using Image Lab 4.0 software 
(Bio-Rad) by analysis of the intensity of the bands, showing a three-fold increase in protein 
from the D11 fusion partner compared to the wild-type celB23 partner (Table 3-7). The D11-
IFN-α2b also produced 1.5 times more protein than the pelB-IFN-α2b fusion. 
To investigate the sequence features of the pelB, celB, D11-ifn-α2b gene fusions, as well as of 
the original ifn-α2b 5’ coding sequence, their CAI, tAI and translation initiation rates were 
examined as described in chapter 2.4 (Table 3-7). Sequence from transcriptional start site to 
+69 was included in the analysis for T.I.R, and from +1 to +69 for tAI and CAI.  No 
correlation was found between the tAI or CAI and the relative quantification values. The 
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variation in predicted T.I.R. values of the transcripts matched the detected proteins’ relative 
quantification values, except for the ifn-α2b transcript without a fusion partner. 
Table 3-7: mRNA sequence analysis and relative quantification of protein expression from 
Western blot analysis of the IFN-α2b fusion constructs.  
 
CAI1 tAI1 Translation initiation rate 
Relative 
quantification2 
pelB-ifn-α2b 0.422 0.208 4743 1.84 
celB69-ifn-α2b 0.575 0.227 3461 1 
celB69-D11-ifn-α2b 0.642 0.210 5679 3.76 
ifn-α2b (no fusion) 0.958 0.327 4335 Not detectable 
1) Calculated as described in 2.4 from the first 69 codons. 
2) Calculated relative to celB69-ifn-α2b from band intensities of the 10 µg total protein bands 
of the Western Blot analysis (Figure 3-15) using Image Lab 4.0 software (Bio-Rad 
Laboratories). 
The secondary structures of the ifn-α2b transcripts were predicted by Quikfold as described in 
chapter 2.4, and the most stable predicted secondary structures are shown in Figure 3-16. The 
UTR and 69 nucleotides following the translational start codon were included to be able to 
compare the structures. The ifn-α2b transcript without a fusion partner showed no structures 
that included the SD or the translational start site, unlike the others. The number of- and 
stability of predicted structures forming in the translation initiation region was lowered in the 
D11 celB69 based fusion partner compared to the wild-type celB69 fusion partner.   
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Figure 3-16: The most stable secondary structures of the fusion partner-ifn-α2b transcripts, 
predicted by Quikfold as described in 2.4. pelB-ifn-α2b: pelB fusion partner; celB69-ifn-α2b: 
wild type celB69 fusion partner; D11-ifn-α2b: D11 celB69 based fusion partner; ifn-α2b: ifn-
α2b gene expressed without a fusion partner. SD sites are marked green, translational start 
sites are marked yellow. Red bonds indicate GC pairs. The analyzed sequences have U bases 
instead of T, as they were analyzed on the RNA level. 
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4 Discussion 
The 5’ terminal end of the mRNA coding sequence has been shown to affect the translational 
efficiency of the transcript by taking part in secondary structures and by its codon usage 
(Kudla et al., 2009; Tuller et al., 2010; Goltermann et al., 2011), and optimization of these 
features may thus lead to increased protein expression. The aim of this study was to 
investigate the effect of changes to the 5’ coding sequence of recombinant mRNAs on protein 
expression in order to improve heterologous protein production. This was examined by three 
different approaches; combinatorial synonymous mutagenesis of the 5’ end of the bla gene, 
introduction of 2nd codon synonymous mutations in three reporter genes, and lastly 
combinatorial mutagenesis of a 5’ fusion partner leading to high-level expression of a 
medically important protein. The results obtained by the three codon optimization strategies 
will be discussed in the following chapters. 
4.1 Selection for Enhanced 5’ bla Coding Sequences by Directed 
Evolution 
By changing the 5’ coding region synonymously with respect to its codon usage, the 
transcript’s propensity to form secondary structures in the translation initiation region may be 
altered while retaining the original amino-acid sequence. This is an advantage over mutations 
that change the peptide sequence as such changes may lead to altered biological activity of the 
produced protein.  
A synonymous library, termed SII, was constructed in the 5’ coding sequence of the bla gene, 
conserving a positive 2nd codon mutation effect identified in a previous library (SI library). 
Screening of the SII library yielded three synonymous variants, termed 19, C20 and C22, 
conferring 8.25, 5.25 and 8.5 fold higher ampicillin tolerance than the bla wild-type, 
respectively (Table 3-1). The improvement over pBS2P1 containing the AGTTCT 2nd 
codon mutation was 1.65, 1.05 and 1.70-fold, respectively. C22 had been identified in the SI 
library, and the SII candidates did not confer higher ampicillin tolerance than the best mutants 
from the SI library, which were also characterized in this study. The identification of 
relatively few synonymous candidates from the SII library indicated that besides the dramatic 
effect from the 2nd codon change, additional alteration of the bla 5’ coding region does not 
lead to big improvements in expression. Besides, 83% of the sequenced SII candidates had 
82 
non-synonymous mutations or deletions in the mutated bla signal sequence, indicating that 
the selection pressure from the library screening leads to selection for any bla gene variant 
that allows the host-cells to survive.  
Characterization of expression levels by qRT-PCR analysis and β-lactamase enzyme assays 
showed that all the tested 5’ synonymous bla mutants conferred increased levels of both 
accumulated transcript and active protein (Figure 3-2). Western blot analysis also confirmed 
increases in protein amounts (Figure 3-3). One possible explanation for the increases in the 
expression levels of the synonymous candidates might be an increased translational initiation 
efficiency of the transcript. That could in turn lead to better resistance from RNaseE 
degradation for the transcript, due to closer ribosomal spacing (Deana and Belasco, 2005). 
The changes in the sequence could also lead to higher stability of the transcripts by affecting 
the secondary structures of their 5’ ends (Deana et al., 2008). To investigate if increases in 
mRNA stabilities could be causing the higher accumulated transcript levels, the transcript 
degradation profile of the best performing SII candidate, C19, was examined using the 
inducer wash-out method. When compared with the pBSP1 wild-type, it was clear that the 
stability of the C19 transcript was not increased (Figure 3-5), and it appeared to that of the 
original bla gene. The stability of the C22 candidate’s transcript was also determined to be 
similar to the wild type bla transcript (Kucharova, unpublished). 
The sequences of the different 5’ bla coding regions were subjected to bioinformatics 
analyses to identify reasons for the increased expression values. The RBS calculator predicted 
no change in T.I.R. for most synonymous mutants (Table 3-1), and the changes in the 
predicted secondary structures did not appear to allow better ribosomal access to the transcript 
as stabilities and structures did not correspond to expression levels (Figure 3-4). Interestingly, 
the CSP sequence, which served as a positive control in the expression experiments, had a 
Quikfold predicted structure with no hairpins forming in the translation initiation and its 
T.I.R. was predicted to 4279, compared to the 2207 predicted for most synonymous 
candidates (Table 3-1). It also showed a 2 to 1 translation to transcription ratio, indicating 
that the bioinformatics tools could be used for translational efficiency analysis. The fact that 
the translation to transcription ratio for the bla synonymous mutants were similar, which was 
supported by the bioinformatics tools, indicated that it was the transcription of the genes that 
was improved by the synonymous mutations of the 5’ bla sequence.  
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An explanation for the increased accumulated transcript values might be that the mutations 
directly affect transcriptional efficiency. Features of the DNA sequence were suggested to 
cause transcriptional stalling up to 108 nucleotides downstream of the transcriptional start-
sites of the lacZ, cspA and tnaA σ70 promoters (Hatoum and Roberts, 2008). If such a feature 
is present in the bla 5’ coding region, it might have been changed by the synonymous 
mutations, leading to less frequent stalling and thus more efficient transcription as stalling 
may lead to termination (Weisberg and Gottesman, 1999).  
The increase in transcriptional efficiency may also be explained by changes in promoter 
escape efficiencies by the RNA polymerase. Changes in the DNA region corresponding to the 
UTR of the Pm promoter was shown to strongly stimulate transcription of the bla gene (Berg 
et al., 2009). However, the effect was shown to be dependent on the 5’ coding region of the 
transcript as well, as celB and ifn-α2b transcript accumulation rated did not increase to the 
same extent when expressed with the strong UTRs (Berg et al., 2012). As there is an interplay 
between the UTR and the coding region determining transcriptional efficiency, the efficiency 
might be affected by the bla 5’ coding region changes. 
All the synonymous candidates with the beneficial TCT 2nd codon had obtained codons with 
lowered tAI, and showed higher expression than the pBS2P1 containing only the TCT change 
(Table 3-1). Lowered tAI of the 5’ coding region may cause slower translation of the 5’ end 
of the transcript and provide a more even distribution of ribosomes on the transcript, 
preventing ribosome “traffic jams” and increasing the rate of successful translations (Tuller et 
al., 2010). The authors discovered an evolutionary conserved “ramp” of low tAI in the 5’ 
coding region of the genes of several genomes, and also showed a correlation between such a 
ramp and the fitness of E. coli overexpressing GFP (Kudla et al., 2009; Tuller et al., 2010). 
Such an effect in the analyzed bla candidates could be leading to higher fitness of the host-
cells as the burden of expressing the protein at the given expression level is reduced, and thus 
allow further improvement from the already strong expression from the 2nd codon change. 
The combinatorial mutagenesis of the bla signal sequence pointed out that the 2nd codon 
affects gene expression to a large extent.  The next investigation was therefore focused on the 
characterization of the discovered effect. 
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4.2 2nd codon Synonymous Mutation Effects on Protein 
Expression 
To study the 2nd codon’s effect on gene expression, variants were constructed of three reporter 
genes phoA, celB and bla, with all synonymous mutations in their 2nd codons, encoding 
lysine, proline and serine, respectively. The effect on expression was most apparent in bla 
(Figure 3-6), where the relative expression could be improved three-fold, as opposed to phoA 
where only small changes in expression were observed (Figure 3-9). celB showed slight 
variations in expression from approximately 0.6- to 1.3-fold changes in transcript and active 
enzyme values (Figure 3-11). 
As predicted from the bla library screenings, the TCT 2nd codon gave the best expression of 
the serine variants. TCC gave the second highest, followed by TCG and TCA, and AGC gave 
as low expression as the wild-type AGT. Western blot of the samples (Figure 3-7), showed a 
slightly weaker than expected band for TCG, which had about the same level of active 
enzyme as TCC and TCA. There was no correlation between the CAI, tAI, the stability of the 
predicted secondary structures, or the predicted T.I.R to the accumulated transcript levels or 
the relative active enzyme amount, indicating a codon-specific effect. A study analyzing all 
possible 2nd codons in the lacZ and the 3A’ assay system also indicated a codon-specific 
effect on expression, that was not dependent on mRNA stability or secondary structures 
(Stenstrom et al., 2001). The study included codons for all amino acids, but also identified 
differences between synonymous 2nd codons. The authors identified high adenine content in 
position 1 and 2 as an important factor for high expression, and AGT and AGC as giving the 
highest expression for serine, with an average of 5.44- and 4.90-fold protein amounts, 
respectively, relative to the lowest expressing TCC. When comparing this study with the 
characterization of the bla 2nd codons where AGT and AGC gave the lowest expression, and 
TCC gave the second highest, it appears that the observed effects from the 2nd codon are gene 
specific.  
The expression levels from the AGT and AGC variants were similar (Figure 3-6), indicating 
a tRNA specific effect as the two are both decoded by Ser3 tRNA (Stenstrom et al., 2001). 
TCT and TCC, which gave similar high expression in this study, are both decoded by Ser5, 
which further strengthens the notion of tRNA specific effects affecting the expression. This 
was also the case for the phoA gene, as the AAA and AAG codons encoding lysine are 
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decoded by the same tRNA and gave the same expression. Similarly, a study expressing 
human immunoglobulin α also showed no change in expression between AAA and AAG in 
the 2nd codon (Bivona et al., 2010). In contrast, major differences in expression were found 
between AAA and AAG in other studies (Looman et al., 1987; Stenstrom et al., 2001), further 
indicating that the 2nd codon effect is gene specific as well as tRNA specific. The comparison 
with the well expressed protein containing CSP fused to the mature AP enzyme indicates that 
the original alkaline phosphatase has a well-adapted translocation signal peptide, and there is 
a possibility that small changes from the synonymous mutations might have been over-
shadowed by its already effective expression. 
For the celB 2nd codon variants there was no correlation between expression and CAI or 
predicted secondary structure stability (Figure 3-11, Table 3-5). However, there was an 
indication of a positive correlation between T.I.R. and relative enzyme amount (Pearson: 
0.913, P=0.087), as the CCG 2nd codon gave a lower predicted T.I.R. and expression than the 
others. A lower rate of translation could lead to lower mRNA stability, as the decrease in 
ribosomal density on the transcript allows RNaseE easier access (Deana and Belasco, 2005), 
which could explain the lowered accumulated transcript and enzyme amount. A tRNA 
specific effect was not present in this case, as the CCA and CCG codons are both decoded by 
the Pro3 tRNA. The contribution from the 2nd codons on expression did not correlate with 
Stenstrom et al., 2001, as they identified CCA giving the lowest relative expression, further 
supporting that the 2nd codon effect is sequence context specific. 
In contrast to the three-fold changes in expression of active β-lactamase observed in this study 
(by varying the serine 2nd codon) the protein amounts stayed the same when expressing 
human immunoglobulin α with the six variants as the 2nd codon (Bivona et al., 2010). This, 
along with the discrepancies between this study and others (Looman et al., 1987; Stenstrom et 
al., 2001; Bivona et al., 2010), strongly suggests that the effect on expression from 
synonymously mutating the 2nd codon is gene dependent, and probably influenced by the 
downstream nucleotide sequence. As transcript levels are affected by the 2nd codon, the 
observed effects may arise due to increased transcriptional efficiency as described for the bla 
synonymous library. There also appears to be tRNA specific effects for some codons or 
genes, but not for others, as was previously observed (Looman et al., 1987; Stenstrom et al., 
2001).  
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4.3 Randomization of an N-terminal CelB Fusion Peptide for 
Increased Protein Expression 
The features causing the improved expression of the synonymous mutations were hard to 
pinpoint, and did not show sufficient potential to improve expression of poorly expressed 
heterologous genes. It was recently shown that the first 69 nucleotides of the celB greatly 
stimulates expression of ifn-α2b when fused 5’ to its coding sequence (Kucharova, 
unpublished), and this fusion was chosen for optimization instead of proceeding with 
synonymous mutations. To further improve the celB69 gene fusion tag, a combinatorial 
mutagenesis library was created in the celB69-aac(3)-IV gene fusion and screened for 
increased apramycin resistance. 14 unique celB69 sequences conferring higher apramycin 
resistance to the cells were identified (Table 3-6), indicating their possible positive effects on 
expression. Interestingly, also in this library the 2nd codon appeared to have an important 
effect on expression, as most of the candidates were changed from CCC to TCC, changing the 
amino acid from proline to serine.  
In the previously mentioned study investigating the effect of the 2nd amino acid on the 
expression of human immunoglobulin α, a ten-fold variation in expression was observed by 
its exchange with various amino acids (Bivona et al., 2010). Both proline and serine as the 2nd 
residues were found to give similar high expressions in the tested protein. This again indicates 
that the 2nd codon effect is gene specific, as there was a positive selection for serine in the 
sequence variants based on celB69, which has a native proline 2nd residue. The Bivona et al. 
study also identified a bias towards serine and alanine as the second amino acids of highly 
expressed genes of E. coli, which might explain the increase in expression observed in this 
study as the new fusion may be more adapted to high-level expression. There was also a 
statistically significant correlation between increased AT content of the fusion partner and 
higher apramycin tolerance of the host (Table 3-6, Figure 3-14), indicating higher 
translational efficiency due to lowered stability of secondary structures in the TIR (Krishna 
Rao et al., 2008; Kudla et al., 2009) 
As different amino acids were incorporated in the peptide sequences, the increased resistance 
of the screened candidates might have been due to altered enzymatic activities. In order to 
identify sequence variants positively affecting the overall expression level and not the enzyme 
activity, analysis of accumulated transcript was carried out. qRT-PCR of the aac(3)-IV gene 
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showed that one of the fusion partners, D11, gave an almost five-fold increase in accumulated 
transcript compared to the wild type celB69 (Figure 3-14). This finding indicated that the new 
gene fusion had been optimized with respect to increased gene expression. When fused in 
frame with ifn-α2b, the D11-ifn-α2b gene fusion gave three-fold higher IFN-α2b protein 
levels than the celB69-ifn-α2b, and 1.5 times as high as the pelB- ifn-α2b fusion control 
included (Figure 3-15, Table 3-7).  
To investigate the reasons for the variation in expression from the fusions, the UTR and the 5’ 
coding sequences of the ifn-α2b gene and the pelB-, celB69-, and D11-ifn-α2b fusions were 
analyzed for their CAI, tAI, T.I.R. and predicted secondary structures (Table 3-7, Figure 
3-16). The identified high tAI and CAI values of the ifn-α2b fragment are due to previous 
codon optimization of the gene (Sletta et al., 2007). Interestingly, there were no predicted 
secondary structures in the 5’ end of the ifn-α2b transcript, unlike all other transcripts 
analyzed in this study. As secondary structures in the 5’ terminal end of the transcript lead to 
stabilization of the mRNA (Deana et al., 2008), it may be tempting to speculate that the ifn-
α2b transcript without a fusion partner may be highly unstable due to the absence of 5’ stem-
loops, which could in turn lead to its low protein expression. The low stability of the ifn-α2b 
transcript with no fusion partner was confirmed by an inducer wash-out experiment that 
compared its stability to a celB75-infa2b fusion, showing half-lives of two and six minutes, 
respectively (Kucharova, unpublished). The results are likely to be the same for the celB69 
fusion, as the extra nucleotides of the celB75 are in the end of the fusion, thus probably not 
interfering with the secondary structures of the transcript’s 5’ terminal end.  
A possible explanation for the three-fold increase in protein amount for the D11 fusion 
partner is that the predicted secondary structure of the wild type celB69-infa2b transcript was 
stronger and had more hairpins forming close to the translation initiation region than the D11 
fusion partner (Figure 3-16). This may lead to increased access to the SD sequence and the 
translational start site for the ribosome, thus allowing more efficient translation initiation. 
This could in turn further explain the increase in accumulated transcript the D11 variant 
causes on aac(3)-IV (Figure 3-14), as the closer spacing of ribosomes on the transcript would 
protect it from degradation (Deana and Belasco, 2005). The RBS calculator also predicted 
that the D11-infa2b has a higher translation initiation rate than celB69-ifn-α2b, further 
corroborating the possible stabilization by increased translation initiation.  
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5 Concluding Remarks 
From the results obtained in this study and current literature, it is clear that the 5’ coding 
region’s effect on gene expression is very complex, and that it can affect expression in a 
myriad of ways. The bla library screenings showed that the gene expression was dramatically 
increased by altering the 2nd codon synonymously, and that it could be further increased by 
additional synonymous mutations. The main contributor to the stimulation was found to be an 
increase in transcriptional activity, and not increased transcript stability. The second codon 
variation of three reporter genes demonstrated that the sequence context at the 5’ terminal end 
plays a crucial role in how changes in the sequence affect the expression, as the results 
contradicted some literature findings while supporting others.  
Synonymous optimization however, did not show a great potential or a clear feature to be 
used for optimization of poorly expressed heterologous genes, as there was only a 3.5-fold 
increase in active protein amounts. Combinatorial mutagenesis optimization of an N-terminal 
celB fusion partner that had been shown to improve IFN-α2b expression to high-level 
production from undetectable levels, led to a three-fold further improvement in protein. 
Based on the described findings, the effects of changes to the 5’ terminal coding sequence 
appear to be gene specific and dependent on the adjacent genetic context. This makes it 
difficult to pinpoint which features should be addressed in a genetic optimization. However, 
as intertwined and complex these regulatory mechanisms may be, the increased expressions 
of the bla library candidates show that already established expression may be increased by 
simple synonymous changes of the 5’ coding region, optimizing the gene sequence to the 
promoter and the UTR sequence. The successful identification of an improved fusion partner 
for IFN-α2b shows that optimization of the coding region of fusion partners is a powerful tool 
for enhancing the expression of poorly expressed genes. 
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6 Future Perspectives 
More research is needed to further elucidate how the features of the 5’ coding region affect 
gene expression. As the features are clearly influenced by their adjacent genetic context, it 
would be interesting to investigate the interplay between the UTR and the 5’ coding region by 
combinatorial mutagenesis of both regions simultaneously, in for example the bla reporter 
gene system. By rationally designing the UTR and 5’ coding region to maximize and 
minimize secondary structures and T.I.R., more insight in their contribution of bla transcript 
translation could be gained. Changing the signal sequence of bla to only low or high tAI 
codons would also be interesting, as there was a tendency of lowered tAI in the coding region 
of the bla variants. 
In the applied aspect of utilizing the obtained results, it would be interesting to further 
develop the identified D11 fusion partner variant for use in heterologous expression. As there 
was a significant correlation between the fusion partner’s AT content and survival of the 
apramycin fusion partners, further optimization could involve maximizing the AT content of 
D11 by synonymous mutations. The development of the candidate would also require the 
introduction of a protease cleavage site to be able to obtain the protein of interest without the 
fusion and retain its native N-terminal end, and several such cleavage sites are available 
(Terpe, 2003). It would also be interesting to examine the D11 fusion partner’s effect on 
protein solubility, and measures could be taken to improve it (Fox et al., 2001; Terpe, 2003).  
To further investigate the molecular aspects causing the improvement of D11 over wild-type, 
an inducer wash-out experiment could be performed to compare their stabilities. More 
bioinformatic analyses should also be done to the up-mutants of the fp-aac(3)-IV library to 
further examine reasons for their increased translational efficiencies.  
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Appendix A Mastercycler® ”ANNEAL” program 
Lid 103 °C 
1. 95 °C 3 min 
2. 90 °C 1 min 
3. 85 °C 2 min 
4. 80 °C 5 min 
5. 75 °C 5 min 
6. 70 °C 10 min 
7. 65 °C 10 min 
8. 60 °C 5 min 
9. 55 °C 5 min 
10. 50 °C 5 min 
11. 45 °C 2 min 
12. 40 °C 2 min 
13. 35 °C 1 min 
14. 30 °C 1 min 
15. 25 °C 1min 
16. 20 °C 1 min 
17. HOLD 4 °C 
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Appendix B UTR sequences from Pm promoter  
pBSP1 derivatives, pASP1 derivatives, pAR69 derivatives, pAT63 derivatives, pIN69 
derivatives: 
 +1 
5’-AACAGAAACAAUAAUAAUGGAGUCAUGAACAU AUG-‘3 
 
 
pLB11 derivatives, pCSP1 derivatives: 
 +1 
5’-AACATGTACAATAATAATGGAGTCATGAACAT AUG-‘3 
 
+1 denotes translational start site, sequence shown from transcriptional start site. 
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Appendix C Sequence alignments 
Table C-1: Sequenced bla signal sequence of 12 randomly picked clones from kanamycin plate of SII library screening aligned to wild-type 
signal sequence of pBSP1-TCT. Sequencing was performed by Eurofins MWG Operong using the PmUTR.fwd primer shown in Table 2-4. 
 DNA SEQUENCE AMINO ACID SEQUENCE 
TCT TATGTCTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTCGC MSIQHFRVALIPFFAAFCLPVF 
R1 ..................................................................... ...................... 
R2 ..................................................................... ...................... 
R3 ..................................................................... ...................... 
R4 ..................................................................... ...................... 
R5 ......A..C..T.....A..G.....T..A..C...........C..T.....A..A..A..A..A.. ...H.L...........*...L 
R6 ..................................................................... ...................... 
R7 ......A..C..T.....A..A..T..T..A..C..T........C..G.....A..A..A..A..... ...H.L...........*.... 
R8 ..................................................................... ...................... 
R9 ...............................................T..................... ...............V...... 
R10 ..................................................................... ...................... 
R11 ..................................................................... ...................... 
R12 ..................................................................... ...................... 
 
Table C-2: Sequenced celB69 gene fusion sequence of 12 randomly picked clones from kanamycin plate of the celB69-aac(3)-IV library screening 
aligned to wild-type celB69. Sequencing was performed by Eurofins MWG Operong using the PmUTR.fwd primer shown in Table 2-4. 
 DNA SEQUENCE AMINO ACID SEQUENCE 
CELB69 ATGCCCAGCATAAGCCCATTTGCCGGCAAGCCGGTCGATCCGGACCGTCTTGTC-AATATCGACGCCC-TGGC MPSISPFAGKPVDPDRLVNIDAL 
K1 ......................................................-.............-.... ....................... 
K2 ......................................................-.............-.... ....................... 
K3 ......................................................C.............-.... ..................QYRRP 
K4 ......................................................-.------......-.... ...................AL.M 
K5 ......................................................-.............-.... ....................... 
K6 ....G.....G..................A........A............A..-...T..T......-.... .R.R........E....I.FY.. 
K7 ........G.........A...........T.............T....---------.......T..-.... ..R...I...S.....HRRPGHG 
K8 ...........C.......A.A....................A...........-......A......-.... ......YT......N.....N.. 
K9 .....................................G.....CT.........--..C.....T...-.... ............G.A...ISTPW 
K10 ......................................................-.............-.... ....................... 
K11 ......................................................-.............C.... ......................P 
K12 ......................................................-.............-.... ....................... 
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Appendix D Survival frequencies from library screenings 
Small 1 Small 2
Big w/o 
satellite cols
Avg big 
plate
% of kan50 
plate log %
Kanamycin 
50ug/ml 221 - - 22100 100 % 2
Amp g/L
Dilution 
plated
0.8 1.00E+05 239 - - 23900 108 % 2.034005627
1 1.00E+05 225 202 - 21350 97 % 1.985005606
1.2 1.00E+05 137 149 - 14300 65 % 1.810943764
1.4 1.00E+04 89 (smear) 726 - 7260 33 % 1.516544347
1.6 1.00E+04 178 208 - 1930 9 % 0.941165035
1.8 1.00E+04 76 75 - 755 3 % 0.533554678
2 1.00E+04 21 23 160 190 1 % -0.065638673
2.2 - - 134 134 1 % -0.217287475
2.4 - - 87 87 0 % -0.404873021
2.6 - - 58 58 0 % -0.58096428
2.8 - - 59 59 0 % -0.573540262
3 - - 43 43 0 % -0.710923818
3.5 - - 32 32 0 % -0.839242295
4 - - 10 10 0 % -1.344392274
4.5 - - 4 4 0 % -1.742332282
5 - - 3 3 0 % -1.867271019
5.5 - - 2 2 0 % -2.043362278
6 - - 0 0 0 %
Small 1 Small 2 Big w/o 
satellite cols
Avg big 
plate
% of kan50 
plate log %
Kanamycin 
50ug/ml 218 - 21800 100 % 2
Amp g/L Dilution plated
0.05 1.00E+05 204 167 18550 85 % 1.92988742
0.1 1.00E+05 100 125 11250 52 % 1.712696029
0.15 1.00E+05 127 85 10600 49 % 1.686849372
0.2 1.00E+05 84 65 7450 34 % 1.533699779
0.4 1.00E+05 20 22 164 187 1 % -0.066614887
0.6 1.00E+04 10 - 106 103 0 % -0.325619269
0.8 1.00E+04 1 - 41 25.5 0 % -0.931916313
1 10000 - - 36 36 0 % -0.782153993
1.2 - - 28 28 0 % -0.891298462
1.4 - - 7 7 0 % -1.493358454
1.6 - - 7 7 0 % -1.493358454
1.8 - - 2 2 0 % -2.037426498
2 - - 1 1 0 % -2.338456494
2.6 - - 0 0 0 % -
SI library
SII library
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WILD TYPE pBSP1
Ampicillin (g/l) Log %
0.00 2.00
0.05 2.00
0.08 2.00
0.10 1.95
0.12 1.85
0.14 1.78
0.16 1.70
0.18 1.60
0.20 0.00
0.22 -0.52
0.24 -0.60
0.26 -0.82
 
Apramycin concentration 
(g/L)
Small 1 
(10^-5)
Small 2 
(10^-5)
Big (10^-
3)
Avg big 
plate % of kan50 plate log %
0                     (Kanamycin 
50mg/ml) 1264 1289 - 126400 100 % 2
0.08 2 1 453 251.00 0.199 % -0.702073352
0.1 2 2 233 211.00 0.167 % -0.777464619
0.12 1 1 150 116.67 0.092 % -1.034800284
0.15 2 0 51 83.67 0.066 % -1.179194607
0.2 0 0 35 11.67 0.009 % -2.034800284
Big (10^-
3)
Big (10^-
3)
Big (10^-
3)
0.4 2 5 3 3.33 0.003 % -2.578868329
0.5 5 12 4 7.00 0.006 % -2.256649034
0.6 3 3 2 2.67 0.002 % -2.675778342
0.7 - 1 0 0.50 0.000 % -3.40277707
0.8 - - 0 0.00
0.9 - - 0 0.00
1.0 - - 0 0.00
fp 69 -aac(3)-IV  library
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Appendix E BSA standard curves 
Average Stand. Dev.
0.0 0.4105 0.4357 0.418 0.4257 0.4135 0.421 0.010
0.1 0.4993 0.5186 0.5174 0.5071 0.5263 0.514 0.011
0.2 0.5982 0.6233 0.6123 0.6025 0.6073 0.609 0.010
0.3 0.7289 0.7263 0.7384 0.7005 0.7255 0.724 0.014
0.4 0.782 0.7736 0.7907 0.8067 0.788 0.014
0.5 0.8577 0.8504 0.8388 0.8549 0.8548 0.851 0.007
BSA standard curve for  3/3-2011, 21/3-2011 assays
y = 0.8834x + 0.4303
R2 = 0.99
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
1.000
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Average Stand. Dev.
0.0 0.4105 0.4357 0.418 0.4257 0.4135 0.421 0.010
0.1 0.4993 0.5186 0.5174 0.5071 0.5263 0.514 0.011
0.2 0.5982 0.6233 0.6123 0.6025 0.6073 0.609 0.010
0.3 0.7289 0.7263 0.7384 0.7005 0.7255 0.724 0.014
0.4 0.782 0.7736 0.8223 0.7907 0.8067 0.795 0.020
0.5 0.8577 0.8504 0.8388 0.8549 0.8548 0.851 0.007
Biorad BSAstandard curve for  4/5-2011 assay
y = 0.8892x + 0.4299
R2 = 0.9894
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
1.000
0.0 0.1 0.2 0.3 0.4 0.5 0.6
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Average Stand. Dev.
0.0 0.3837 0.3894 0.3929 0.391 0.3917 0.3963 0.391 0.004
0.1 0.6498 0.6591 0.669 0.663 0.6688 0.662 0.008
0.2 0.8558 0.8474 0.8432 0.872 0.8546 0.8165 0.848 0.018
0.3 0.996 0.9632 0.9862 0.934 1.0109 0.9639 0.976 0.028
0.4 1.1518 1.135 1.0976 1.095 1.1879 1.2002 1.145 0.044
0.5 1.2066 1.2181 1.228 1.204 1.2155 1.2769 1.225 0.027
Biorad measurment standard curve 12/5-2011
y = 1.6417x + 0.4639
R20.9709 = 
0.000
0.200
0.400
0.600
0.800
1.000
1.200
1.400
0.00 0.10 0.20 0.30 0.40 0.50 0.60
[BSA] ug/ml
A
59
5
 
BSA 
(mg/mL)
1 2 3 4 5 6 AVG STDEV
0 0.391 0.372 0.361 0.384 0.395 0.381 0.014
0.1 0.540 0.627 0.580 0.584 0.607 0.570 0.585 0.030
0.2 0.659 0.679 0.681 0.667 0.662 0.635 0.664 0.016
0.3 0.750 0.735 0.722 0.731 0.704 0.735 0.729 0.015
0.4 0.785 0.799 0.807 0.829 0.857 0.765 0.807 0.033
0.5 0.872 0.866 0.879 0.874 0.869 0.904 0.877 0.014
BSA standard curve for bla assays 29/10-2011, 30/10-2011
y = 0.7285x + 0.5138
R2 = 0.9994
0.0
0.2
0.4
0.6
0.8
1.0
0 0.1 0.2 0.3 0.4 0.5 0.6
 
109 
Average Stand. Dev.
0.0 0.299 0.3157 0.3052 0.3189 0.3129 0.3145 0.311 0.007
0.1 0.473 0.4948 0.503 0.4759 0.4922 0.4785 0.486 0.012
0.2 0.5474 0.5853 0.6066 0.5847 0.5646 0.5636 0.575 0.021
0.3 0.7017 0.6798 0.6591 0.6852 0.681 0.018
0.4 0.7999 0.8239 0.8431 0.8034 0.818 0.020
0.5 0.9168 0.8953 0.9527 0.9296 0.924 0.024
Biorad BSAstandard curve for  25/5-2011 assay
y = 1.1894x + 0.3352
R2 = 0.9927
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
1.000
0.0 0.1 0.2 0.3 0.4 0.5 0.6
 
 
Average Stand. Dev.
0.0 0.5249 0.5489 0.5462 0.5557 0.543925 0.013
0.1 0.7238 0.7439 0.7534 0.7437 0.7395 0.74086 0.011
0.2 0.7842 0.8298 0.8439 0.8411 0.8226 0.82432 0.024
0.3 0.8786 0.9134 0.8845 0.8743 0.893 0.88876 0.015
0.4 0.9413 0.9906 0.9739 0.9445 0.9847 0.967 0.023
0.5 1.1352 1.1384 1.1031 1.1298 1.1382 1.12894 0.015
Biorad BSAstandard curve for 2/11-2011, 11/11-2011 assay
y = 1.048x + 0.587
R2 = 0.9646
0
0.2
0.4
0.6
0.8
1
1.2
0.0 0.1 0.2 0.3 0.4 0.5 0.6
 
110 
Average Stand. Dev.
0.1 0.6079 0.6158 0.6078 0.611 0.6096 0.61042 0.003
0.2 0.7326 0.7518 0.7401 0.7619 0.7267 0.74262 0.014
0.3 0.8737 0.9004 0.908 0.891 0.8837 0.89136 0.014
0.4 0.9906 1.0692 1.0921 1.034 1.046475 0.044
0.5 1.1635 1.196 1.2446 1.2362 1.2378 1.21562 0.035
Biorad BSAstandard curve for 8/12-2011, 13/12-2011 assays
y = 1.5143x + 0.447
R2 = 0.998
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0.0 0.1 0.2 0.3 0.4 0.5 0.6
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Appendix F β-lactamase assay data 
 
pBS2P1
Average
Slope/ 
avg 
protein 
concentr
.
STDEV
Parallell 1 102.70 110.60 98.96 110.30 105.64 504.14 10.26
Parallell 2 102.20 112.60 110.70 109.40 108.73
pBSP1
Parallell 1 30.97 30.85 33.61 33.81 32.31 134.49 9.77
Parallell 2 28.24 29.08 29.28 30.01 29.15
CSP
Parallell 1 88.82 91.52 98.02 99.06 94.36 421.44 30.64
Parallell 2 76.01 86.38 87.73 90.39 85.13
pBSP1 Average Stand. Dev.
Concentra
tion 
(mg/ml)
Parallell 1 0.611 0.6376 0.613 0.622 0.6131 0.62 0.01 0.21
Parallell 2 0.6054 0.6307 0.6131 0.598 0.6194 0.6346 0.62 0.01 0.21
pBSP2
Parallell 1 0.6238 0.6119 0.6114 0.645 0.641 0.6376 0.63 0.01 0.22
Parallell 2 0.6219 0.6354 0.6443 0.6416 0.64 0.01 0.23
CSP
Parallell 1 0.6072 0.6264 0.6165 0.625 0.6073 0.62 0.01 0.21
Parallell 2 0.6227 0.6308 0.606 0.6125 0.6296 0.62 0.01 0.22
BioRad measurements
Slope from Bla assay
BLA assay 03.03.2011 0,05M inducer 2nd codons
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pBS2P1 Average
Slope/ 
avg 
protein 
concentr
. STDEV
Parallell 1 106.00 99.67 109.90 110.70 106.57 1327.95 136.32
Parallell 2 106.10 112.50 120.60 153.80 123.25
pBSP1
Parallell 1 31.75 31.90 33.32 33.17 32.54 368.87 84.29
Parallell 2 44.19 45.44 44.78 45.89 45.08
CSP
Parallell 1 101.20 99.52 101.60 102.40 101.18 1052.12 27.57
Parallell 2 102.90 106.30 109.10 101.70 105.00
pBS2P1 Average
Stand. 
Dev.
Concentra
tion 
(mg/ml)
Parallell 1 0.4849 0.5107 0.5064 0.489 0.5051 0.5071 0.50 0.01 0.08
Parallell 2 0.5033 0.5112 0.5111 0.527 0.5054 0.5198 0.51 0.01 0.09
pBSP1
Parallell 1 0.4805 0.5064 0.5015 0.508 0.5095 0.5084 0.50 0.01 0.08
Parallell 2 0.5451 0.5404 0.5516 0.55 0.5322 0.5449 0.54 0.01 0.13
CSP
Parallell 1 0.5007 0.5122 0.5253 0.521 0.5276 0.5215 0.52 0.01 0.10
Parallell 2 0.5132 0.511 0.5057 0.515 0.5208 0.5288 0.52 0.01 0.10
BioRad measurements
Slope from Bla assay
BLA assay 21.03.2011 0,05M inducer 2nd codons
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1 2 3 4 5 6 AVG STDEV
Slope /    total 
protein
pBSP1 60.77 67.76 62.94 65.21 63.99 63.99 64.11 2.33 329.94
pBS2P1 92.480 85.840 90.090 92.22 95.830 94.490 91.83 3.54 462.50
AGC 37.090 38.300 37.710 37.940 38.370 40.620 38.34 1.21 189.51
TCC 84.450 93.060 84.190 92.540 91.900 90.200 89.39 4.04 442.82
TCA 60.080 66.230 57.120 59.430 58.200 51.650 58.79 4.72 339.57
TCG 56.700 58.650 60.040 64.300 62.730 60.48 3.06 436.56
CSP 105.200 104.400 106.200 111.200 109.400 109.500 107.65 2.75 618.29
1 2 3 4 5 6 AVG STDEV
Protein 
concentration 
(mg/mL)
VK6 1 0.5768 0.5758 0.5605 0.5899 0.5569 0.5363 0.5660 0.0189 0.1943
AN1 0.5731 0.5861 0.563 0.5566 0.5831 0.5645 0.5711 0.0118 0.1985
AGC 0.5928 0.5547 0.5518 0.6094 0.5649 0.5796 0.5755 0.0227 0.2023
TCC 0.5742 0.5816 0.5301 0.6 0.5877 0.5765 0.5750 0.0239 0.2019
TCA 0.5511 0.5303 0.5541 0.5528 0.5193 0.5374 0.5408 0.0142 0.1731
TCG 0.5051 0.4903 0.4897 0.4944 0.5044 0.5145 0.4997 0.0099 0.1385
CSP 0.5438 0.5482 0.5466 0.5447 0.5309 0.5379 0.5420 0.0065 0.1741
Protein activity (slope x -1)
Total Protein concentration (BioRad A595)
25.05.2011 0.05mM inducer bla assay 2nd codons
 
pBS2P1
Average
avg Slope/ 
protein 
concentr.
STDEV
Parallell 1 137.50 136.50 135.80 135.80 136.30 136.38 769.73 42.62
Parallell 2 148.00 145.30 148.80 148.30 147.10 147.50
pBSP1
Parallell 1 51.64 50.42 44.66 50.63 57.05 50.88 338.88 12.34
Parallell 2 46.56 49.18 47.10 50.15 48.24 48.25
CSP
Parallell 1 139.70 161.70 159.40 160.90 157.20 155.78 1069.86 57.89
Parallell 2 138.90 136.60 147.30 124.90 171.50 143.84
pBS2P1
Average Stand. Dev.
Concentrat
ion 
(mg/ml)
Average
Parallell 1 0.5684 0.5883 0.59 0.598 0.59 0.01 0.18 0.184
Parallell 2 0.5872 0.609 0.606 0.605 0.60 0.01 0.19
pBSP1
Parallell 1 0.5256 0.5497 0.5319 0.564 0.54 0.02 0.13 0.151
Parallell 2 0.5688 0.5912 0.5845 0.597 0.59 0.01 0.17
CSP
Parallell 1 0.5767 0.5836 0.5944 0.575 0.58 0.01 0.17 0.146
Parallell 2 0.5452 0.546 0.5229 0.532 0.54 0.01 0.12
Slope from Bla assay
BLA assay 04.05.2011 0,05M inducer 2nd codons
BioRad measurements
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BLA assay 12.05.2011 0,05M inducer 2nd codons
pBSP1 Average
Slope/ 
avg 
protein 
concentr
.
STDEV
Parallell 1 29.420 27.730 29.300 23.950 29.470 26.350 27.70 277.13 61.53
Parallell 2 36.180 36.470 35.350 34.900 32.380 35.370 35.11
pBS2P1
Parallell 1 95.500 91.450 92.350 89.300 86.750 91.07 987.96 151.82
Parallell 2 97.340 92.260 98.000 86.450 93.51
AGC
Parallell 1 39.850 39.160 39.880 38.080 41.290 36.250 39.09 264.56 8.51
Parallell 2 34.440 37.200 37.830 35.670 35.820 34.950 35.99
TCA
Parallell 3 67.730 68.560 68.620 62.910 63.910 57.200 64.82 554.12 158.52
Parallell 4 70.510 72.560 70.560 71.560 75.040 73.210 72.24
TCG
Parallell 3 82.790 83.050 97.330 81.330 85.190 83.250 85.49 591.88 101.64
Parallell 4 72.540 75.440 75.910 73.650 76.660 77.040 75.21
pBSP1 Average Stand. Dev.
Concentra
tion 
(mg/ml)
Parallell 1 0.6463 0.6494 0.6238 0.6617 0.7117 0.66 0.03 0.12
Parallell 2 0.6377 0.6 0.6407 0.668 0.672 0.64 0.03 0.11
pBS2P1
Parallell 1 0.5865 0.626 0.6168 0.601 0.5546 0.6172 0.60 0.03 0.08
Parallell 2 0.6377 0.6141 0.6036 0.657 0.6659 0.651 0.64 0.02 0.11
AGC
Parallell 1 0.7115 0.7148 0.7114 0.704 0.7229 0.7075 0.71 0.01 0.15
Parallell 2 0.6841 0.6848 0.7113 0.667 0.6607 0.6856 0.68 0.02 0.13
TCA
Parallell 3 0.702 0.7241 0.7086 0.707 0.7038 0.6825 0.70 0.01 0.15
Parallell 4 0.6515 0.6467 0.6282 0.656 0.6403 0.6285 0.64 0.01 0.11
TCG
Parallell 3 0.6998 0.6868 0.688 0.661 0.664 0.6526 0.68 0.02 0.13
Parallell 4 0.7116 0.7066 0.6949 0.702 0.6999 0.6932 0.70 0.01 0.14
BioRad measurements
Slope from Bla assay
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1 2 3 4 5 AVG STDEV
Slope /    total 
protein
pBSP1 35.6 37.6 37.03 38.09 37.08 1.08 205.26
pBS2P1 98.63 110.5 85.99 97.53 100.7 98.67 8.75 512.85
TCC 87.66 90.89 90.93 90.63 93.46 90.71 2.06 461.04
1 2 3 4 5 AVG STDEV
Protein 
concentration 
(mg/mL)
VK6 1 0.6214 0.6581 0.6516 0.6418 0.6541 0.6454 0.0147 0.1806
AN1 0.6668 0.6339 0.6694 0.6482 0.6515 0.6540 0.0145 0.1924
TCC 0.6398 0.6648 0.6419 0.6715 0.6677 0.6571 0.0151 0.1968
Protein activity (slope x -1)
Total Protein concentration (BioRad A595)
29.10.2011 0.05mM inducer bla assay 2nd codons
 
29.10.11 0,1mM inducer  bla assay 29.10 Library clones
1 2 3 4 5 AVG STDEV
Slope /    total 
protein
pBSP1 1 #37,18 39.76 45.35 41.45 42.04 42.15 2.34 264.57
pBSP1 2 49.13 50.04 50.04 48.72 50 49.59 0.62 271.60
pBS2P1 110.1 102.1 112.1 113.2 112.3 109.96 4.54 516.55
C19 166.0 152.6 178.4 182.6 145.3 164.98 16.06 844.85
C20 131.7 133.8 125.9 131.4 137.5 132.06 4.22 695.43
MS2 169.5 172.1 165.4 164.8 172.0 168.76 3.51 851.04
C22 174.1 178.8 170.2 188.7 178.8 178.12 6.92 744.89
MS4 194.5 195.5 208.9 209.8 218.6 205.46 10.28 905.05
CSP 143.4 160.4 142.3 148.1 148.0 148.44 7.18 774.19
1 2 3 4 5 AVG STDEV
Protein 
concentration 
(mg/mL)
pBSP1 1 0.6209 0.6436 0.6266 0.6448 0.6134 0.6299 0.0139 0.1593
pBSP1 2 0.6312 0.6453 0.6478 0.6579 0.6518 0.6468 0.0099 0.1826
pBS2P1 0.6372 0.6768 0.6885 0.6832 0.6587 0.6689 0.0210 0.2129
C19 0.6367 0.6457 0.6686 0.6705 0.6588 0.6561 0.0146 0.1953
C20 0.6446 0.6414 0.6648 0.6617 0.6482 0.6521 0.0105 0.1899
MS2 0.6561 0.6574 0.656 0.6442 0.6776 0.6583 0.0121 0.1983
C22 0.6686 0.6849 0.7048 0.7006 0.6811 0.6880 0.0148 0.2391
MS4 0.6698 0.6798 0.6939 0.675 0.6774 0.6792 0.0090 0.2270
CSP 0.661 0.663 0.6483 0.6318 0.6633 0.6535 0.0136 0.1917
Protein activity (slope x -1)
Total Protein concentration (BioRad A595)
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30.10.11 0,1mM inducer bla assay Library clones
1 2 3 4 5 AVG STDEV
Slope /    total 
protein
pBSP1 1 60.77 67.76 62.94 65.21 63.99 64.13 2.60 234.97
pBSP1 2 55.09 55.21 54.21 53.51 55.71 54.75 0.88 248.58
pBS2P1 119.8 116.8 124.8 118.1 117.8 119.46 3.17 494.81
C19 178.8 171.2 185.1 189.4 185.9 182.08 7.18 777.34
C20 126.9 132.9 133.5 137.1 132.5 132.58 3.66 531.97
MS2 201.9 207.2 209.1 208.9 210.3 207.48 3.31 949.19
C22 183 182.3 182.9 186.5 185.5 184.04 1.84 841.01
MS4 194.4 208.9 207 207.3 202.3 203.98 5.89 864.55
CSP 154.4 138.4 160.2 163.3 156.3 154.52 9.65 756.50
TMB17 3.508 3.334 2.708 3.568 3.9 3.41 0.45 16.26
1 2 3 4 5 AVG STDEV
Protein 
concentration 
(mg/mL)
pBSP1 1 0.6932 0.7381 0.7211 0.7167 0.6941 0.7126 0.0171 0.2729
pBSP1 2 0.6395 0.6827 0.6893 0.6734 0.6863 0.6742 0.0182 0.2202
pBS2P1 0.6839 0.7376 0.588 0.7247 0.7142 0.6897 0.0538 0.2414
C19 0.6433 0.7051 0.7068 0.6663 0.7007 0.6844 0.0253 0.2342
C20 0.7125 0.6895 0.6987 0.6922 0.6839 0.6954 0.0098 0.2492
MS2 0.6649 0.6663 0.7069 0.669 0.6581 0.6730 0.0173 0.2186
C22 0.6762 0.64 0.6877 0.6887 0.6735 0.6732 0.0177 0.2188
MS4 0.6974 0.6758 0.6783 0.6856 0.6913 0.6857 0.0080 0.2359
CSP 0.6649 0.6435 0.6793 0.6624 0.6629 0.6626 0.0114 0.2043
TMB17 0.6798 0.6664 0.6714 0.6609 0.6543 0.6666 0.0087 0.2097
Standard curve: y=ax+b x=(y-b) /a
Protein activity (slope x -1)
Total Protein concentration (BioRad A595)
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Appendix G Alkaline phosphatase assay data 
1 2 3 4 5 AVG STDEV
Slope /    total 
protein
pASP1 1 1015.7 1007.4 1016.4 953.32 1010.6 1000.68 23.91 8347.00
pASP1 2 1046.3 1001 1003.8 923.14 995.75 994.00 39.76 10859.63
phoA AAG 1064 1012.6 1046.8 1064.4 975.13 1032.59 34.36 8447.70
CSP phoA 893.5 899.36 863.66 865.22 891.7 882.69 15.12 11627.16
1 2 3 4 5 AVG STDEV
Protein 
concentration 
(mg/mL)
VK8 1 0.6932 0.7381 0.7211 0.7167 0.6941 0.7126 0.0171 0.1199
VK8 2 #0,6395 0.6827 0.6893 0.6734 0.6863 0.6829 0.0060 0.0915
phoA AAG 0.6839 0.7376 #0,588 0.7247 0.7142 0.7151 0.0198 0.1222
CSP phoA 0.6798 0.6664 0.6714 0.6609 0.6543 0.6666 0.0087 0.0759
phoA assay 0,1mM 02.11.2011
Protein activity (slope x -1)
Total Protein concentration (BioRad A595)
 
1 2 3 4 5 AVG STDEV
Slope /    
total protein
VK8 1 722.87 714.41 716.13 731.84 751.38 727.33 13.50 19901.77
VK8 2 726.87 698.54 719.2 735.39 734.57 722.91 13.53 19918.34
phoA AAG 729.22 686.61 686.69 702.79 722.42 705.55 17.70 19604.74
CSP phoA 711.65 663.03 694.42 649.62 687.25 681.19 22.21 18306.78
1 2 3 4 5 AVG STDEV
Protein 
concentratio
n (mg/mL)
VK8 1 0.7827 0.7921 0.8047 0.7812 0.7318 0.7785 0.0248 0.1827
VK8 2 0.7807 0.8072 0.7793 0.7733 0.7454 0.7772 0.0197 0.1815
phoA AAG 0.7634 0.8025 0.7841 0.7842 0.7437 0.7756 0.0202 0.1799
VK9 0.7764 0.7955 0.7841 0.7665 0.7874 0.7820 0.0099 0.1860
phoA assay 0,1mM  11.11.2011; Assay = 5x dillution
Protein activity (slope x -1)
Total Protein concentration (BioRad A595) 
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Appendix H Phosphoglucomutase assay data 
December 8th, celB (phosphoglucomutase) assay  
0,1mM induction, 2nd codon synonymous mutants
1 2 3 4 5 AVG STDEV
Slope /    total 
protein
celB wt 0.0036 0.0034 0.0034 0.0034 0.0032 0.0034 0.00014 0.033
CCA 0.0048 0.0048 0.0049 0.0048 0.0050 0.0049 0.00009 0.041
CCG 0.0030 0.0031 0.0030 0.0030 0.0030 0.0030 0.00004 0.023
CCT 0.0040 0.0041 0.0042 0.0041 0.0043 0.0041 0.00011 0.037
1 2 3 4 5 AVG STDEV
Protein 
concentratio
n (mg/mL)
celB wt 0.5949 0.5976 0.6088 0.609 0.6145 0.6050 0.0074 0.1043
CCA 0.6094 0.6281 0.6283 0.6269 0.6438 0.6273 0.0109 0.1191
CCG 0.6285 0.6492 0.6410 0.6437 0.6511 0.6427 0.0080 0.1292
CCT 0.5893 0.6136 0.6162 0.6223 0.6393 0.6161 0.0161 0.1117
Protein activity (slope from assay)
Total Protein concentration (BioRad A595)
 
December 13th, celB (phosphoglucomutase) assay  
0,1mM induction, 2nd codon synonymous mutants
1 2 3 4 5 AVG STDEV
Slope /    
total protein
celB wt 0.0035 0.0033 0.0034 0.0033 0.0031 0.0033 0.00015 0.026
CCA 0.0044 0.0045 0.0040 0.0037 0.0043 0.0042 0.00033 0.030
CCG 0.0026 0.0026 0.0026 0.0026 0.0025 0.0026 0.00004 0.019
CCT 0.0038 0.0037 0.0037 0.0037 0.0035 0.0037 0.00011 0.031
1 2 3 4 5 AVG STDEV
Protein 
concentratio
n (mg/mL)
celB wt 0.6241 0.6352 0.6465 0.6546 0.6515 0.6424 0.0113 0.1290
CCA 0.6311 0.6594 0.6694 0.6638 0.6528 0.6553 0.0133 0.1376
CCG 0.6512 0.6589 0.6635 0.6674 0.6482 0.6578 0.0072 0.1392
CCT 0.6051 0.6355 0.6281 0.6352 0.6295 0.6267 0.0112 0.1187
Protein activity (slope from assay)
Total Protein concentration (BioRad A595)
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Appendix I qRT-PCR data 
Avg CT 
Bla
Avg CT 
16S
∆CT     Bla, 
16S
∆CT     
StDev
∆∆CT      
Relative 
to VK6
RQ         (2^-
∆∆Ct)
pBSP1 22.762 12.462 10.300 0.101 0.000 1.000 0.067 0.072
pBS2P1 21.415 12.421 8.993 0.108 -1.307 2.474 0.178 0.192
AGC 23.442 12.822 10.621 0.054 0.321 0.801 0.029 0.030
TCC 21.818 12.943 8.876 0.141 -1.424 2.683 0.251 0.276
TCA 22.704 12.676 10.028 0.076 -0.272 1.207 0.062 0.065
TCG 22.448 12.786 9.662 0.115 -0.638 1.556 0.119 0.129
CSP 22.859 12.477 10.382 0.085 0.083 0.944 0.054 0.057
Ct (bla) Ct(16s) Ct (bla) Ct(16s) Ct (bla) Ct(16s) Ct (bla) Ct(16s)
pBSP1 22.76 12.453 TCC 21.8 12.957 CSP 22.828 12.484
pBSP1 22.73 12.381 TCC 21.796 12.912 CSP 22.936 12.469
pBSP1 22.71 12.566 TCC 21.677 12.901 CSP 22.814 12.414
pBSP1 22.85 12.447 TCC 22 13 CSP 12.541
Average 22.762 12.462 Average 21.8183 12.9425 Average 22.8593 12.477
StDev 0.065 0.077 StDev 0.13393 0.045347 StDev 0.06676 0.052211
pBS2P1 21.422 12.484 TCA 22.714 12.617
pBS2P1 21.345 12.371 TCA 22.748 12.628
pBS2P1 21.35 12.409 TCA 22.661 12.698
pBS2P1 21.541 TCA 22.692 12.76
Average 21.4145 12.4213 Average 22.7038 12.67575
StDev 0.09138 0.0575 StDev 0.03665 0.066645
AGC 23.415 12.805 TCG 22.453 12.845
AGC 23.418 12.845 TCG 22.382 12.769
AGC 23.42 12.834 TCG 22.36 12.748
AGC 23.516 12.802 TCG 22.597 12.782
Average 23.4423 12.8215 Average 22.448 12.786
StDev 0.04921 0.0213 StDev 0.10697 0.041753
Incorporated StDev                  
-               + 
Bla 2nd codon qRT-PCR 27.05.2011
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Avg CT Bla Avg CT 16S
∆CT     Bla, 
16S
∆CT     
StDev
∆∆CT      
Relative 
to VK6
RQ         
(2^-∆∆Ct)
pBSP1 23.592 13.441 10.150 0.243 0.000 1.000 0.155 0.184
pBS2P1 22.405 13.496 8.909 0.054 -1.242 2.365 0.087 0.090
C19 21.465 13.329 8.136 0.068 -2.014 4.040 0.186 0.195
C20 21.815 12.788 9.027 0.333 -1.123 2.178 0.450 0.566
MS2 21.470 13.216 8.254 0.072 -1.896 3.722 0.181 0.190
MS3 21.468 14.152 7.316 0.033 -2.834 7.130 0.162 0.165
MS4 21.819 13.392 8.427 0.213 -1.723 3.301 0.453 0.526
CSP 22.397 13.139 9.258 0.120 -0.892 1.856 0.148 0.161
Ct (bla) Ct (16s) Ct (bla) Ct (16s) Ct (bla) Ct (16s)
pBSP1 1 23.70 13.693 C19 21.462 13.340 MS3 21.471 14.132
pBSP1 1 23.87 13.579 C19 21.512 13.274 MS3 21.45 14.172
pBSP1 1 23.66 13.336 C19 21.42 13.372 MS3 21.484
pBSP1 2 23.524 13.335 Average 21.46467 13.32867 Average 21.46833 14.152
pBSP1 2 23.434 13.330 StDev 0.046058 0.049973 StDev 0.017156 0.028284
pBSP1 2 23.362 13.375
Average 23.592 13.441 C20 22.000 12.906 MS4 21.765 13.202
StDev 0.187 0.156 C20 21.682 12.458 MS4 21.849 13.359
C20 21.763 13.000 MS4 21.843 13.614
pBS2P1 22.455 13.465 Average 21.815 12.788 Average 21.819 13.39167
pBS2P1 22.395 13.52 StDev 0.165254 0.289627 StDev 0.046861 0.207933
pBS2P1 22.364 13.503
Average 22.4046667 13.496 MS2 21.519 13.207 CSP 22.42 13.262
StDev 0.04626374 0.02816026 MS2 21.444 13.278 CSP 22.394 13.129
MS2 21.448 13.163 CSP 22.378 13.026
Average 21.47033 13.216 Average 22.39733 13.139
StDev 0.042194 0.058026 StDev 0.021197 0.118317
Incorporated StDev            
-               + 
Bla synonymous library qRT-PCR 02.11.2011
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Avg CT Bla Avg CT 16S
∆CT     Bla, 
16S
∆CT     
StDev
∆∆CT      
Relative 
to VK6
RQ         
(2^-∆∆Ct)
pBSP1 21.966 12.904 9.062 0.175 0.000 1.000 0.114 0.129
pBS2P1 20.411 12.929 7.482 0.184 -1.581 2.991 0.358 0.407
C19 20.174 13.241 6.933 0.071 -2.130 4.376 0.210 0.221
C20 21.677 13.787 7.890 0.166 -1.172 2.254 0.245 0.275
MS2 21.266 13.074 8.192 0.061 -0.870 1.828 0.075 0.078
MS3 20.756 13.577 7.179 0.063 -1.883 3.689 0.157 0.164
MS4 20.995 13.495 7.501 0.075 -1.562 2.952 0.149 0.157
CSP 22.352 13.399 8.953 0.144 -0.110 1.079 0.102 0.113
pTMB18 24.964 13.916 11.048 0.058 1.986 0.252 0.010 0.010
Ct (bla) Ct (16s) Ct (bla) Ct (16s) Ct (bla) Ct (16s)
pBSP1 21.89 12.995 C19 20.137 13.260 MS3 20.801 13.567
pBSP1 22.00 12.717 C19 20.153 13.185 MS3 20.742 13.629
pBSP1 22.01 13 C19 20.232 13.279 MS3 20.724 13.534
Average 21.966 12.904 Average 20.174 13.24133 Average 20.75567 13.57667
StDev 0.067 0.162 StDev 0.050863 0.049702 StDev 0.040278 0.048232
pBS2P1 20.385 12.725 C20 21.827 13.897 MS4 20.925 13.475
pBS2P1 20.382 13.052 C20 21.598 13.769 MS4 20.996 13.524
pBS2P1 20.465 13.01 C20 21.605 13.694 MS4 21.065 13.485
Average 20.4106667 12.929 Average 21.67667 13.78667 Average 20.99533 13.49467
StDev 0.04707795 0.1779129 StDev 0.13024 0.102647 StDev 0.070002 0.025891
pTMB18 24.93 13.949 MS2 21.298 13.069 CSP 22.276 13.352
pTMB18 25 13.883 MS2 21.261 13.024 CSP 22.33 13.528
pTMB18 24.962 MS2 21.239 13.129 CSP 22.45 13.318
Average 24.964 13.916 Average 21.266 13.074 Average 22.352 13.39933
StDev 0.03504283 0.04666905 StDev 0.029816 0.052678 StDev 0.089062 0.112718
Incorporated StDev            
-               + 
Bla synonymous library qRT-PCR 08.12.2011
 
Avg CT 
bla
Avg CT 
16S
∆CT, bla 
16S
∆CT     
StDev
∆∆CT      
Relative 
to C19 0
RQ         
(2^-∆∆Ct)
pBSP1 23.051 14.533 8.517 0.285 0.000 1.000 0.179 0.218
pBS2P1 21.731 14.651 7.080 0.256 -1.437 2.708 0.440 0.526
C19 21.111 14.725 6.386 0.083 -2.131 4.380 0.244 0.258
MS3 21.628 14.661 6.967 0.197 -1.550 2.928 0.375 0.430
pBSP1 23.256 14.608 C19 21.144 14.801
pBSP1 23.161 14.490 C19 21.093 14.727
pBSP1 22.735 14.502 C19 21.096 14.646
AVERAGE 23.051 14.533 AVERAGE 21.111 14.725
STDEV 0.277 0.065 STDEV 0.029 0.078
pBS2P1 21.602 14.855 MS3 21.734 14.766
pBS2P1 21.860 14.517 MS3 21.725 14.612
pBS2P1 14.581 MS3 21.426 14.605
AVERAGE 21.731 14.651 AVERAGE 21.628 14.661
STDEV 0.182 0.180 STDEV 0.175 0.091
Incorporated StDev            
-               + 
Bla synonymous library qRT-PCR 23.02.2012
 
122 
Avg CT phoAAvg CT 16S
∆CT, phoA 
16S
∆CT     
StDev
∆∆CT      
Relative 
to pASP1
RQ         
(2^-∆∆Ct)
pASP1 1 23.321 15.054 8.267 0.098 0.000 1.000 0.065 0.070
pASP1 2 22.447 14.483 7.964 0.146 -0.303 1.233 0.119 0.131
phoA AAG 22.517 14.527 7.991 0.059 -0.276 1.211 0.049 0.051
phoA CSP 22.594 14.617 7.977 0.156 -0.290 1.222 0.125 0.139
Ct (phoA) Ct(16s) Ct (phoA) Ct(16s)
pASP1 1 23.33 15.066 phoA AAG 22.501 14.494
pASP1 1 23.40 15.101 phoA AAG 22.566 14.572
pASP1 1 23.23 14.995 phoA AAG 22.485 14.514
Average 23.321 15.054 Average 22.51733 14.52667
StDev 0.081 0.054 StDev 0.042899 0.040513
pASP1 2 22.333 14.456 phoA CSP 22.767 14.622
pASP1 2 22.4 14.508 phoA CSP 22.483 14.580
pASP1 2 22.608 14.485 phoA CSP 22.531 14.648
Average 22.447 14.483 Average 22.59367 14.61667
StDev 0.143398 0.026057628 StDev 0.152018 0.034312
Incorporated StDev            
-               + 
phoA 2nd codons qRT-PCR 23.11.2011
 
Avg CT phoAAvg CT 16S
∆CT, phoA 
16S
∆CT     
StDev
∆∆CT      
Relative 
to VK8
RQ         
(2^-∆∆Ct)
celB wt 22.431 14.446 7.985 0.115 0.000 1.000 0.077 0.083
celB CCA 23.180 15.663 7.517 0.047 -0.469 1.384 0.044 0.046
celB CCG 23.585 14.983 8.602 0.128 0.617 0.652 0.055 0.060
celB CCT 22.205 14.501 7.704 0.095 -0.282 1.216 0.078 0.083
Ct (phoA) Ct(16s) Ct (phoA) Ct(16s)
celB wt 22.52 14.42 celB CCG 23.477 15
celB wt 22.39 14.543 celB CCG 23.555 14.993
celB wt 22.38 14.374 celB CCG 23.723 14.956
Average 22.431 14.446 Average 23.585 14.983
StDev 0.075 0.087 StDev 0.125714 0.023643
Ct (phoA) Ct(16s) Ct (phoA) Ct(16s)
celB CCA 23.176 15.615 celB CCT 22.228 14.459
celB CCA 23.196 15.703 celB CCT 22.187 14.437
celB CCA 23.167 15.671 celB CCT 22.2 14.608
Average 23.17967 15.663 Average 22.205 14.50133
StDev 0.014844 0.044542115 StDev 0.020952 0.093029
Incorporated StDev            
-               + 
celB 2nd codons Transcript amounts, December 14th 2011
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Avg CT celB Avg CT 16S
∆CT, celB 
16S
∆CT     
StDev
∆∆CT      
Relative 
to VK8
RQ         
(2^-∆∆Ct)
celB wt 23.284 14.737 8.547 0.247 0.000 1.000 0.157 0.187
celB CCA 22.446 14.501 7.945 0.058 -0.602 1.517 0.060 0.063
celB CCG 23.897 14.513 9.384 0.105 0.837 0.560 0.039 0.042
celB CCT 23.362 14.764 8.597 0.204 0.050 0.966 0.127 0.147
Ct (celB) Ct(16s) Ct (celB) Ct(16s)
celB wt 23.37 14.977 celB CCG 23.889 14.509
celB wt 23.29 14.716 celB CCG 24 14.549
celB wt 23.19 14.519 celB CCG 23.801 14.481
Average 23.284 14.737 Average 23.89667 14.513
StDev 0.090 0.230 StDev 0.099721 0.034176
Ct (celB) Ct(16s) Ct (celB) Ct(16s)
celB CCA 22.425 14.553 celB CCT 23.353 14.650
celB CCA 22.426 14.465 celB CCT 23.368 14.643
celB CCA 22.487 14.484 celB CCT 23.364 15.000
Average 22.446 14.50066667 Average 23.36167 14.76433
StDev 0.035511 0.046306947 StDev 0.007767 0.204123
Incorporated StDev            
-               + 
celB 2nd codons Transcript amounts, December 21st 2011
 
Avg CT aac Avg CT 16S
∆CT     
aac, 16S
∆CT     
StDev
∆∆CT      
Relative 
to wt
RQ         
(2^-∆∆Ct)
pAR69 wt 23.158 10.305 12.852 0.435 0.000 1.000 0.260 0.352
D2 23.228 10.742 12.486 0.200 -0.367 1.289 0.167 0.192
D4 24.051 10.845 13.206 0.388 0.354 0.782 0.185 0.242
D7 23.574 10.201 13.373 0.337 0.521 0.697 0.145 0.183
D11 21.202 11.019 10.182 0.559 -2.670 6.364 2.045 3.012
D13 23.956 10.777 13.179 0.295 0.327 0.797 0.147 0.181
D19 23.160 11.183 11.977 0.100 -0.876 1.835 0.123 0.131
D20 24.397 12.812 11.585 0.078 -1.267 2.407 0.127 0.134
Ct (aac) Ct(16s) Ct (aac) Ct(16s) Ct (aac) Ct(16s)
pAR69 wt 23.114 10.723 D7 23.580 10.030 D19 23.252 11.225
pAR69 wt 23.355 10.259 D7 23.538 10.587 D19 23.109 11.141
pAR69 wt 23.004 9.934 D7 23.604 9.986 D19 23.118 #12,42
Average 23.158 10.305 Average 23.574 10.201 Average 23.160 11.183
StDev 0.180 0.397 StDev 0.033 0.335 StDev 0.080 0.059
D2 23.207 10.525 D11 21.768 11.076 D20 24.322 #14
D2 23.278 10.799 D11 21.129 10.832 D20 24.409 12.836
D2 23.199 10.903 D11 20.708 11.150 D20 24.461 12.788
Average 23.228 10.742 Average 21.202 11.019 Average 24.397 12.812
StDev 0.043 0.195 StDev 0.534 0.166 StDev 0.070 0.034
D4 24.083 10.696 D13 24.040 10.584
D4 24.044 11.284 D13 23.829 #12,22
D4 24.026 10.554 D13 24.000 10.970
Average 24.051 10.845 Average 23.956 10.777
StDev 0.029 0.387 StDev 0.112 0.273
Incorporated StDev                
-               + 
qRT-PCR celB69 aac(3)-IV  library 01.03.2012 
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Avg CT aac Avg CT 16S
∆CT     
aac, 16S
∆CT     
StDev
∆∆CT      
Relative 
to wt
RQ         
(2^-∆∆Ct)
pAR69 wt 23.439 12.103 11.336 0.215 0.000 1.000 0.138 0.160
D3 22.792 12.141 10.651 0.142 -0.685 1.607 0.150 0.166
D5 23.219 12.376 10.843 0.141 -0.493 1.408 0.131 0.145
D9 23.225 12.666 10.559 0.142 -0.777 1.714 0.160 0.177
D10 22.500 12.090 10.409 0.065 -0.927 1.901 0.083 0.087
D11 21.010 11.849 9.161 0.088 -2.176 4.517 0.266 0.283
D15 23.678 13.071 10.608 0.113 -0.728 1.657 0.125 0.135
D17 22.517 11.433 11.084 0.091 -0.252 1.191 0.073 0.077
D21 22.931 12.828 10.103 0.086 -1.233 2.351 0.137 0.145
Ct (aac) Ct(16s) Ct (aac) Ct(16s) Ct (aac) Ct(16s)
pAR69 wt 23.400 12.140 D9 23.186 12.709 D15 23.639 13.128
pAR69 wt 23.633 12.199 D9 23.170 12.754 D15 23.612 13.084
pAR69 wt 23.283 11.969 D9 23.319 12.535 D15 23.784 13.000
Average 23.439 12.103 Average 23.225 12.666 Average 23.678 13.071
StDev 0.178 0.119 StDev 0.082 0.116 StDev 0.093 0.065
D3 22.819 #12,636 D10 22.533 12.092 D17 22.501 11.517
D3 22.650 12.179 D10 22.446 12.134 D17 22.478 11.366
D3 22.908 12.103 D10 22.520 12.045 D17 22.571 11.416
Average 22.792 12.141 Average 22.500 12.090 Average 22.517 11.433
StDev 0.131 0.054 StDev 0.047 0.045 StDev 0.048 0.077
D5 23.224 12.278 D11 #21,585 #12,173 D21 22.843 12.851
D5 23.202 12.314 D11 20.959 11.885 D21 23.000 #13,522
D5 23.231 12.537 D11 21.060 11.813 D21 22.949 12.805
Average 23.219 12.376 Average 21.010 11.849 Average 22.931 12.828
StDev 0.015 0.140 StDev 0.071 0.051 StDev 0.080 0.033
Incorporated StDev            
-               + 
qRT-PCR celB69 aac(3)-IV  library 11.03.2012 
 
bla 16S
∆CT, bla 
16S
Average ∆CT, 
bla 16S
∆∆CT toative    
to pBSP1 0
Fold difference to 
pBSP1  0min
21.359 13.061 8.298 -0.129 1.094
21.684 13.136 8.548 8.427 0.121 0.920
21.295 12.859 8.436 0.009 0.994
22.09 13.735 8.355 0.043 0.970
21.996 13.973 8.023 8.312 -0.289 1.222
22.369 13.812 8.557 0.245 0.844
20.471 13.123 7.348 -0.009 1.006
20.601 13.235 7.366 7.357 0.009 0.994
22.222 13.127
AVERAGE 21.565 13.340 8.116 0.000 1.005
STDEV 0.689 0.393 0.498 0.159 0.113
pBSP1 mRNA degradation data
0 min
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bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
22.133 13.71 8.423 -0.004 1.003
22.132 14.149 7.983 -0.444 1.361
22.149 14.178 7.971 -0.456 1.372
21.593 12.414 9.179 0.867
21.729 13.18 8.549 0.237 0.848
21.394 13.014 8.38 0.068 0.954
21.148 13.348 7.8 0.443 0.736
21.216 13.393 7.823 0.466 0.724
21.003 13.374 7.629 0.272 0.828
AVERAGE 21.611 13.418 8.193 0.161 0.978
STDEV 0.452 0.551 0.486 0.429 0.258
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
22.122 13.289 8.833 0.406 0.755
22.147 13.353 8.794 0.367 0.776
22.077 13.242 8.835 0.408 0.754
22.133 13.198 8.935 0.623 0.649
22.075 13.142 8.933 0.621 0.650
22.162 13.367 8.795 0.483 0.715
20.94 13.13 7.81 0.453 0.731
21.104 13.124 7.98 0.623 0.649
21.215 13.016 8.199 0.842
AVERAGE 21.775 13.207 8.568 0.536 0.710
STDEV 0.522 0.116 0.443 0.153 0.053
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
22.338 13.066 9.272 0.845 0.557
22.314 13.019 9.295 0.868 0.548
22.402 13.048 9.354 0.927 0.526
22.604 12.796 9.808 1.496 0.354
22.253 12.459 9.794 1.482 0.358
22.427 12.424 10.003 1.691 0.310
21.837 12.994 8.843 1.486 0.357
21.796 12.908 8.888 1.531 0.346
21.921 13 8.921 1.564
AVERAGE 22.210 12.857 9.353 1.321 0.419
STDEV 0.288 0.249 0.433 0.338 0.104
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bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
23.701 13.649 10.052 1.625 0.324
23.238 13.792 9.446 1.019
23.242 13.68 9.562 1.135
24.203 13.083 11.12 2.808 0.143
23.121 13.499 9.622 1.310
23.27 13.019 10.251 1.939 0.261
23 12.615 10.385 3.028 0.123
22.449 13.219 9.23 1.873 0.273
22.441 13.085 9.356 1.999
AVERAGE 23.185 13.293 9.892 1.860 0.225
STDEV 0.553 0.387 0.614 0.696 0.088
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
23.107 12.652 10.455 2.028 0.245
23.143 12.642 10.501 2.074 0.238
23.137 12.579 10.558 2.131 0.228
23.245 14.261 8.984 0.672
23.507 14.29 9.217 0.905
23.383 14.324 9.059 0.747
22.943 13.188 9.755 2.398 0.190
22.863 13.021 9.842 2.485 0.179
22.901 13.196 9.705 2.348
AVERAGE 23.137 13.350 9.786 1.754 0.216
STDEV 0.217 0.742 0.619 0.752 0.030
8 min
10 min
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pBSP1 mRNA degradation data
 
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1  0min
19.151 12.767 6.384 -2.043 4.122
19.142 12.761 6.381 -2.046 4.131
19.137 12.808 6.329 -2.098 4.282
19.098 12.487 6.611 -1.816
19.098 12.571 6.527 -1.785
19.084 12.676 6.408 -1.904 3.742
18.248 12.861 5.387 -1.970 3.918
18.250 12.809 5.441 -1.916 3.774
18.183 12.891 5.292 -2.065 4.184
AVERAGE 18.821 12.737 6.084 -1.960 4.022
STDEV 0.447 0.134 0.541 0.112 0.211
C19 mRNA degradation data
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bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
21.359 15.085 6.274 -2.153 4.449
21.280 15.147 6.133 -2.294
21.281 15.108 6.173 -2.254 4.771
19.176 12.292 6.884 -1.428
19.147 12.599 6.548 -1.764 3.396
19.165 12.409 6.756 -1.556 2.940
18.733 13.260 5.473 -1.884 3.691
18.670 13.122 5.548 -1.809 3.504
18.780 12.863 5.917 -1.440
AVERAGE 19.732 13.543 6.190 -1.842 3.792
STDEV 1.196 1.218 0.493 0.335 0.688
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
21.147 14.042 7.105 -1.322 2.501
21.156 13.996 7.160 -1.267 2.407
21.199 13.989 7.210 -1.217 2.325
21.409 21.409 13.097
20.400 17.666 2.734 -5.578
20.321 13.000 7.321 -0.991 1.987
20.676 13.522 7.154 -0.203
20.370 13.600 6.770 -0.587
20.259 13.687 6.572 -0.785 1.723
AVERAGE 20.771 14.188 8.159 0.127 2.189
STDEV 0.454 1.446 5.174 5.115 0.324
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
21.469 14.034 7.435 -0.992 1.989
21.508 14.036 7.472 -0.955 1.939
21.524 14.023 7.501 -0.926 1.900
22.475 12.601 9.874 1.562
22.332 12.704 9.628 1.316
23.034 12.581 10.453 2.141
20.298 12.712 7.586 0.229 0.853
20.429 12.886 7.543 0.186 0.879
20.210 12.867 7.343 -0.014 1.010
AVERAGE 21.475 13.160 8.315 0.283 1.428
STDEV 1.015 0.661 1.272 1.166 0.567
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C19 mRNA degradation data
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bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
22.772 13.721 9.051 0.624 0.649
22.546 13.805 8.741 0.314 0.805
23.000 13.745 9.255 0.828 0.563
21.122 12.245 8.877 0.565 0.676
21.156 12.185 8.971 0.659 0.633
21.237 12.324 8.913 0.601 0.659
21.132 12.844 8.288 0.931 0.524
21.010 12.963 8.047 0.690 0.620
20.924 12.932 7.992 0.635 0.644
AVERAGE 21.655 12.974 8.682 0.650 0.641
STDEV 0.850 0.656 0.458 0.172 0.078
bla 16S
∆CT, bla 
16S
∆∆CT Relative 
to pBSP1 0
Fold difference to 
pBSP1 0min
22.822 13.847 8.975 0.548 0.684
22.593 13.568 9.025 0.598 0.661
22.630 14.000 8.630 0.203 0.869
21.509 15.469 6.040 -2.272
21.502 12.233 9.269 0.957 0.515
22.773 12.665 10.108 1.796 0.288
21.137 12.610 8.527 1.170 0.444
21.266 12.475 8.791 1.434 0.370
21.521 12.946 8.575 1.218 0.430
AVERAGE 21.973 13.313 8.660 0.628 0.533
STDEV 0.709 1.024 1.096 1.192 0.192
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Appendix J tAIcalc.py code and tAI.csv 
#OPEN tAI TABLE 
f=open("tAI.csv") 
tAI=[] 
i=0 
import math 
 
def geomeanlog(numbers):     ##Geometric mean of tAIs from all codons using  
    summ=0    ##log transformation 
    for n in numbers: 
        summ+=math.log10(n) 
    logG=summ/len(numbers) 
    return 10**logG     
 
##Split comma-separated values 
for line in f: 
    linje=line.split(";") 
    tAI.append(linje) 
    tAI[i][1]=tAI[i][1].rstrip() 
    i+=1 
f.close() 
 
toggle=1    ##Toggle for program loop 
#while toggle==1:   ##Run program 
    f=open('output.csv','w') ##Open/create outputfile 
    print 'Please remember to copy the output.csv file for every analysis 
if you want to keep it.' 
    sequ=raw_input("Type / Paste sequence in CAPS! Whitespace allowed, 
exclude stop codon: ") 
 
    seq=''    ##Split DNA sequence, remove whitespace 
    for i in range(0,len(sequ)): 
        if sequ[i]=='A'or sequ[i]=='T'or sequ[i]=='C'or sequ[i]=='G': 
            seq+=sequ[i] 
 
    a=0 
    b=3 
    codons=[] 
    values=[] 
    strings=['Codon no;tAI\n'] #ASSIGN tAI to individual codons 
    if (len(seq)%3)==0: 
        while a<len(seq): 
            codons.append(seq[a:b]) 
            a+=3 
            b+=3 
        for x in range(0,len(codons)): 
            for i in range(1,65): 
                if codons[x]==tAI[i][0]: 
                    codons[x]=[codons[x],tAI[i][1]] 
                    values.append(float(tAI[i][1])) 
                    strings.append(str(x+1)+';'+str(values[x])+'\n') 
                         
        tai=geomeanlog(values) ##Geometric mean of tAIs from all codons 
        f.writelines(strings)  ##Write to outputfile 
        f.close() 
 
        print codons   ##Display results 
        print "The tAI of the given sequence is: ",tai 
        print "Would you like to analyze one more sequence?" 
130 
        ans=raw_input("yes / no: ")  ##Prompt for new run 
        if 'yes' not in ans: 
             
            f.close() 
            toggle=0 
    else: 
        print "Invalid number of bases!" ##If not divided by three, prompt 
        print"Would you like to analyze on more sequence?" 
        ans=raw_input("yes / no: " ) 
        if ans!='yes': 
            toggle=0 
            f.close() 
             
print "Thank you for using this awesome program!" 
f.close() 
 
tAI.csv  
CODON;TAI 
AAA;0.75 
AAC;0.5 
AAG;0.24 
AAT;0.2195 
ACA;0.125 
ACC;0.25 
ACG;0.29 
ACT;0.10975 
AGA;0.125 
AGC;0.125 
AGG;0.165 
AGT;0.054875 
ATA;0.163204 
ATC;0.375 
ATG;1 
ATT;0.164625 
CAA;0.25 
CAC;0.125 
CAG;0.33 
CAT;0.054875 
CCA;0.125 
CCC;0.125 
CCG;0.165 
CCT;0.054875 
CGA;0.00005 
CGC;0.36 
CGG;0.125 
CGT;0.5 
CTA;0.125 
CTC;0.125 
CTG;0.54 
CTT;0.054875 
GAA;0.5 
GAC;0.375 
GAG;0.16 
GAT;0.164625 
GCA;0.375 
GCC;0.25 
GCG;0.12 
GCT;0.10975 
GGA;0.125 
GGC;0.5 
GGG;0.165 
GGT;0.2195 
GTA;0.625 
GTC;0.25 
GTG;0.2 
GTT;0.10975 
TAA;0.163204 
TAC;0.375 
TAG;0.163204 
TAT;0.164625 
TCA;0.125 
TCC;0.25 
TCG;0.165 
TCT;0.10975 
TGA;0.125 
TGC;0.125 
TGG;0.165 
TGT;0.054875 
TTA;0.125 
TTC;0.25 
TTG;0.165 
TTT;0.10975 
 
 
 
 
